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Prostate cancer development and progression to lethal metastatic castration-resistant 
prostate cancer (CRPCa) is driven by the androgen receptor. Androgen deprivation 
therapy (ADT) is the first line of treatment used to control cancer growth. Although ADT 
is usually effective, the recurrence of castration-resistant prostate cancer is common and 
ultimately lethal. Progression to CRPCa is thought to involve persistence of AR signalling 
and reprogramming of the AR transcriptional landscape, allowing tumour cells to 
continue to grow despite low levels of circulating androgens.  
 
The overall aim of this study was to identify and characterise mechanisms affecting 
prostate cancer cell growth. To do this I used RNA-sequencing in the androgen-
responsive LNCaP cell line, coupled with previously published RNA-sequencing of 
advanced prostate cancer treated with ADT and clinical prostate cancer expression data 
to identify androgen-regulated genes, alternative isoforms and pathways. A set of 660 
genes showed reciprocal changes in expression in response to acute androgen 
stimulation in culture, and androgen deprivation in patients with prostate cancer. A 
multiple dataset meta-analysis strategy coupled with gene ontology analysis has 
identified glycosylation as a novel androgen regulated pathway. Although patterns of 
glycosylation are known to change in prostate cancer the mechanisms underlying these 
changes are not well understood. The data in this study suggest androgens may increase 
the aggressiveness and metastatic potential of PCa cells through mediating changes in 
glycosylation patterns.  
 
Further investigation into the sialyltransferase enzyme ST6Gal1 has shown that high 
levels alter the expression of key epithelial to mesenchymal transition (EMT) makers and 
increase the invasion potential of prostate cancer cells, whilst reduction significantly 
decreased cell proliferation, cell to matrix adhesion, migration and invasion capability. 
Together with the androgen regulated transcriptional changes, the RNA sequencing data 
also identified a number of androgen regulated alternative mRNA isoforms, including 




In summary correlation of gene expression changes in prostate cancer cells in response 
to acute androgen stimulation with those repressed in patients by ADT has revealed a 
new panel of clinically relevant androgen regulated genes. Analysis of this panel has 
demonstrated important androgen control over glycosylation modifications has important 
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Chapter 1 Introduction 
 
1.1 Prostate cancer 
1.1.1 The prostate gland 
The prostate is a small glandular organ found within the male reproductive and urinary 
system. It is situated within the pelvic cavity, beneath the bladder and surrounding the 
urethra. The prostate consists of approximately 70% glandular tissue and 30% 
fibromuscular stroma. Arranged within the basement membrane of these glandular 
epithelium structures are several different cell types including luminal secretory cells 
(60%), basal cells (40%) and transient stem cells (~1%) with a small number of 
interspersed neuroendocrine cells. The surrounding stromal tissue contains smooth 
muscle cells, fibroblasts, nerve cells, blood vessels, extracellular matrix and lymphatics 
(Figure 1.1) (Mcneal, 1988). The main function of the prostate is to produce prostatic 
fluid, a component of semen containing sugars, enzymes and alkaline chemicals which 
protects and enhances the survival of spermatozoa. The glandular secretory cells are 
responsible for producing this seminal fluid whilst the fibromuscular stromal tissue 
provides a structural network and controls ejaculation. As the prostate gland surrounds 
the urethra it also assists in controlling the flow of urine from the bladder. 
 
Structurally, the mature prostate is divided into four distinct zones, (1) the transition zone, 
(2) the central zone, (3) the peripheral zone and (4) a fibromuscular stroma (Figure 1.1). 
The transition zone is situated in the centre of the prostate surrounding the urethra and 
is between the central and peripheral zones (Figure 1.2). The transition, central and 
peripheral zones contain highly organised glandular epithelium structures which are 







Figure 1.1 Cellular structure of the prostate gland.  
Arranged within the basement membrane of prostate glands are basal cells, luminal 
secretory cells and a small number of neuroendocrine cells. The fibromuscular stroma 






Figure 1.2  Zonal anatomy of the prostate.  
The prostate is divided into four distinct zones; three glandular zones (peripheral zone, 
central zone and transition zone) and a fibromuscular stroma. 
 
The size of the prostate can increase with age, resulting in a condition termed benign 
prostatic hyperplasia (BPH). This non-malignant condition is common in men > 60 years 
(Isaacs, 1994) and is characterised by progressive hyperplasia of glandular and stromal 
tissues within the transitional zone of the prostate (McNeal, 1978). As the transition zone 
increases in size it pushes the peripheral zone towards the rectum. BPH is not usually 
serious, however the increased growth can sometimes impact on the urethra causing 
discomfort and leading to complications such as acute urinary tract infections (UTI) and 
acute urinary retention (AUR) (Berry et al., 1984; Briganti et al., 2009). Although BPH 
and prostate cancer (PCa) can be linked at the molecular and cellular levels there 
remains no substantial evidence to suggest an increased cancer risk for men with BPH 
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(Fukushima et al., 1998; Rudd et al., 2001; Chang et al., 2012; Orsted and Bojesen, 
2013). 
 
1.1.2 Prostate cancer 
PCa is the most common type of cancer in men in the United Kingdom. Incidence rates 
have increased since the late 1970s and there were around 46,700 new cases of PCa 
in 2014 (corresponding to 130 cases diagnosed every day). With around 11,287 deaths 
a year prostate cancer accounts for 13% of all cancer deaths. It is predicted that 
approximately 1 in every 8 men will be diagnosed with PCa during his lifetime (Cancer 
Research UK, 2013; Ferlay et al., 2015). Over half of all cases are diagnosed in men 
aged 70 and over and these figures are expected to rise with an increasingly aging 
population. Risk factors include family history, age, ethnicity, diet, hormones, sexual 
activity and environmental influences (Bonilla et al., 2016; Lynch et al., 2016; Rider et al., 
2016; Shui et al., 2016; Travis et al., 2016; Harrison et al., 2017; Taylor et al., 2017; Wu 
et al., 2017).  
 
Adenocarcinoma accounts for the majority of tumours, and originates from the glandular 
structures within the peripheral zone of the prostate. PCa is a heterogeneous disease 
and the process of initiation is not fully understood. As with many cancers, two main 
models of tumour initiation and progression have been proposed. The clonal evolution 
model involves multiple genetic and epigenetic changes within a single cell of origin 
which confer a selective growth and survival advantage to produce a dominant clone. 
Genetic instability within the expanding tumour population produces further mutant cells 
creating tumour cell heterogeneity (Nowell, 1976). The alternative cancer stem cell 
model suggests that the tumour originates from a small sub-population of tumour 
initiating cells that have retained the ability to self-renew, generating heterogeneity 
through differentiation (Collins et al., 2005; Visvader and Lindeman, 2012). Whatever the 




In some cases, PCa is preceded by a premalignant condition called prostatic 
intraepithelial neoplasia (PIN). PIN involves neoplastic cellular proliferation which is 
confined to pre-existing ducts and acini with nuclear and nucleolar enlargement (Amano 
et al., 2003).  PIN can be sub-categorised based on histological characteristics into low-
grade (LGPIN) and high-grade (HGPIN). Other possible premalignant prostate 
conditions include atypical adenomatous hyperplasia (AAH) and proliferative 
inflammatory atrophy (PIA). AAH is characterised by localised proliferation of acini within 
the transition zone of the prostate that are histologically similar to adenocarcinoma (Park 
et al., 2012), whilst PIA is proliferation that occurs in association with chronic 
inflammation. HGPIN is the only premalignant condition that has a significant association 
with the development of PCa (Shaikh et al., 2008; Liu et al., 2014b; Meng et al., 2015; 
Hsieh et al., 2017). 
 
1.1.3 Androgen receptor  
Androgens play a key role in the growth and function of the prostate. In 1941, Huggins 
and Hodge were the first to demonstrate the androgen dependency of PCa growth and 
progression (Huggins and Hodges, 1972; Huggins and Hodges, 2002).  Androgens and 
the androgen receptor (AR) have since been portrayed as the crucial players in both 
localised and advanced disease (Harris et al., 2009; Livermore et al., 2016) and have 
been the major target for therapeutic treatment of PCa for many years (Guo et al., 2017).  
 
Androgens are a group of steroid hormones of which testosterone is the most prevalent 
in males. Testosterone is primarily produced in the testes by the Leydig cells (90%), 
although small amounts are also produced by the adrenal glands (10%). Testosterone 
production is regulated through the hypothalamic-pituitary-gonadal (HPG) axis. Pulses 
of gonadotropin releasing hormone (GnRH) are secreted from the hypothalamus to 
stimulate the release of luteinising hormone (LH) and follicle stimulating hormone (FSH) 
from the anterior pituitary gland, and this in turn stimulates the synthesis of testosterone. 
Circulating testosterone levels regulate the further production of GnRH to create a 
feedback loop (Conn and Crowley, 1994).  
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In the prostate, testosterone is converted to dihydrotestosterone (DHT) by 5α-reductase 
enzymes (Radmayr et al., 2008). The action of DHT is dependent upon binding to the 
AR. In the prostate DHT has a 10-fold higher binding affinity for the AR than testosterone 
(Saartok et al., 1984). In its inactive form, the AR is located in the cytoplasm bound to 
heat shock proteins (HSP), specifically HSP90 and other chaperone molecules (Cano et 
al., 2013). Binding of DHT to the ligand binding domain (LBD) of the AR induces a series 
of conformational changes that dissociate the AR from the HSPs and chaperone 
molecules. These changes promote AR phosphorylation and translocation to the nucleus, 
where the activated AR interacts with co-activators and binds as a dimer to androgen 
response elements (AREs) found in the promoter regions of target genes (He et al., 
1999). The AR controls transcription of many genes which are involved in cell growth 
and survival (Massie et al., 2011) as well as prostate-specific antigen (PSA) (Cleutjens 







Figure 1.3 Androgen signalling in the prostate.  
Testosterone enters the prostate cell where it is converted to DHT by the enzyme 5α-
reductase. Inactive AR is located in the cytoplasm bound to heat shock proteins (HSP) 
and other chaperone molecules. Binding of DHT to the AR induces a series of 
conformational changes that dissociate the AR from the HSPs and promotes AR 
phosphorylation and translocation to the nucleus. Inside the nucleus, the activated AR 
interacts with co-activators and binds as a dimer to androgen response elements (AREs) 





The AR is a nuclear steroid hormone receptor which functions as a ligand dependant 
transcription factor. The human AR gene is located on the X chromosome (Xq11-12) and 
spans > 90-kb of DNA (Lubahn et al., 1988). It has eight coding exons (Gelmann, 2002) 
which produce a 919 amino acid protein with four functionally distinct domains: an N-
terminal domain (NTD), a DNA binding domain (DBD), a small hinge region and a ligand 
binding domain (LBD). The first large exon encodes the highly variable NTD, which 
contains several regions of repetitive DNA sequences (CAG tri-nucleotide repeat) 
(Edwards et al., 1992). The highly conserved DBD contains two zinc finger domains and 
is encoded by exons 2 and 3 (Verrijdt et al., 2003), whilst exons 4 to 8 code for the C-
terminal LBD (Figure 1.4). The AR contains two trans-activation domains, the hormone 
independent activation function 1 (AF1) is located within the NTD and the hormone-
dependent activation function 2 (AF2) within the LBD. The most common AR splice 
variants AR-V7 and Arv567es lack a functional LBD and are constitutively active as 
transcription factors in the absence even of androgens. Not all cell types within the 
normal prostate gland are AR-positive. Whilst the luminal secretory cells express high 
levels of AR (Maitland et al., 2011), the majority of basal cells, neuroendocrine cells, and 
stem cells express little or no AR and function independently of androgens (Mirosevich 




Figure 1.4 Androgen receptor gene and common cancer associated splice 
variants. The AR gene is located on the X chromosome (Xq11-12) and has eight coding 
exons. The full-length AR protein has four functionally distinct domains: an N-terminal 
domain (NTD), a DNA-binding domain (DBD), a small hinge region and a ligand-binding 
domain (LBD). The most common AR splice variants AR-V7 and Arv567es lack a 
functional LBD and are constitutively active. 
 
1.1.4 Diagnosis and treatment  
PCa diagnosis usually involves measurement of serum prostate-specific antigen (PSA) 
levels, a digital rectal examination, and a needle core biopsy sampling. PSA is a serine 
protease which is secreted almost exclusively by the epithelial cells of the prostate (Ablin 
et al., 1970). PSA is commonly used as a biomarker of PCa as disruption of the prostatic 
epithelium allows PSA to leak into the circulating blood stream (Papsidero et al., 1980). 
However, its use as a PCa biomarker is controversial as it does not distinguish between 
PCa and other non-malignant conditions such as BPH, viral infections or chronic 
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prostatitis (Nadler et al., 1995; Shappell, 2008; Joshi et al., 2010; Henning et al., 2017). 
Several new PCa biomarkers are currently being investigated, including the use of 
tumour specific PSA isoforms (Romero Otero et al., 2014; Heidegger et al., 2015) and 
PSA glycan signatures (Gilgunn et al., 2013; Ishikawa et al., 2017), as well as non-
invasive urine-based assays such as microRNA (miRNA) profiling (Fabris et al., 2016; 
Luu et al., 2017) and exosome/ microvesicle gene expression analysis (McKiernan et al., 
2016; Motamedinia et al., 2016). These new approaches may prove to be more reliable 
at detecting PCa, thus helping to reduce the over diagnosis and over treatment issues 
associated PSA screening.  
 
The Gleason grading system is used in combination with PSA screening to categorise 
haematoxylin and eosin (H&E) stained prostatic tissue sections from biopsy samples. 
The size, morphology and structural arrangement of carcinoma cells help separate 
prostate tumours into five basic grades, from grade 1 (well-differentiated, small uniform 
glands) to grade 5 (poorly-differentiated, occasional gland formation) (Figure 1.5) 
(Gleason and Mellinger, 1974). These grades are used to generate an average Gleason 
score indicating the clinical stage of the tumour, possibility of progression to metastatic 






Figure 1.5 Schematic diagrams of the Gleason grading systems.  
Schematic diagrams of the Gleason grading system (a) the original Gleason grading 
system and (b) the updated modified Gleason grading system (Mondal et al., 2010). 
 
The current treatment options for localised PCa and locally advanced PCa include active 
surveillance, radical prostatectomy and radiation type therapy such as external beam 
radiotherapy, permanent seed brachytherapy, high-intensity focused ultrasound (HIFU) 
or cryotherapy to remove or kill tumour cells. The main treatment options for more 
advanced PCa include taxane chemotherapy treatment with docetaxel (Taxotere®) or 
cabazitaxel (Jevtana®) and androgen deprivation therapy (ADT), or a combination of 
both (Rajan et al., 2015; Tucci et al., 2016). ADT targets the androgen axis by reducing 
serum testosterone levels. This can be achieved by surgically removing the testicles 
13 
 
(orchidectomy) (Klugo et al., 1981) or using a combination of luteinising hormone-
releasing hormone (LHRH) agonists and antagonists to suppress the production of 
testosterone (Labrie et al., 1986) and AR antagonists such as bicalutamide (Casodex®) 
and flutamide (Eulexin®), which block AR function (Labrie et al., 1993; George, 2013; 
Ritch and Cookson, 2016).  
 
Despite an initial response to ADT, many patients go on to develop castration-resistant 
prostate cancer (CRPC) within a few years (Karantanos et al., 2013). CRPC occurs when 
tumour cells develop mechanisms which allow them to continue to grow despite depleted 
androgen levels. This has led to the development of second generation AR signalling 
inhibitors such as Abiraterone (Zytiga®) and Enzalutamide (Xtandi®). Abiraterone is an 
irreversible inhibitor of the enzyme CYP17A1, which is designed to inhibit extra-gonadal 
testosterone synthesis from the adrenal glands and the tumour microenvironment (de 
Bono et al., 2011). Enzalutamide is an AR antagonist which works by binding to the LBD 
of the AR, inhibiting its translocation to the nucleus, chromatin binding and interactions 
with co-regulators (Tran et al., 2009). Radium-233 (Xofigo®), a radiopharmaceutical 
agent has recently been approved for the treatment of CRPC patients with bone 
metastases (Kluetz et al., 2014; Suominen et al., 2017) and immunotherapy treatment 
with sipuleucel-T (SIP-T) in combination with the monoclonal antibody Ipilimumab is in 
clinical trials (Scholz et al., 2017). Although these agents have been modestly successful 
at prolonging the overall survival of PCa patients, resistance mechanisms inevitably 
develop which will continue to drive disease progression. CRPC is highly aggressive and 
ultimately lethal, meaning there is an urgent need to understand the mechanisms that 
drive this form of the disease and to develop new therapeutic targets.  
 
1.1.5 Mechanisms of castrate resistant prostate cancer  
There are many mechanisms and alternative pathways that have been associated with 
the androgen-independent growth observed in CRPC, the majority of which involve 
androgens and are mediated by the AR.  
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1.1.5.1  Altered steroidogenesis  
Despite the low serum testosterone levels obtained by ADT, intratumoral testosterone 
levels remain sufficient enough to induce cancer progression, suggesting that altered 
steroidogenesis pathways have been activated. Several studies have demonstrated that 
PCa cells are able to produce testosterone from different androgen precursors, such as 
cholesterol (Mostaghel et al., 2012) and the adrenal androgen dehydroepiandrosterone 
(DHEA) (Hamid et al., 2012). Several genes involved in testosterone biosynthesis 
become up-regulated in CRPCs compared with primary prostate tumours (Mohler et al., 
2004; Stanbrough et al., 2006; Montgomery et al., 2008). These include aldo-keto 
reductase family 1, member C3 (AKR1C3), which encodes an enzyme which catalyses 
the conversion of androstenedione to testosterone, steroid-5-alpha-reductase, alpha 
polypeptide 1/2 (SRD5A1/2) which converts testosterone to DHT, cytochrome P450 
17A1 (CYP17A1) and hydroxysteroid (17-Beta) dehydrogenase 6 (HSD17B6) (Knuuttila 
et al., 2014). Osteoblasts have been shown to mediate intratumoral steroidogenesis and 
may be responsible for castration-resistant growth in bone by stimulating increased 
expression of steroidogenic enzymes and DHT-inactivating enzymes in osteogenic 
CRPC cells (Hagberg Thulin et al., 2016).  
 
1.1.5.2  AR amplification and hypersensitivity  
Increased AR levels have been identified in CRPC cell lines (Liu et al., 2008) and CRPC 
patient samples (Taylor et al., 2010; Grasso et al., 2012). AR amplification allows the 
tumour cells to become hypersensitive to low levels of testosterone. An excess in AR 
production can result from AR gene amplification, increased mRNA transcription or 
stabilisation of the AR mRNA or protein (Edwards et al., 2003). The mechanisms 
underlying AR hypersensitivity remain unclear but are thought to be a response 
mechanism to the selective pressure within an androgen-depleted environment 





1.1.5.3  AR mutations and splice variants 
AR mutations have been found in around 20% of CRPC patients and account for almost 
60% of cases when combined with AR amplification (Wallen et al., 1999; Taylor et al., 
2010; Robinson et al., 2015). The McGilll Androgen Receptor Gene Mutation Database 
(available at: http://androgendb.mcgill.ca) contains extensive details of 1110 AR 
mutations, 168 of which have been associated with PCa. The majority of mutations 
identified in CRPC are found within the LBD (49%) followed by the NTD (40%), DBD (7%) 
and hinge region (2%) (Gottlieb et al., 2012). The most frequent AR mutation is the point 
mutation T877A which substitutes a threonine for alanine at position 877. The T877A  
mutation is found within the LBD of the AR (Gaddipati et al., 1994). Mutations in the LBD 
broaden binding specificity resulting in activation by multiple endogenous hormones 
including estrogens, progesterone and even the androgen antagonist flutamide 
(Steketee et al., 2002). Mutations that occur in the NTD and DBD could modulate the 
receptor’s affinity for co-regulators and influence nuclear localisation (Steinkamp et al., 
2009). AR mutations have been detected in plasma derived cell-free DNA (cfDNA) using 
next generation sequencing technology, although techniques still require further 
optimisation (Lallous et al., 2016; Goldstein et al., 2017).  
 
A large number of constitutively active AR splice variants have been identified in CRPC 
patients. AR splice variants are usually truncated variants of the full-length AR that lack 
the LBD and therefore retain transcriptional activity (Kumar and McEwan, 2012). The 
clinically most prevalent AR isoforms are AR-V7 (Hu et al., 2009) and ARv567es (Sun et 
al., 2010), both of which lack a functional LBD and facilitate ligand-independent AR 
signalling (Figure 1.4). AR-V7 and ARv567es levels are significantly increased in CRPC 
and CRPC bone metastases (Hornberg et al., 2011; Zhang et al., 2011). Patients with 
high expression levels of AR-V7 and ARv567es have a particularly poor prognosis with 
significantly shorter survival rates (Hornberg et al., 2011). RNA binding protein such as 
the KH domain-containing, RNA-binding, signal transduction-associated protein 1 
(KHDRBS1, also known as Sam68) can control the expression of AR-V7 and its 
transcriptional function (Stockley et al., 2015).  
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New treatments which directly target AR and its mutated forms and splice variants are in 
development to help overcome the acquired resistance seen with these therapies. The 
FDA approved antihelminthic drug niclosamide, originally developed to treat tapeworm 
infections, binds both full length AR and ARv7, reducing their DNA binding capacity and 
enhancing protein degradation. Furthermore, when used in combination with 
enzalutamide, niclosamide significantly inhibited enzalutamide-resistant tumour growth 
(Liu et al., 2014a; Liu et al., 2016). Galeterone, a CYP17 inhibitor and potent AR 
antagonist (Vasaitis et al., 2008), inhibits androgen synthesis and promotes degradation 
of full length AR and ARv7 (Kwegyir-Afful et al., 2015). Other new therapies include, 
ASC-J9®, an AR degradation enhancer (Wang et al., 2016c), EPI-001 (De Mol et al., 
2016) and AR silencing with siRNAs (Wang et al., 2014a; Yamamoto et al., 2015). 
 
1.1.5.4  Ligand independent activation   
Although ADT works to repress AR signalling, there are a number of cytokines and 
growth factors that continue to activate and stabilise the AR, enhancing transcriptional 
activity independently of ligand binding. Interleukin-6 (IL-6) is a multifunctional cytokine 
important for immune regulation and which regulates cell growth (Kishimoto, 1989). 
Androgens induce the expression of IL-6 in the androgen sensitive LNCaP PCa cell line 
(Okamoto et al., 1997). Reciprocally, IL-6 can regulate AR activity in a ligand-
independent and synergistic manner even in low concentrations of androgens (Hobisch 
et al., 2000; Culig et al., 2002; Malinowska et al., 2009). Serum IL-6 levels are a 
significant prognostic factor in PCa and elevated IL-6 serum levels have been reported 
in CRPC patients (Twillie et al., 1995). The JAK-STAT (janus kinase - signal transducers 
and activators of transcription), MAPK (mitogen-activated protein kinase) and PI3K-AKT 
(phosphoinositol 3-kinase) signalling pathways have been shown to be important in AR 
activation by IL-6 (Chen et al., 2000; Heinrich et al., 2003). Reciprocal regulation 
between AR signalling and the PI3K signalling pathway has been observed in PCa cells 
(Carver et al., 2011). AR mediated repression of the PI3K regulatory subunit PI3KR1 




The epidermal growth factor receptor (Her2/neu) is a receptor tyrosine kinase onco-
protein that plays a major role in cell growth and differentiation (Olayioye et al., 2000). 
Gene amplification and over expression of the Her2/neu protein drive the progression of 
many types of cancers, including breast and ovarian cancers (Her2/neu gene 
amplification is found in ~25% of breast cancers) (Slamon et al., 1989). In PCa, Her2/neu 
expression has been shown to increase with progression to CRPC (Signoretti et al., 
2000), promoting cell growth and survival in the absence of androgens through the 
activation of protein kinase B (Akt) (Wen et al., 2000).  
 
The transcription factor nuclear factor kappa B (NF-κB) plays a critical role in cancer 
development and progression (Karin, 2006). The AR is thought to activate NF-κB 
signalling in the absence of androgens and repress NF-κB in the presence of androgens 
(Suh et al., 2002).  Constitutive activation of NF-κB signalling in the absence of 
androgens significantly increases AR mRNA and protein levels, AR trans-activation 
activity and cell proliferation in vitro (Zhang et al., 2009). NF-κB2 (p52) interacts directly 
with the NTD of the AR, enhancing nuclear translocation, activation and enhancing the 
recruitment of co-activators such as p300 to the promoter region of AR-dependent genes 
(Nadiminty et al., 2010).  
 
1.1.5.5  Neuroendocrine differentiation 
Neuroendocrine cells in the prostate are rare and are found interspersed between the 
luminal secretory and basal cells within the prostate gland. Unlike the luminal secretory 
and basal cells, neuroendocrine cells do not express the AR or PSA and are independent 
from androgen regulation (Krijnen et al., 1993; Bonkhoff et al., 1995). Instead, they act 
in an autocrine/paracrine fashion, secreting a range of growth factors and hormones 
which can stimulate proliferation and inhibit apoptosis in surrounding tumour cells; these 
include chromogranin A (CgA), neuron-specific enolase (NSE), parathyroid hormone-
related protein (PTHrp), bombesin (BBN), vascular endothelial growth factor (VEGF) and 
many more (Li et al., 2016b).  
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Neuroendocrine differentiation (NED) is a unique feature of PCa which refers to the 
trans-differentiation of PCa cells toward a neuroendocrine phenotype. NED is 
significantly increased in CRPC (Hirano et al., 2004), and relates to a more aggressive 
cancer behaviour and less favourable prognosis due to late recognition and limited 
effective therapies (Sagnak et al., 2011; Terry and Beltran, 2014). The process of NED 
is thought to be induced either in response to treatments such as ADT (Hirano et al., 
2004; Ma et al., 2014; Chen et al., 2016) and radiotherapy (Zhang et al., 2016) or  by 
molecular signalling molecules which activate distinct signalling pathways. A number of 
agents and pathways have been shown to promote NED in PCa cells including, cAMP 
activating the PKA/CREB signalling pathway (Chen and Colley, 2000; Clamp et al., 2007; 
Antony et al., 2014) and IL-6 activation of the PI3K/Etk/Bmx and STAT3 pathways  (Qiu 
et al., 1998; Spiotto and Chung, 2000; Jensen, 2004; Wu and Huang, 2007).  
 
Neuroendocrine prostate cancer (NEPC) is difficult to diagnose and treat and there is 
currently no standard treatment for patients. This is mainly due to a lack of predictive 
biomarkers and understanding of the genetic and epigenetic mechanisms involved. The 
vast majority of NEPC over-express the cell cycle aurora kinase A (AURKA) and the 
proto-oncogene V-myc avian myelocytomatosis viral oncogene neuroblastoma derived 
homolog (MYCN) compared to adenocarcinoma (Beltran et al., 2011). Epigenetic 
modifiers have been shown to play a role in the induction and maintenance of a 
neuroendocrine phenotype in CRPC patients (Lander, 2011). Genome wide DNA 
methylation analysis of metastatic tumour samples showed significant differences 
between prostate adenocarcinomas and CRPC-NE subtypes. These include 
hypermethylation of the tumour suppressor gene SAM pointed domain containing ETS 
transcription factor (SPDEF) and increased expression of the histone methyltransferase 
enhancer of zeste homolog 2 (EZH2) in CRPC-NE samples (Beltran et al., 2016). In 
contrast to prostate adenocarcinomas, no AR mutations have been observed in CRPC-
NE and the ratio of ARv7 to wild type AR is significantly decreased (Beltran et al., 2016). 
Circulating tumour cells (CTCs) from patients with CRPC-NE have unique morphologic 
characteristics which could be used to identify patients transitioning toward a 
neuroendocrine phenotype (Beltran et al., 2014).  
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1.1.5.6  Tumour micro-environment  
The tumour micro-environment also plays an important role in regulating PCa 
progression. In the normal prostate, signalling cross-talk between the stromal and 
epithelial compartments maintains cellular homeostasis. Stromal AR activity can regulate 
the composition of the prostate micro-environment. The AR activity of cancer-associated 
fibroblasts (CAFs) has been shown to promote PCa cell growth and invasion through the 
regulation of growth factors (Yu et al., 2013). An important regulator which inhibits 
epithelial proliferation called transforming growth factor-β (TGF-β) is under control of the 
AR (Roberts et al., 1985). Over expression of TGF-β has been observed in prostate 
tumours isolated from patients following ADT (Fuzio et al., 2012). Elevated levels of TGF-
β in prostate stroma have been shown to promote prostate tumour growth and 
angiogenesis (Yang et al., 2005), and indirectly activate the AR (Yang et al., 2014). 
 
1.2 Glycosylation 
1.2.1 N-linked and O-linked glycosylation 
Glycosylation is a common post transcriptional modification (PTM) which involves the 
addition of carbohydrate chains (glycans) to proteins, lipids and other macromolecules. 
There are two major types of glycosylation that occur on proteins, named according to 
their linkage; nitrogen (N) or oxygen (O). N-linked protein glycosylation occurs at 
Asparagine (Asn) residues in the consensus peptide sequences Asn-X-Ser/Thr (X 
denotes any amino acid except proline (Pro)). Pre-assembled glycan chains, which share 
the same initial core region of 2 N-acetyl-glucosamine (GlcNAc) molecules followed 3 
mannose (Man) molecules are transferred to the asparagine residue on the target protein. 
These structures are modified further by the addition of terminal structures such as 
GlcNAc, galactose (Gal) and sialic acid. O-linked protein glycosylation is initiated by the 
addition of a single N-acetyl-galactosamine (GalNAc) residue to the hydroxyl group of 
serine (Ser) or threonine (Thr) which can be extended into various structures (Figure 1.6). 
Other types of O-linked glycosylation including those attached via mannose (O-Man) and 
N-acetyl-glucosamine (O-GlcNAc) (reviewed in (Keren et al., 2010; Pinho and Reis, 2015; 
Munkley et al., 2016a).  
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Glycosylation can produce an abundant and diverse range of glycan structures on the 
cell surface as well as secreted and intracellular proteins. Glycan biosynthesis takes 
place in the lumen of the endoplasmic reticulum (ER) and in the Golgi apparatus and 
requires a complex series of tightly regulated steps involving multiple glycoenzymes. In 
humans, there are around 500 glycoenzymes including glycosyltransferases and 
glycosidases (Rajan et al., 2009). The expression and activity of these glycoenzymes is 




Figure 1.6 N-linked and O-linked protein glycosylation.  
Protein glycosylation: N-linkage to asparagine (Asn) residues via a nitrogen atom or O-
linkage to serine and/or threonine (Ser/Thr) residues via an oxygen atom. Image taken 
form a recent review by (Munkley et al., 2016a).  
 
 
1.2.2 Cancer associated glycans 
The combination of glycans on a cells surface acts as an important interface between 
cells and their surrounding environment. The development and progression of cancer 
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can lead to fundamental changes in the glycan composition of cells (glycome). Changes 
in the glycome can alter important regulatory processes and can affect protein structure 
(Shental-Bechor and Levy, 2009), cell interactions, signalling (Haltiwanger, 2002), 
immune surveillance (Rudd et al., 2001) and metabolism (Munkley and Elliott, 2016). 
Aberrant glycosylation, primarily caused by altered expression or the mislocalisation of 
glycoenzymes is a common feature of cancer cells (Pinho and Reis, 2015; Stowell et al., 
2015). The most frequently observed cancer-associated glycosylation changes include 
altered sialylation, fucosylation, O-glycan truncation, and glycan branching (Hakomori, 
2002; Christiansen et al., 2014). 
 
The incomplete synthesis of O-glycans usually occurs in the early stages of cancer on 
and can lead to expression of truncated structures such as the T (Galβ1–3GalNAc-α1-
O-Ser/Thr),   Tn (GalNAcα-O-Ser/Thr) and the sialyl-Tn (sTn) (NeuAcα2-6GalNAcα-O-
Ser/Thr) antigens (Miles et al., 1994; Radhakrishnan et al., 2014). Glycan neo-synthesis 
is observed in more advanced cancers and involves the induction of genes linked to the 
expression of the sialyl Lewis a (SLea) and sialyl Lewis x (SLex) epitopes (Narita et al., 
1993; Amado et al., 1998; Baldus et al., 1998). Increased sialylation and fucosylation 
due to altered glycosyltransferase and fucosyltransferase expression has also been 
associated with cancer (Dall'Olio and Chiricolo, 2001; Saldova et al., 2011; Osuga et al., 
2016). Sialic acid is often found at the terminal position on cell membrane glycoproteins 
and plays an important role in cell communication, signalling and adhesion. Abnormal 
sialylation observed in cancer has been associated with malignant properties including 
adhesion, invasiveness and metastatic potential in part due to their negative electric 
charge (Dall'Olio et al., 2000; Lu et al., 2014; Suzuki et al., 2015; Wei et al., 2016).  
 
1.2.3 Glycosylation in prostate cancer development and progression  
The differential expression of glycoenzymes has been linked to PCa (Chen et al., 2014; 
Itkonen et al., 2014; Munkley et al., 2015b; Munkley et al., 2016b). A recently published 
meta-analysis study of clinical PCa gene expression data identified a novel prostate 
cancer gene signature which included 4 glycoenzymes: ST6 N-acetylgalactosaminide α-
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2,6-sialyltransferase 1 (ST6GalNAc1), glucosaminyl (N-acetyl) transferase 1 (GCNT1), 
UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1), and β-1,3-
Glucuronyltransferase 1 (B3GAT1) (Barfeld et al., 2014). Previous work in our laboratory 
has found that expression of ST6GalNAc1, a sialytransferase that catalyses the transfer 
of sialic acid onto the Tn antigen, is regulated by andorgens and can affect cell adhesion. 
Increased ST6GalNAc1 expression is found in primary prostate tumours, although this 
expression is down-regulated in metastatic tissue compared to non-malignant prostate 
tissue, suggesting a more transient role in tumour progression (Munkley et al., 2015b). 
Increased expression of GCNT1, which is involved in the formation of branched O-linked 
glycans, has been shown to positively correlate with the aggressive potential of PCa 
(Hagisawa et al., 2005; Chen et al., 2014). UAP1 is the last enzyme in the hexosamine 
biosynthetic pathway (HBP) and is highly over-expressed in patients with PCa and 
negatively correlates with Gleason score (Itkonen et al., 2015). Polypeptide N-
acetylgalactosaminyltransferase 7 (GALNT7), an enzyme involved in O-glycosylation 
initiation, is also up-regulated in several cancers including malignant PCa (Barfeld et al., 
2014; Lu et al., 2016; Nie et al., 2016) and GALNT7 knockdown has been found to inhibit 
tumour cell migration and invasion (Brockhausen, 2006; Nie et al., 2016). Increased 
glycan fucosylation has been detected in the serum of PCa patients compared to patients 
with BPH (Saldova et al., 2011). Expression of α1-6 fucosyltransferase 8 (FUT8), which 
is involved in the attachment of fucose to the innermost N-acetylglucosamine in N-
glycans is increased in metastatic PCa and is associated with aggressive disease (Wang 
et al., 2014b).  
 
1.2.4 Glycans and glycoproteins as biomarkers for prostate cancer 
“Biomarkers (or biological markers) are any substance, structure, or process that can be 
measured in the body, or its products, that influence or predict the incidence of outcome 
or disease” (WHO International Programme on Chemical Safety Biomarkers in Risk 
Assessment: Validity and Validation., 2001). The main methods to monitor cancer 
biomarkers include gene expression measurements using DNA, RNA, and microRNA 
gene arrays and protein microarray technologies. However, increasing interest in the role 
of glycosylation in cancer has uncovered several new promising glycomics-based 
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biomarkers, including cancer associated global glycan signatures (Kang et al., 2012; 
Ozcan et al., 2014; Krishn et al., 2016; Ruhaak et al., 2016) and protein-specific 
glycosylation changes (Haab et al., 2010; Kim et al., 2016; Drabik et al., 2017).  
 
As a secretory gland, the prostate secretes glycoproteins of all types. The prostate 
cancer biomarker, PSA has a single N-glycosylation site at asparagine (Asn) 69. A 
tumour specific PSA glycan signature has recently been identified in which decreased 
core fucosylation and increased α2,3-linked sialylation of PSA is found in PCa patients 
compared to healthy controls or BPH patients (Dwek et al., 2010; Sarrats et al., 2010; 
Gilgunn et al., 2013; Hsiao et al., 2016; Llop et al., 2016). Serum levels of fucosylated 
PSA (Fuc-PSA) are significantly increased in PCa and can differentiate between 
aggressive and nonaggressive forms of PCa (Li et al., 2015), whereas decreased urinary 
Fuc-PSA is associated with high Gleason score (Fujita et al., 2016). This has lead to the 
development of lectin based immunoassays which can detect changes in the 
glycosylation patterns of PSA in serum of PCa patients and could potentially improve the 
accuracy of PCa diagnosis (Bhanushali et al., 2016; Ishikawa et al., 2017).  
 
 
1.3 ST6 β-galactoside α-2,6-sialytransferase 1 (ST6Gal1) 
 
1.3.1 The structure and function of ST6Gal1 
Sialic acids represent a family of nine-carbon sugar neuraminic acids of which N-
acetylneuraminic acid (Neu5Ac) is the most common form in humans. Variability comes 
from their location on cells and molecules. Sialic acids can be linked to sugar molecules 
through an α2-6-bond to GalNAc or GlcNAc; an α2,3 or α2,6 bond to galactose or through 
a α2-8-bond to another sialic acid. Sialic acids are hydrophilic molecules with a strong 
electronegative charge and often found at the terminal end of glycoconjugates. Given 
their location, sialic acids play a crucial role in regulating molecular and cellular 
interactions including transmembrane signalling, cell-cell interactions and recognition, 
differentiation and membrane stabilisation (Traving and Schauer, 1998). 
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Sialyltransferases are a class of glycosyltransferase enzymes which catalyse the 
transfer of sialic acid from a common donor substrate, cytidine monophosphate (CMP-
sialic acid) to the carbohydrate chain of glycans. At least 20 distinct sialyltransferases 
have been identified in humans (Table 1.1), which can be divided into 4 subgroups 
according to their carbohydrate linkage: ST3Gal, ST6Gal, ST6GalNAc and ST8sia (Lu 




Table 1.1 Human sialyltransferases. 
Table of the 20 different human sialyltransferases discovered to date with their substrate 
and glycan specificity. Modified from Wang et al, 2016. 
 
 
ST6 β-galactoside α-2,6-sialytransferase 1 (ST6Gal1) is a member of the ST6 
sialytransferase family which catalyses the transfer of sialic acid from CMP-sialic acid to 
galactose containing acceptor substrates on N-glycans in the α-2,6 formation (Weijers et 
al., 2008). The human ST6Gal1 gene is located on chromosome 3: 186930485 - 
187078553 (q27.3). Three mRNA transcript variants have been identified which encode 
two protein isoforms. All the variants share a common protein coding region (Dall'Olio, 
2000). Variants 1 and 2 have different 5′ un-translated regions but both encode the same 
protein isoform, whereas variant 3 lacks the exon containing the translation start site of 
variants 1 and 2 and produces a protein isoform with a shorter N-terminus (Figure 1.7).  
Abbreviation Sialyltransferase Substrate Glycan specificity
ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 Galβ1,3GalNAc O-glycan
ST3GAL2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 Galβ1,3GalNAc O-glycan
ST3GAL3 ST3 beta-galactoside alpha-2,3-sialyltransferase 3 Galβ1,3(4)GlcNAc O-glycan, N-glycan
ST3GAL4 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 Galβ1,4(3)GlcNAc N-glycan, O-glycan
ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 Galβ1,4Glc-ceramide Glycolipid
ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 Galβ1,4GlcNAc N-glycan, glycolipid
ST6GALNAC1 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 GalβNAcα1, O-Ser/Thr O-glycan
ST6GALNAC2 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 Galβ1,3GalNAcα1, O-Ser/Thr O-glycans
ST6GALNAC3 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 Siaα2,3Galβ1,3GalNAc O-glycan
ST6GALNAC4 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4 Siaα2,3Galβ1,3GalNAc O-glycan
ST6GALNAC5 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 GM1b Glycolipid
ST6GALNAC6 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 All α-series gangliosides Glycolipid
ST6GAL1 ST6 beta-galactoside alpha-2,6-sialyltransferase 1 Galβ1,4GlcNAc N-glycan
ST6GAL2 ST6 beta-galactoside alpha-2,6-sialyltransferase 2 Galβ1,4GlcNAc N-glycan
ST8SIA1 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 Siaα2,3Galβ1,4Glc-ceramide Glycolipid
ST8SIA2 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 Siaα2,3Galβ1,4GlcNAc N-glycan on NCAMa
ST8SIA3 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 Siaα2,3Galβ1,4GlcNAc N-glycan on NCAM
ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 (Siaα2,8)nSiaα2,3Galβ1-R N-glycan on NCAM
ST8SIA5 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 GM1b, GT1b, GD1a, GD3 Glycolipid
ST8SIA6 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6 Siaα2,3(6)Gal Sialic acid on O-glycan
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ST6Gal1 is a trans-membrane protein which is localised to the Golgi apparatus 
(Fenteany and Colley, 2005). The full length ST6Gal1 protein sequence comprises 406 
amino acids; the first nine N-terminal residues are cytoplasimic, followed by a 
hydrophobic trans-membrane region and a C-terminal catalytic luminal domain (Kuhn et 
al., 2013). The cytoplasmic domain contains two asparagine-X-serine/threonine (NXS/T) 
motifs required for N-glycosylation and protein stabilisation (Chen and Colley, 2000). The 
shorter protein sequence comprises of just 175 amino acids and is missing the N-
terminal cytoplasmic and trans-membrane domains and is more likely to be soluble 
rather than membrane-bound. 
 
 
Figure 1.7 ST6Gal1 protein isoforms 
There are three ST6Gal1 mRNA transcript variants (NM_173216, NM_003032 and 
NM_173217), which encode two protein isoforms. Variants 1 and 2 have different 5′ 
un-translated regions but both encode the same protein, which contains a cytoplasmic 
N-terminal domain (CD), transmembrane domain (TM) and a catalytic luminal domain. 
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Variant 3 lacks the exon containing the translation start site of variants 1 and 2 and 
produces a protein with a shorter N-terminus, lacking the CD and TM. 
 
1.3.2 The role of ST6Gal1 in cancer 
Increased sialyation is already known to be associated with cancer cell progression and 
metastasis affecting cell adhesion, migration and invasion (Seales et al., 2005; Bull et 
al., 2013; Pinho and Reis, 2015). Up-regulation of ST6Gal1 has been described in 
several cancers including colon cancer (Dall'Olio et al., 1989), breast cancer (Lin et al., 
2002), choriocarcinoma (Fukushima et al., 1998), hepatocarcinoma (Dall'Olio et al., 2004; 
Poon et al., 2005), cervical cancer (Wang et al., 2001), and myeloid leukaemias (Skacel 
et al., 1991). Previous studies have shown that ST6Gal1 functions as a regulator of cell 
survival; α2,6 sialylation of the Fas death receptor reduces apoptotic signalling by 
obstructing internalisation of Fas after ligand induced activation (Swindall and Bellis, 
2011). ST6Gal1 sialylation of tumour necrosis receptor 1 (TNFR1) and the CD45 
receptor inhibits apoptosis (Amano et al., 2003; Liu et al., 2011). ST6Gal1 up-regulation 
promotes cell migration and invasion through its interaction with the β1 integrin and 
EGFR receptors (Seales et al., 2005; Shaikh et al., 2008; Park et al., 2012), whilst 
knockdown of ST6Gal1 inhibits metastasis in breast cancer (Lin et al., 2002), 
osteosarcoma (Meng et al., 2015) and colon cancer (Zhu et al., 2001). Expression of 
ST6Gal1 promotes TGF- β induced epithelial to mesenchymal transition (EMT), through 
the down-regulation of E-cadherin mediated cell adhesion and up-regulation of integrin 
mediated cell migration (Lu et al., 2014). ST6Gal1 expression is an adverse predictor of 
survival and recurrence in localised clear-cell renal carcinoma (Liu et al., 2014b), whilst 
in pancreatic cancer, high ST6Gal1 expression was a predictor of poorer patient 
prognosis (Hsieh et al., 2017). High ST6Gal1 expression also positively correlates with 
high risk of paediatric acute leukemia (Mondal et al., 2010). Although the role for 
ST6Gal1 in PCa is yet to be established, a recent study has found that ST6Gal1 
expression up-regulated in PCa tumour tissue and is related to poor overall survival and 
poor progression-free survival (Wei et al., 2016). Knockdown of ST6Gal1 in prostate 
cancer cell lines significantly inhibits the proliferation, growth, migration and invasion 
capabilities (Wei et al., 2016). Targeting ST6Gal1 therapeutically has shown potential, 
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the fluorinated sialic acid analogue P-3Fax-Neu5Ac is a potent inhibitor of α2,3 and α2,6 
sialylation (Bull et al., 2013). P-3Fax-Neu5Ac treatment blocks tumour cell adhesion to 
extra cellular matrix and migration in vitro and tumour engraftment in vivo (Bull et al., 
2013). 
 
Furthermore, increased ST6Gal1 expression can regulate the effects of chemotherapy 
and radiotherapy treatments. ST6Gal1 over-expression facilitates resistance to the 
chemotherapy drug cisplatin in ovarian tumour cells (Schultz et al., 2013) and ST6Gal1 
knockdown increased cisplatin sensitivity in cervical cancer cells (Zhang et al., 2016). 
Over-expression of ST6Gal1 enhanced the resistance of chronic myelogenous leukemia 
(CML) cells to the chemotherapy drugs adriamycin, paclitaxel and vincristine and 
suppression of ST6Gal1 enhanced sensitivity (Ma et al., 2014). Reciprocally, ST6Gal1 
knockdown increased the sensitivity of hepatocarcinoma cells to docetaxel treatment by 
instigating the process of apoptosis (Chen et al., 2016). 
 
Whilst there are many studies that support the oncogenic role of ST6Gal1 in cancer, 
there is also contradictory evidence to suggest that ST6Gal1 may also have tumour 
suppressor potential. Down-regulation of ST6Gal1 in colorectal cancer cell lines 
increased cell proliferation and tumour growth (Park et al., 2012). ST6Gal1 is down-
regulated in invasive bladder cancer compared to normal urothelium and ST6Gal1 
expression loss correlates with high grade, invasive clinical tumours (Wild et al., 2005). 
This expression loss is caused by aberrant ST6Gal1 promoter methylation, suggesting 








1.4 Alternative splicing in cancer  
1.4.1 One gene, multiple mRNAs 
The human genome contains around 21,000 protein-coding genes (Clamp et al., 2007), 
yet it is estimated to produce over one million different protein species (Harrison et al., 
2002; Jensen, 2004). This is because almost every human gene can produce more than 
one mRNA isoform through the use of post-translational modifications including 
alternative splicing, alternative polyadenylation, RNA editing and epigenetic modulation 
(Lander, 2011). These transcriptional modifications increase transcriptome complexity 
and expand the number of proteins encoded by the genome enormously. 
 
1.4.2 Alternative splicing 
Alternative splicing (AS) is a common post-transcriptional process that generates 
multiple distinctive mRNA transcripts from a single gene. In pre-mRNA transcripts, 
coding exons are interrupted by non-coding introns. Removal of these intronic 
sequences and the subsequent ligation of exons is achieved by the spliceosome, a large 
ribonucleoprotein (RNP) complex composed of five different small nuclear RNP (snRNP) 
subunits (U1, U2, U3, U4, U5 and U6), together with many hundreds of additional 
proteins (Chow et al., 1977). AS allows different combinations of exons in a gene to be 
joined to each other generating alternative mRNA transcripts, all of which increase 
mRNA diversity (Reviewed in (Matlin et al., 2005; Keren et al., 2010). There are several 
different types of AS events, including competing alternative 5’ and 3’ splice sites 
whereby two or more splice sites are differentially recognised at one end of an exon 
(Figure 1.7 a & b). Mutually exclusive exons are alternatively selected from two or more 
exons within the pre-mRNA (Figure 1.7 c). Exons within a gene can be included or 
skipped (Figure 1.7 d). Intronic sequences can remain within the mature mRNA transcript 
(Figure 1.7 e) and the use of alternative promoters and polyadenylation sites can 




The majority (~95%) of multi-exon genes undergo alternative splicing (Pan et al., 2008). 
AS has been observed in all tissues, can be can be cell and tissue specific and can occur 
at different developmental stages. The different translated protein isoforms often have 
distinct functions and localisations (Stamm et al., 2005). AS is a tightly regulated and 
complex process, involving hundreds of regulatory factors and proteins, such as RNA-
binding proteins, regulatory RNAs, and cis-acting RNA sequences. These cis-acting 
regulatory sequences are characterised by their location and activity and can be divided 
into four categories: exon splicing enhancers (ESEs) and silencers (ESSs) and intron 
splicing enhancers (ISEs) and silencers (ISSs). Splicing enhancers assemble to promote 
the use of a weak or regulated splice site and silencers repress the use of splice sites. 
Successful AS can depend upon the expression levels of these splicing regulators 
(Matlin et al., 2005).  
 
 
Figure 1.8 Alternative splicing events.  
Alternative splicing events and their alternative outcomes: (a) competing 5’ splice sites, 
(b) competing 3’ splice sites, (c) mutually exclusive exons, (d) cassette exons, (e) intron 
30 
 
retention, (f) alternative promoters and (g) alternative polyadenylation. Image taken form 
a review by (Rajan et al., 2009).  
 
1.4.3 Alternative splicing in prostate cancer  
Aberrant splicing is a common feature or ‘hallmark’ in cancer (Venables, 2004; Hanahan 
and Weinberg, 2011; Ladomery, 2013; Oltean and Bates, 2014). These aberrant splicing 
events can produce novel mRNA transcripts and altered transcript ratios which have 
oncogenic properties (Figure 1.9) (reviewed in (Rajan et al., 2009; Sette et al., 2013; 
Munkley et al., 2017a). As previously mentioned, AR splice variants play a major role in 
enabling prostate cancer cells to develop hormone resistance (Lu and Luo, 2013). 
Around 22 AR splice variants have been described, many of which encode protein 
isoforms, which unlike the full-length AR protein, lack the LBD and can operate in the 
absence of androgens. The most prevalent AR splice variant, ARv7 is produced by the 
inclusion of a cryptic exon (3b). Exon 3b is located within intron 3 and introduces a new 
poly (A) site, creating a truncated protein, which lacks the LBD, the target of 
enzalutamide and abiraterone treatment. Unlike full length AR, the ARv7 splice variant 
is located within the nucleus and functions independently of androgen stimulation, 










Figure 1.9 Alternative splicing in cancer.  
Changes in AS can contribute to tumour progression through the production of oncogenic 
protein isoforms. Novel protein isoforms or changes in the ratio of pre-existing isoforms 
can contribute to changes in cell phenotype. Image taken from (Pajares et al., 2007).  
 
There is increasing evidence which suggests ARv7 expression could be used as a 
potential predictive biomarker and a therapeutic target in advanced prostate cancer. 
Expression levels of ARv7 RNA transcripts are higher in CRPC tumours compared to 
hormone-naïve tumours (Hu et al., 2009; Hornberg et al., 2011; Welti et al., 2016). 
Patients expressing high levels of ARv7 transcripts also have significantly shorter 
survival than those with low expression (Hornberg et al., 2011; Welti et al., 2016; Qu et 
al., 2017). The expression and localisation of ARv7 in CTCs from patients with CRPC is 
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associated with resistance to enzalutamide and abiraterone (Antonarakis et al., 2014) 
but is not associated with resistance to taxane based chemotherapy (docetaxel or 
cabazitaxel) (Antonarakis et al., 2015; Onstenk et al., 2015; van Soest et al., 2015). ARv7 
detection shows promise as a biomarker of CRPC poor prognosis, and as a predictive 
marker of enzalutamide or abiraterone resistance (Antonarakis, 2015).  
 
Cancer cells can also exploit the tightly regulated process of alternative splicing to their 
advantage by disrupting core spliceosome components and regulators. Mis-regulation of 
several splicing regulators has been observed in clinical PCa tumours including over-
expression of the RNA binding proteins SAM68, heterogeneous nuclear 
ribonucleoprotein A2/B1 (HNRNPA2B1), DEAD-box helicase 5 (DDX5, also known as 
p68) and transformer 2 Beta Homolog (Tra2-β) (Busa et al., 2007; Clark et al., 2008; 
Rajan et al., 2008; Diao et al., 2015; Stockley et al., 2015). Serine-arginine protein kinase 
1 (SRPK1), a splicing regulator of VEGF is u p-regulated in PCa and correlates with 
disease stage and invasion (Bullock et al., 2016). Increased expression of the RNA 
splicing factor serine/arginine repetitive matrix 4 (SRRM4) drives the trans-differentiation 
to neuroendocrine PCa (Zhang et al., 2015b; Li et al., 2017).  
 
Recent advances in genome annotation and high-throughput technologies such as 
splicing-specific microarrays and RNA sequencing, have highlighted a number of genes 
that change their splice isoform expression in PCa compared to normal tissue (Rajan et 
al., 2011; Erho et al., 2012; Srinivasan et al., 2012). Steroid hormones have been shown 
to regulate the production of novel isoforms in hormone responsive cancer. Estrogen 
stimulated novel mRNA isoforms have been shown to affect cell mobility, migration and 
division in breast cancer which correlates with disease prognosis (Dutertre et al., 
2010). Androgen regulated alternative mRNA isoforms have also previously been 
described (Rajan et al., 2011). The tumour suppressor gene tuberous sclerosis complex 
2 (TSC2) produces an alternative mRNA isoform derived from an androgen-regulated 
alternative promoter (Rajan et al., 2011). TSC2 isoform A has been shown to increase 
cell proliferation in PCa cells (Munkley et al., 2014). Androgens induce the expression of 
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a novel splice variant of the ST6GalNAc1 protein in PCa cells. This androgen regulated 
splice variant encodes a shorter protein isoform which is missing 132 amino acids from 
the N-terminal, but is still fully functional as a sialyltransferase. Expression of this 
ST6GalNAc1 isoform in PCa cells reduces adhesion, increases motility and promotes a 
transition towards a mesenchymal like phenotype (Munkley et al., 2015b). Androgen 
regulated phosphodiesterase 4D7 (PDE4D) alternative promoter isoform switches have 
also been described; PDE4D7 isoform expression positively correlates 
with primary tumour development but is significantly decreased in CRPC (Bottcher et al., 
2015). The PDE4D5 and PDE4D9 isoforms are significantly down-regulated in primary 
PCa and CRPC compared to benign samples (Bottcher et al., 2016). This evidence 
suggests that the AR can switch the pattern of isoforms produced in prostate cancer cells 
towards those with pro-oncogenic functions. 
 
1.5 Relaxin peptide hormones  
1.5.1 The relaxin gene family  
Relaxins are peptide hormones that belong to the insulin-like super family. In humans, 
the family consists of seven cystine-rich peptides; relaxin 1, 2 and 3 (RLN1, RLN2 and 
RLN3) and the insulin-like peptides INSL3, INSL4, INSL5 and INSL6. The evolutionary 
history of this family originates from a common ancestor - insulin. Early in the chordate 
lineage, the peptide relaxin 3 (RLN3) evolved and became the ancestral gene from which 
successive duplication events give rise to other members of the relaxin family. RLN3 and 
INSL5 are closely related to each other and cluster within a sub-tree that is distinct from 
the group comprising RLN1, RLN2, INSL3, INSL4, and INSL6 (Figure 1.10) (Wilkinson 







1.5.2 The structure and function of relaxin peptide hormones  
1.5.2.1  RLN1 and RLN2 
In higher primates, the RLN1 gene is thought to be the result of an ancestral duplication 
of the human RLN2 gene on chromosome 9 (location 9p24) (Crawford et al., 1984; 
Arroyo et al., 2014), as other mammals have only have RLN2. The RLN1 and RLN2 
genes share 90% DNA sequence similarity and have 82% predicted sequence identity 
at amino acid level. All relaxin family peptides are synthesised as pro-hormones with four 
distinct regions: a signal peptide, a B-chain a C-chain and a COOH-terminal A-chain 
(Hudson et al., 1981; Haley et al., 1982). The signal peptide is required for secretion of 
the immature pre-prohormone, whilst the C-chain facilitates protein folding. Following 
secretion, enzymatic removal of the C-peptide produces an asymmetrical mature peptide 
heterodimer (Marriott et al., 1992). The relaxin peptides bind to G-protein-coupled-
receptors (GPCRs). Both RLN1 and RLN2 peptides signal through the leucine-rich-
repeat relaxin family GCPR peptide receptor RXFP1 (previously known as LGR7) (Hsu 
et al., 2002). Relaxin stimulation of RXFP1 can activate several signalling pathways 
including the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway, 
the mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 
(MAPK/ERK1/2) pathway, the PI3K/Akt pathway and the notch pathway (Zhang et al., 
2002; Nguyen et al., 2003; Sun et al., 2003; Halls et al., 2006; Halls et al., 2007; Halls et 




Figure 1.10 Phylogenetic relationships of the relaxin-family peptides. A simplified 
phylogenetic relationship between relaxin family peptides, insulin, and insulin-like 
peptides. RLN3 divergence and successive duplication events give rise to the relaxin 
family. Image taken from (Ivell et al., 2011).  
 
In humans, RLN2 is predominantly known for its roles in reproduction and pregnancy, 
however it is now clear that it performs vital roles in many other physiological functions. 
In females, RLN2 is expressed intermittently by the corpus luteum during the luteal phase 
of the menstrual cycle and by the corpus luteum and placenta during pregnancy (Ivell et 
al., 1989). During pregnancy, RLN2 acts by promoting cervical development, remodelling 
and growth of the uterus and in the development of mammary nipples. In addition, RLN2 
has also been shown to play an important role in pregnancy related cardiovascular 
adaptations, such as increased plasma volume, cardiac output and heart rate, as well as 
decreased blood pressure and vascular resistance (reviewed in (Bathgate et al., 2013). 
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In males, RLN2 is produced by the secretory epithelial cell of the prostate gland and 
secreted into the seminal fluid (Yki-Jarvinen et al., 1983; Ivell et al., 1989). Although the 
function of RLN2 in males is not entirely understood, it is thought to play a role in prostate 
growth, development of the reproductive tract and sperm motility as the prostate, testis 
and sperm express the RXFP1 receptor (Hsu et al., 2002; Samuel et al., 2003; Ferlin et 
al., 2012). Unlike RLN2, the function of the RLN1 remains unclear. Synthetic RLN1 
peptides have been shown to activate the RXFP1 receptor and expression of RLN1 
mRNA has been detected in prostate cancer cells (Garibay-Tupas et al., 2000).   
 
1.5.2.2  RLN3 
The human RLN3 gene was first discovered in 2002 (Bathgate et al., 2002) and is located 
on chromosome 19 (19p13.2). RLN3 has a low overall sequence identity to RLN1 (26%) 
and RLN2 (22%) and is more structurally like INSL5, with a shorter C-chain. RLN3 
signals through the RXFP3 receptor but can also activate RXFP1 and RXFP4 receptors 
(Hsu et al., 2002; Liu et al., 2003a; Liu et al., 2003b). Unlike the other relaxin family 
members, RLN3 is known to be a neuropeptide. Highest RLN3 expression levels are 
found in the central nervous system (Smith et al., 2011; Bathgate et al., 2013), but low 
levels of RLN3 and the receptors RXFP3 and RXFP4 have also been detected in the 
testes and stromal cells of the prostate (Silvertown et al., 2010). Although the exact 
physiological mechanisms of RLN3 action in humans remain unclear, recent studies in 
mice have suggested that RLN3 plays a role in arousal, feeding, anxiety and stress and 
drug addiction (Ryan et al., 2013; Smith et al., 2014; Hosken et al., 2015; Zhang et al., 
2015a; Shirahase et al., 2016).    
 
1.5.3 The role of relaxins in prostate cancer 
Relaxin 2 has been shown to promote cancer progression in multiple cancers including 
breast cancer (Binder et al., 2004), thyroid cancer (Bialek et al., 2011), endometrial 
cancer (Kamat et al., 2006), osteosarcoma (Ma et al., 2013; Ren et al., 2015) and 
prostate cancer (Feng et al., 2007; Feng et al., 2009). In PCa, RLN2 expression is 
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elevated relative to BPH samples (Vinall et al., 2011). RLN2 expression is negatively 
regulated by androgens and increases during the progression of PCa to androgen 
independence by promoting tumour growth and vascularisation (Silvertown et al., 2006; 
Thompson et al., 2006). RLN2 expression is also increased in PCa cells undergoing 
neuroendocrine differentiation (Figueiredo et al., 2005). RNAi mediated RXFP1 
knockdown and inhibition RLN2/ RXFP1 signalling impairs PCa tumour growth and 
invasion capabilities (Feng et al., 2007; Silvertown et al., 2007). A synthetic RLN2 
antagonist (AT-001) has been shown to reduce the growth of human CRPC xenografts 
by up to 60% (Neschadim et al., 2014). Combined inhibition of the PKA and NF-κB 
signalling pathways, which are activated by RLN2, reduced PCa tumour growth and 
induced apoptosis (Vinall et al., 2011).   
 
Although there is a clear role for RLN2 in the progression of prostate cancer, the role of 
RLN1 is yet to be investigated. Expression levels of RLN1 are up-regulated in LNCaP 
cells in response to androgens (Tevz et al., 2016) and RLN1 is abundantly expressed in 
PCa LNCaP cell lines, normal prostate tissue and PCa tissue (Hansell et al., 1991; 
Gunnersen et al., 1996; Tevz et al., 2016). Recently, a novel fusion transcript has been 
identified by next generation sequencing which contains incomplete sequences of both 
RLN1 and RLN2. This fusion transcript is expressed in PCa LNCaP cells and normal 
prostate tissue and is down-regulated by androgens. The fusion is predicted to encode 
a protein which contains intact RLN2 functional domains but has lost the signalling 









1.6 Research aims and objectives  
1.6.1 Preliminary data 
Prior to the start of my project RNA sequencing had been used to analyse a single pooled 
library of PCa LNCaP cells grown in two different media condition: steroid deplete (SD) 
media and synthetic androgen (10nM R1881) stimulated (A+) media for 24 hours. Our 
collaborator Dr Ian Mills correlated the up-regulated genes with associated AR binding 
sites in the genome (Massie et al., 2011). This highlighted three genes, two of which 
have well known roles in PCa; ATP-binding cassette, sub-family C, member 4 (ABBC4) 
(Ho et al., 2008) and calcium/calmodulin-dependent protein kinase 2, beta (CAMKK2) 
(Massie et al., 2011); and a less characterised gene called ST6GALNac1. Work from Dr 
Jennifer Munkley has shown that ST6GalNAc1 is rapidly induced within the first three 
hours of androgen stimulation and increased expression is also observed in primary 
prostate tumours compared to non-malignant prostate tissue. Androgens also induced 
the expression of a shorter isoform of ST6GalNAc1, which when over-expressed in 
DU145 cells reduced adhesion and increased the rate of cell migration. Changes in the 
expression of key epithelial to mesenchymal transition (EMT) markers were also 
observed suggesting that the shorter isoform may induce a mesenchymal switch in 
prostate cancer, promoting cell invasion and metastasis (Munkley et al., 2015b). 
 
The original RNA sequencing analysis was carried out on a single pooled library and 
there were quite a high level of false positives. To remedy this, the RNA sequencing was 
repeated in separate triplicate samples of LNCaP cells again grown in steroid deplete 
(SD) and androgen stimulated (A+) conditions for 24 hours. The data produced showed 
changes in gene expression and mRNA isoform switches that were regulated by 
androgens. To identify changes that were clinically relevant, a collaborator in Oslo, Dr 
Daniel Vodak correlated the RNA sequencing data with clinical RNA sequencing data 





1.6.2 Research aims and objective 
The hypothesis of my PhD project was that exposure to androgens will change gene 
transcription and drive the production of different mRNA isoforms in prostate cancer cells 
which will be clinically relevant. The main objective was to use the correlated the RNA 
sequencing datasets to identify and characterise clinically relevant gene expression 
changes and alternative events.  
 
The combined RNA sequencing identified almost 700 androgen reciprocally regulated 
gene expression changes and 73 alternative events (56 alternative promoters, 4 
alternative 3’ ends and 13 alternative splicing events). To focus the project, gene 
ontology (GO) analysis and a meta-analysis was carried out using publically available 
datasets. This identified the PCa glycoproteome and specifically a core of seven 
glycosylation enzymes that significantly changed expression in clinical PCa for further 
investigation. Of the alternative events, androgen regulated alternative promoter usage 
were identified for two relaxin genes RLN1 and RLN2. Main aims of my project were to 
establish the downstream effects and functional properties of one of the glycosylation 
enzymes, the sialytransferase enzyme ST6Gal1, and the alternative isoforms of RLN1 




























Chapter 2 Materials and Methods 
 
2.1  General laboratory practice  
 
All experimental procedures were conducted in accordance with Newcastle University 
standards for safe working with chemical substances in laboratories, which comply with 
the Control of Substances Hazardous to Health (COSHH) regulations. Tissue culture 
experiments were carried out in compliance with regulations for containment of class II 
pathogens. 
 
2.2 Media and solutions  
All media and solutions were prepared in Type 1 (18.2 Mega Ohms) Ultrapure H20 (dH2O) 
produced by Barnstead Nanopure (Thermo Scientific) filtration systems and were 
sterilised by autoclaving (Astell). 
Luria Bertani (LB) medium (500 ml): 
 5 g sodium chloride (Sigma S3014) 
 5 g tryptone (Fisher Scientific BPE1421) 
 2.5 g yeast extract (Fisher Scientific BP1422) 
 to 500 ml with sterile dH20 
Luria Bertani (LB) agar (500 ml):  
 5 g chloride (Sigma S3014) 
 5 g tryptone (Fisher Scientific BPE1421) 
 2.5 g yeast extract (Fisher Scientific BP1422) 
 7.5 g agar (Fisher Scientific BP1423) 
 to 500 ml with sterile dH20 
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Media was supplemented with 50 µg/ml ampicillin (Sigma A5354) as appropriate. 
1X phosphate-buffered saline (PBS): 
 1 x 0.1M PBS tablet (Sigma P4417) 
 to 200 ml with dH20 
50X tris-acetate-EDTA (TAE): 
 8 g paraformaldehyde (Sigma P6148)   
 to 200 ml 1X PBS 
Tris buffered saline with Tween 20 (TBS-T): 
 8.75 g sodium chloride (Sigma S3014) 
6.5 g Tris base (Sigma T1503) 
0.2 % Tween 20 (Sigma P9416) 
to 1000 ml with dH20 - pH to 7.5 
Block for protein Western immunoblotting analyses: 
1 g skimmed dried milk powder (Asda)  
to 20 ml with TBS-T 
20% sodium dodecyl sulphate (SDS): 
 20 g sodium dodecyl sulphate (Sigma 71725) 






1X Western blot transfer buffer 
 2.9 g glycine (Sigma G8898) 
 5.8 g Tris-base (Sigma T1503) 
 1.85 ml 20% SDS 
200 ml methanol (VWR Chemicals K977)  
 to 1000 ml with dH20 
2X sodium dodecyl sulphate (SDS) sample loading buffer: 
100 mM Tris-HCl (Sigma T5941) - pH 6.8 
20 % glycerol (Sigma G9012) 
4 % SDS 
0.2 % bromophenol blue (Sigma B0126) 
200 mM DL-Dithiothreitol (DTT) (Sigma D0632) 
10X SDS-polyacrylamide gel electrophoresis (PAGE) running buffer: 
30.2 g Tris base (Sigma T1503) 
50 ml 20 % SDS 
188 g glycine (Sigma G8898) 
to 1000 ml with dH20 
4% (w/v) paraformaldehyde (PFA) 
 8g paraformaldehyde (Sigma P6148) 




3% (w/v) bovine serum albumin (BSA) 
 1.5 g bovine serum albumin (Thermo Scientific 10270106) 
to 50 ml with 1X PBS 
1X Laemmli running buffer 
 3.02 g Tris-base (Sigma T1530) 
 18.8 g glycine (Sigma G8898) – pH 8.3 
 to 1000 ml with dH20 
1M sodium hydrogen phosphate 
 53.61 g sodium hydrogen phosphate Sigma D5670) 
 to 200 ml with dH20 
1M monobasic sodium phosphate 
 119.98 g monobasic sodium phosphate (Fluka 71505) 
 to 500 ml with dH20 
0.1M sodium phosphate buffer pH 8 
 93.2 ml 1M sodium hydrogen phosphate 
 6.8 ml 1M monobasic sodium phosphate 







2.3 Standard molecular biology techniques  
2.3.1 Polymerase chain reactions (PCR) 
2.3.1.1  Colony PCR  
PCR screening of transformed bacterial colonies was performed using GoTaq G2 DNA 
polymerase (Promega M7845). The template was a single bacterial colony (picked using 
a sterile 20 μl filter tip). Primers used are listed in appendix B.  
 















Reagent  Volume (μl) 
5X green GoTaq buffer 5 
dNTPs (10 mM) 0.5 
Forward primer (10μM) 0.5 
Reverse primer (10μM)  0.5 
GoTaq G2 DNA polymerase 0.125 
RNAse-free H20 to 25 
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PCR was carried out using the SensoQuest Thermal Cycler (Geneflow) as follows: 
Stage Temperature Time 
1. Initial denaturation 95 °C 5 minutes 
2. Denaturation 95 °C 30 seconds 
3. Annealing 58 °C 30 seconds 
4. Extension 72 °C variable depending on product 
size (cycle to step 2 x 29) 
5. Final Extension  72 °C 5 minutes 
6. Cooling 4 °C ∞ 
 
Table 2.2  Thermocycler programme for colony PCR. 
 
The size of the PCR products was verified by agarose-TAE gel electrophoresis. 
 
2.3.1.2   Reverse transcription PCR (RT-PCR)  
cDNA was transcribed from RNA using SuperScript VILO cDNA Synthesis Kit (Thermo 
Scientific 11754-250), following the standard manufacturer’s instruction (see section 
2.3.3 RNA extraction and cDNA synthesis). The cDNA was used as a template for PCR 
amplification using GoTaq G2 DNA polymerase (Promega M7845). Primers used are 






Reaction mixes were set up as follows: 
Reagent  Volume (μl) 
5X colourless GoTaq buffer 5 
dNTPs (10 mM) 0.5 
Forward primer (10μM) 0.5 
Reverse primer (10μM)  0.5 
Alternative primer (10μM) 0.5 
cDNA template (50ng/μl) 2 
GoTaq G2 DNA polymerase 0.125 
RNAse-free H20 to 25 
 












PCR was carried out using the SensoQuest Thermal Cycler (Geneflow) as follows: 
 
Stage Temperature Time 
1. Initial denaturation 95 °C 2 minutes 
2. Denaturation 95 °C 30 seconds 
3. Annealing 58 °C 30 seconds 
4. Extension 72 °C variable depending on product 
size (cycle to step 2 x 29) 
5. Final Extension  72 °C 5 minutes 
6. Cooling 4 °C ∞ 
 
Table 2.4  Thermocycler programme for RT-PCR. 
 











2.3.1.3  Cloning PCR (nested PCR) 
Initial PCR reactions were performed using Phusion High-Fidelity DNA polymerase 
(Thermo Scientific F-530S). Primers used are listed in Appendix B.  
 
Reaction mixes were set up as follows: 
Reagent  Volume (μl) 
5X HF reaction buffer 10 
dNTPs (10 mM) 1 
Forward primer (10μM) 2.5 
Reverse primer (10μM)  2.5 
DMSO 1.5 
cDNA template (50ng/μl) 4 
RNAse-free H20 to 50 
Phusion DNA polymerase 0.5 
 








PCR was carried out using the SensoQuest Thermal Cycler (Geneflow) as follows: 
Stage Temperature Time 
1. Initial denaturation 98 °C 30 seconds 
2. Denaturation 98 °C 20 seconds 
3. Annealing/Extension 72 °C 45 seconds (cycle to step 2 x 34) 
4. Final Extension  72 °C 10 minutes 
5. Cooling 4 °C ∞ 
 
Table 2.6  2-step thermocycler programme for initial nested PCR. 
 
PCR products were column purified using QIAquick PCR Purification Kit (Qiagen 28106), 
following the standard manufacturer’s instruction and eluted into 30 μl dH2O. The PCR 
products were quantified and used in a subsequent PCR reaction with primers deigned 
with specific restriction sites. The PCR reaction was performed using Phusion High-











Reaction mixes were set up as follows: 
Reagent  Volume (μl) 
5X HF reaction buffer 10 
dNTPs (10 mM) 1 
Forward primer (10μM) 2.5 
Reverse primer (10μM)  2.5 
DNA template (50ng/μl) - 
RNAse-free H20 to 50 
Phusion DNA polymerase 0.5 
 













PCR was carried out using the SensoQuest Thermal Cycler (Geneflow) as follows: 
Stage Temperature Time 
1. Initial denaturation 98 °C 30 seconds 
2. Denaturation 98 °C 10 seconds 
3. Annealing 64 °C 20 seconds 
4. Extension 72 °C 30 seconds (cycle to step 2 x 31) 
5. Final Extension  72 °C 5 minutes 
6. Cooling 4 °C ∞ 
 
Table 2.8  Thermocycler programme for cloning PCR. 
 
The size of the PCR products was verified by agarose-TAE gel electrophoresis. DNA 
fragments were purified from the agarose gel using the QIAquick Gel Extraction Kit 
(Qiagen 28706) according to manufacturer’s instructions and eluted into 30 μl dH2O. 
 
2.3.1.4  Quantitative real-time PCR (qPCR) 
Relative gene expression was determined by quantitative real-time PCR (qPCR) using 
a SYBR Green PCR Master Mix Kit (Applied Biosystems 4309155) and the QuantStudio 
7 Flex Real-Time PCR System (Applied Biosystems). cDNA was synthesised as 






1X SYBR Green reaction mixes were set up as follows: 
Reagent  Volume (μl) 
2X SYBR Green PCR master mix 5 
Forward primer (10μM) 1 
Reverse primer (10μM)  1 
RNAse-free H20 2 
TOTAL 9 
 
Table 2.9  Standard 1X SYBR Green PCR reaction mix for quantitative PCR 
(qPCR). 
 
For each reaction, 9μl of PCR master mix was added per well to a 384-well qPCR plate, 
1μl of the diluted cDNA was added per well and the plate was sealed with MicroAmp 
Optical Adhesive Film (Thermo Scientific 4311971). All qPCR experiments were 
performed using 3 biological replicates and a ‘no template control’ (NTC) reaction was 










The thermo-cycling conditions used were as follows:  
Stage Temperature Time 
1. Hold 95 °C 20 seconds 
2. PCR  95 °C 1 second 
 60 °C 60 seconds (cycle to step 2 x 39) 
3. Melt curve  95 °C 15 seconds 
 60 °C 1 minute 
4. Dissociation 95 °C 15 seconds 
 
Table 2.10  Thermocycler programme for SYBR Green quantitative PCR (qPCR). 
 
Gene expression was calculated relative to three housekeeping genes β-Actin (A CTB), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-Tubulin (TUBB). Ct values 
for each sample were calculated using QuantStuio 7 System Software v1.0 (Applied 
Biosystems). Melt curves were checked to ensure a single product and NTC’s checked 
for contamination. Relative mRNA expression was calculated using the 2-ΔΔCt method. 









2.3.2 Gel electrophoresis  
2.3.2.1  Agarose TAE gel electrophoresis 
DNA samples containing 5X green GoTaq reaction buffer were fractionated by 
submerged horizontal 1.3% w/v agarose gel electrophoresis in 1X TAE buffer at a 
constant voltage of 80-100 volts (Owl EC-105 power supply).  
1.2% w/v agarose gels were cast as follows:  
1.2 g molecular grade agarose (Bio-line 41025)  
1X TAE buffer  
70 μl 1000X Gel-red nucleic acid gel stain (Biotium 41003)  
Sizes of DNA fragments were determined by comparison with a 1Kb Plus DNA ladder 
(Thermo Scientific 10787018; sizes are 12-2 Kb in evenly spaced 1 Kb intervals and 
1650bp, 850bp, 650bp, 400bp, 300bp, 200bp, 100bp). Bands were visualised under 
ultraviolet light using the GelDoc-IT Imaging System (UVP). Images were printed using 
a Digital Graphic Printer (Sony UP-D897).   
 
2.3.2.2  Capillary gel electrophoresis (QIAxcel)  
RT-PCR samples were diluted with 1:1 with QIAxcel DNA dilution buffer (Qiagen 929601) 
and electrophoresed using the QIAxcel multi-capillary electrophoresis system for 
analysis. Samples were analysed using the QIAxcel Biocalculator Software to determine 
the size of each PCR product and the relative concentration of each band (ng/µl). 
 
 2.3.2.3  SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples for analysis by SDS-PAGE were pulse sonicated to disrupt any intact 
DNA and denatured at 100°C for 5 minutes and centrifuged briefly before loading onto 
an SDS-PAGE gel. Gels were made with a 4% stacking gel (0.125 mM Tris pH 6.8, 0.1% 
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SDS, 0.1% ammonium persulphate (APS), 0.2% tetramethylethylenediamine (TEMED) 
and 4% acrylamide) with either a 8%, 10% or 12% acrylamide resolving gel (375 mM 
Tris pH 8.8, 0.1% SDS, 0.1% APS, 0.2% TEMED and either 8%, 10% or 12% acrylamide) 
depending on the sizes of proteins to be resolved. SDS-PAGE gels were run in 1X SDS-
PAGE running buffer at 100 volts (Bio-Rad Pac 200) until the dye front reached the 
bottom of the gel. Protein sizes were estimated using Page Ruler Plus Pre-Stained 
Protein Ladder (Thermo Scientific 26619) 10 to 250 kDa.  
 
2.3.3 RNA extraction and cDNA synthesis 
Total RNA was extracted from cultured cells using TRIzol reagent (Thermo Scientific 
15596026), following the manufacturer’s instructions. Briefly, cell pellets were re-
suspended in 1 ml TRIzol reagent and incubated at room temperature for 5 minutes. 200 
µl of chloroform (Sigma C2432) was added and the samples vortexed for 15 seconds to 
mix. After further incubation at room temperature for 3 minutes, the samples were 
centrifuged at 9,000 rpm for 15 minutes in a cooled centrifuge (4°C) (Eppendorf 5417R). 
The top aqueous layer was transferred to a new tube and 500 µl of 100% isopropanol 
(VWR Chemicals 20880.320) and 1 µl of GlycoBlue Coprecipitant (Thermo Scientific 
AM9516) were added to precipitate the RNA. The samples were incubated at room 
temperature for 10 minutes and then centrifuged again at 9,000 rpm for 15 minutes in a 
cooled centrifuge (4°C). The supernatant was removed and the RNA pellet washed in 
75% ethanol (VWR Chemicals 20821.330). The RNA pellet was centrifuged at 5,500 rpm 
for 5 minutes in a cooled centrifuge (4°C). The supernatant was removed and the RNA 
pellet was left to air dry at room temperature (5-10 minutes). The RNA pellet was re-
suspended in 30 µl nuclease free dH2O and incubated at 55oC for 10 minutes. RNA was 
quantified using a NanoDrop Spectrophotometer (NanoDrop Technologies). RNA not 





RNA was treated with DNase I (Sigma 10104159001) and cDNA was transcribed from 
RNA using SuperScript VILO cDNA Synthesis Kit (Thermo Scientific 11754-250), 
following the standard manufacturer’s instruction. Reaction mixes were set up as follows: 
 
Reagent  Volume (μl) 
5X VILO reaction mix 1 
10X SuperScript enzyme mix 0.5 
1 µg RNA - 
RNAse-free H20 to 5 
 
Table 2.11  Standard SuperScript VILO cDNA synthesis reaction mix. 
 
 
PCR was carried out using the SensoQuest Thermal Cycler (Geneflow) as follows: 
Stage Temperature Time 
Initial incubation 25 °C 10 minutes 
RT Incubation 42 °C 2 hours 
Termination  85 °C 5 minutes 
Cooling 4 °C ∞ 
 




2.4 Molecular cloning 
2.4.1 Restriction digests 
Restriction digests were performed on purified PCR products and selected vectors. For 
each reaction, approximately 1 µg of vector or PCR product was digested using 10 units 
of the appropriate restriction enzymes with the appropriate buffer (Promega or New 
England Biolabs) in a total volume of 50 μl. Samples were incubated at 37°C for 2-3 
hours (or the optimum temperature for the enzyme suggested by the manufacturer), 
followed by an incubation at 65°C for 10 minutes to inactivate enzyme activity. For 
removal of any unincorporated dNTPs, enzymes and buffers the samples were purified 
using a QIAquick PCR Purification Kit (Qiagen 28106) according to the manufacturer’s 
instructions and eluted into 30 µl dH2O. The DNA concentration of each sample after the 
restriction digest was determined using a Nanodrop Spectrophotometer.  Genes, vectors, 
restriction enzymes and recleave enzymes are listed in Table 2.13 
 
Gene Vector Restriction sites Recleave  
ST6Gal1 p3xFLAG CMV-10 (Sigma 
E7658) 
NotI / BamHI XbaI 
ST6Gal1 pcDNA4/TO (Thermo Scientific 
V102020) 
HindIII / XbaI BamHI 
ST6Gal1 pcDNA5/FRT/TO (Thermo 
Scientific V652020) 
BamHI / XhoI NotI 
RLN1 
promoter 2 
pET-32a (+) (Merk Millipore 
69016) 
BamHI / XhoI HindIII 
RLN1 
promoter 2 
pGEX-5X-1 (GE Life Sciences 
28-9545-53) 
























Table 2.13 Vectors and restriction sites used for cloning. 
 
2.4.2 Antarctic phosphatase treatment 
All plasmids were further treated with Antarctic Phosphatase (New England Biolabs 
M0289S) to prevent re-circularisation during ligation. For this the cut plasmids were 
combined with 5 units of Antarctic phosphatase and Antarctic phosphatase reaction 
buffer in a total volume of 100 µl. Samples were incubated at 37°C for 1 hour and the 
enzyme inactivated at 65°C for 10 minutes. For removal of any enzymes and buffers the 
samples were purified using a QIAquick PCR Purification Kit (Qiagen 28106) according 
to the manufacturer’s instructions and eluted into 30 µl dH2O. The concentration of each 








2.4.3 Ligation  
Following purification and quantification of the digested PCR products and plasmids, the 
two fragments were ligated using T4 DNA Ligase (Promega M1801). The following 
equation was used to determine the concentration of DNA insert when using a 1:10 molar 
ratio of plasmid to insert DNA: 
 
ng of vector x kb size of insert   x    molar ratio of insert     =   ng of DNA insert 
       kb size of plasmid                                         plasmid                                       
 
 
The appropriate volume of plasmid and insert DNA were ligated in a 20 μl reaction 
volume including 1 unit of T4 DNA Ligase and T4 DNA Ligase Buffer. Ligations were 
incubated at 22°C for 3 hours in the SensoQuest Thermal Cycler (Geneflow). To remove 
any non-digested or re-circularized plasmid background the ligation mixes were re-
cleaved with restriction enzymes. Re-cleavage mixes were incubated at 37°C for 2 hours, 
followed by heat inactivation at 65°C for 15 minutes.  
  
2.4.4 Heat shock transformation 
Ligated plasmids were transformed in E. coli DH5α competent cells using the heat shock 
protocol. 10 µl of ligated plasmids and 100 µl E. coli DH5α cells were incubated on ice 
for 30 minutes. The samples were placed in a heat block at 42°C for 2 minutes then 
transferred back to ice for 5 minutes. Cells were allowed to recover in 300 µl of LB broth 
at 37°C in a MaxQ 8000 shaker (Thermo Fisher Scientific) at 225 rpm for 30 minutes. LB 
agar plates containing 50µg/ml ampicillin were used to grow and select competent cells 
which had been transformed. The LB agar plates were incubated at 37°C overnight. 
Single colonies from the plates were picked and grown in 5 ml LB broth plus 50 µg/ml 
ampicillin and the tubes were incubated at 37°C in the shaker overnight. The cultures 
were centrifuged at 5,000 rpm for 5 minutes to pellet the cells (Rotanta 460R Benchtop 
Centrifuge). Plasmid DNA was extracted from the cells using a QIAprep Miniprep Kit 
(Qiagen 27106) following manufacturer’s instructions.  
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2.4.5 DNA sequencing  
Plasmids were sent for DNA sequencing at Source Bioscience Lifescience Services to 
confirm the correct sequences had been cloned.   
 
2.5 Protein methods 
2.5.1 Isolation of protein extracts from cultured cells 
To isolate protein extracts from cultured cells the culture media was removed and cells 
were washed in PBS to remove any remaining serum. Following addition of 1 ml of 1X 
Trypsin-EDTA (Thermo Scientific 25300054), cells were incubated at 37°C for 5 minutes. 
Cell suspensions were harvested in fresh media, and samples pelleted at 3,000 rpm for 
10 minutes. Cell pellets were re-suspended in 2X SDS sample loading buffer. 
 
2.5.2 Bacterial expression of fusion proteins  
For expression of glutathione s-transferase (GST) and histidine-tagged fusion proteins, 
E. coli BL21 competent cells were transformed with the appropriate plasmid encoding 
the fusion protein. 1 μl of plasmid DNA and 100 µ of competent E. coli BL21 competent 
cells were incubated on ice for 20 minutes. Samples were placed in a heat block at 42°C 
for 1 minute then transferred back to ice for 5 minutes. Cells were allowed to recover in 
1 ml of LB broth at 37°C in a MaxQ 8000 shaker (Thermo Scientific) at 225 rpm for 1 
hour. LB agar plates containing 50µg/ml ampicillin were used to grow and select 
competent cells which had been transformed. The LB agar plates were incubated at 37°C 
overnight. For protein expression, single colonies from the plates were picked and grown 
in 5 ml LB broth plus 50 µg/ml ampicillin and the tubes were incubated at 37°C in the 
shaker overnight. 100ml of LB broth was inoculated with 1ml of the overnight culture. 
These cultures were incubated with shaking at 37°C for 3 hours or until an optical density 
of 0.5 at A600nm was reached. At this point 500 µl samples of the cultures were taken 
to compare with the protein expression profile after induction. To induce protein 
expression from the plasmids, isopropyl β-D-1-thiogalactopyranoside (IPTG) (Sigma 
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I6758) was added to the 100 ml cultures to a final concentration of 1 mM and incubated 
at 37°C for a further 3 hours. After induction, further 500 µl samples were taken and the 
remaining cultures were centrifuged in a cooled centrifuge (4°C) at 3,000 rpm for 10 
minutes and the supernatants removed. To test for the induction of protein expression, 
the 500 µl samples taken before and after induction were analysed by SDS-PAGE, 
checking for the presence of fusion protein in the post induction sample. 
 
2.5.3 Purification of fusion proteins 
2.5.3.1 Glutathione agarose purification of GST-tagged fusion peptide 
The bacterial cell pellets containing the GST-fusion proteins were re-suspended in 10 ml 
1X PBS. 2 mg of Lysozyme (Sigma L1667) was added and the samples were incubated 
at room temperature for 20 minutes to lyse the cells. The samples were then pulse 
sonicated on ice to disrupt intact DNA. 1mM dithiothreitol (DTT) (Thermo Scientific 
R0861), 2% Triton-X 100 (Plusone 17-1315-01), 1X phenylmethanesulfonyl fluoride 
(PMSF) (Sigma P7626) and 200 units of DNase I (Sigma 10104159001) were added to 
the samples which were incubated with shaking at room temperature for 30 minutes. 5 
ml 1M potassium chloride was added and the sample volume was made up to 20 ml with 
1X PBS. The samples were pulse sonicated on ice and then freeze thawed in an ethanol 
dry ice bath. At this point, 500 µl samples were taken to assess the solubility of the fusion 
protein for purification under non-denaturing conditions. The remaining sample was 
centrifuged in a cooled centrifuge (4°C) at 3,000 rpm for 10 minutes, retaining the 
supernatant and discarding the pellet containing any insoluble material. The samples 
from before and after centrifugation were analysed by SDS-PAGE, examining for the 
presence of the fusion protein in the supernatant after centrifugation. For purification of 
the peptide, 50 mg of glutathione agarose (Sigma G4510) was re-suspended in 1 ml 
dH2O and incubated at room temperature for 2 hours with rotation.  The glutathione 
agarose was washed four times in 1X PBS and after the last wash re-suspended in an 
equal volume of PBS to create 50 % slurry. 300 μl of the slurry was added to 10 ml of 
the cell lysates containing the GST-fusion proteins and incubated at 4°C with rotation for 
30 minutes. Samples were centrifuged at 3,000 rpm for 5 minutes and the supernatants 
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removed. Samples were washed six times in 1ml of wash buffer. The glutathione agarose 
with the GST-fusion protein attached were re-suspended in an equal volume of PBS and 
stored at 4°C. 
 
2.3.5.2  NiCAM resin purification of histidine-tagged fusion peptide  
The bacterial pellets containing the histidine tagged fusion proteins were re-suspended 
in 10 ml Equilibration Buffer (50 mM sodium phosphate pH 8.0, 0.3 M sodium chloride 
and 10 mM imidazole). 2 mg of Lysozyme (Sigma L1667) was added to each sample 
and incubated for 20 minutes at room temperature. Samples were then pulse sonicated 
on ice and 200 units of DNase I (Sigma 10104159001) was added and incubated with 
shaking at room temperature for 30 minutes. The samples were sonicated again and 
freeze-thawed between -80°C and room temperature. The samples were again pulse 
sonicated on ice and then freeze thawed in an ethanol dry ice bath. At this point, a 500 
μl sample was taken to assess the solubility of the fusion proteins for purification under 
non-denaturing conditions as before. The samples were centrifuged at 14,000 rpm in a 
cooled centrifuge (4°C) for 10 minutes, retaining the supernatant and discarding the 
pellet containing any insoluble material. For attachment to nickel resin, Ni-CAM HC Resin 
(Sigma N3158) was re-suspended in dH2O to form a 50% slurry and washed three times 
in dH2O, followed by three washes in Equilibration buffer. 1 ml of 50% slurry was added 
to 10 ml of each of the cell lysates containing the fusion proteins and incubated with 
rotation for 1 hour at room temperature. The samples were centrifuged at 3,000 rpm in 
a cooled centrifuge (4°C) and the supernatants discarded. The samples were then 
washed six times in Wash buffer (50 mM sodium phosphate pH 8.0, 0.3 M sodium 
chloride and 20 mM imidazole). 1 ml of Elution Buffer (50 mM sodium phosphate pH 8.0, 
0.3 M sodium chloride and 250 mM imidazole) was added to the samples and incubated 
with rotation for 10 minutes at room temperature. The samples were then centrifuged at 
3000 rpm for 30 seconds and the supernatants retained. The elution process was 
repeated three times and the supernatants retained. The NiCAM resin with the histidine-




2.6 Immunological methods 
2.6.1 Generation of antibody 
GST-fusion peptides were purified and resolved by SDS-PAGE using preparative gels, 
made with a non-toothed comb. The gels were then washed in dH2O and stained with 
Aqueous Coomassie Brilliant Blue (0.1% Coomassie Brilliant Blue Dye (Thermo 
Scientific 20279) dissolved in 1X Laemmli running buffer) and de-stained with 1X SDS-
PAGE running buffer without SDS. The protein bands were excised from the gels using 
a clean scalpel and frozen at -80°C. The excised gel slices containing the protein were 
then ground to a fine powder using liquid nitrogen and a pestle and mortar on dry ice. 
The powdered antigens were used to inoculate a rabbit (immunization was carried out 
by Scottish Diagnostics, Pentlands Science Park, Midlothian, Scotland). Two further 
injections of the antigens were given after one and two months. After three months of 
the immunization program, sera from the animals were collected for antibody purification.  
 
Total IgG was separated from the rabbit sera using caprylic acid (Sigma C2875). 20 ml 
of the sera was diluted 80 ml of 60 mM sodium acetate pH 4.0. For each ml of sera, 25 
μl of caprylic acid was added dropwise whilst stirring to precipitate non-IgG proteins. The 
mixtures were incubated with stirring at room temperature for 30 minutes and then 
centrifuged at 10,000 rpm in a cooled centrifuge (4°C) for 30 minutes. The supernatant 
was filtered to remove the protein precipitate. The resulting IgG was neutralised with 10 
ml of 10X PBS and cooled to 4°C. To precipitate the IgG, 0.277 g/ml ammonium sulphate 
was added slowly and incubated with stirring for 30 minutes at 4°C. IgG was collected 
by centrifuging at 10,000 rpm in a cooled centrifuge (4°C) for 15 minutes and the 
supernatants discarded. IgG was re-suspended in 1 X PBS and dialysed overnight 
against 1X PBS. The IgG solution was removed from the dialysis tubing, sodium azide 
(Sigma 71289) was added to 0.05% and stored at 4°C. 
 
The histidine-tagged fusion peptide was reduced by adding 1M DTT to a final 
concentration of 0.1M and incubated at 37°C for 1 hour then desalted over a PD-10 
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column contain Sephadex G-25 resin (GE Life Sciences 17085101), following 
manufacturer’s instructions. The desalted histidine-tagged fusion peptide was coupled 
to SulfoLink Resin (Thermo Scientific 20401) in Poly-Prep Chromatography Columns 
(Bio-Rad 731-1550) following manufacturer’s instructions. Non-specific sites were 
blocked with 50 mM cysteine (Sigma C7755). The column was washed with 10 mM Tris 
pH 7.5, followed by washes with 100 mM glycine pH 2.5, 10 mM Tris pH 8.8, 100 mM 
triethylamine pH 11.5 and 10 mM Tris pH 7.5. Isolated IgG was run through the column 
to attach the antibody and the column was washed with 10 mM Tris pH 7.5 and then with 
10 mM Tris pH 7.5 containing 0.5 M sodium chloride. For elution of the antibody under 
acidic conditions, 100 mM glycine pH 2.5 was added to the column in 850 μl fractions 
and the collected 850 μl elutions neutralised by adding to 150 μl 1M Tris pH 8.0. The 
column was then washed with 10 mM Tris pH 8.8. The fractions were assayed for protein 
content using the Bradford Protein Assay Dye (Bio-Rad 5000006) and the protein 
positive fractions were dialysed overnight against 1X PBS and analysed by SDS- PAGE. 
10% glycerol and 0.05% sodium azide were added to the antibody for long term storage 
at -80°C.  
 
2.6.2 Western immunoblotting 
Electrophoresed samples on SDS PAGE gels were electro-blotted onto Immobilon-P 
PVDF transfer membrane 0.45 µm (Merk Millipore IPVH00010) using a Trans- Blot SD 
Semi-Dry Transfer Cell (Bio-Rad) and 1X Western blot transfer buffer at a constant 
voltage of 15 V for 30 minutes. Membranes were stained with Ponceau S Solution 
(Sigma P7170) to determine protein blotting efficiency and washed in TBS-T. 
Membranes were blocked in blocking solution (TBS-T with 5% non-fat dry milk) for one 
hour with rotation. The blocking buffer was removed and membranes incubated with 
primary antibody for 1 hour at room temperature or overnight at 4°C with rotation. 
Membranes were washed three times in TBS-T (5-10 mins/wash) and incubated with a 
secondary antibody conjugated to horseradish peroxidise for 1 hour at room temperature 
with rotation. Membranes were further washed three times in TBS-T (5-10 mins/wash). 
Membranes were incubated for 1 min with Amersham enhanced chemiluminescent (ECL) 
Western Blotting Detection Reagent (GE Life Science RPN2106), mixed at a ratio of 1:1. 
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Excess ECL was removed and the membranes were exposed to medical X-ray film 
(Konica Minolta A9LS). Bands were developed using a SRX-101A X-ray film processor 
(Konica Minolta). Primary and secondary antibodies used for Western immunoblotting 





















Antibody Species Supplier Dilution 
ST6GAL1 Rabbit polyclonal Abgent (AP19891c) 1:1000 
E-cadherin Rabbit polyclonal Proteintech (20874-1-AP) 1:100 
N-cadherin Rabbit monoclonal Cell Signaling (D4R1H) 1:1000 
Vimentin Mouse monoclonal GeneTex (GTX629743) 1:1000 
Desmoplakin Rabbit polyclonal  Bethyl (A303-356A-T) 1:1000 
SNAI1 Rabbit polyclonal GeneTex (GTX125918 1:1000 
Slug Rabbit polyclonal GeneTex (GTX128796) 1:1000 
Twist 1/2 Rabbit polyclonal GeneTex (GTX127310) 1:1000 
Fibronectin Rabbit polyclonal Sigma-Aldrich (HPA027066) 1:1000 
Relaxin 2 Mouse monoclonal Abcam (ab183505) 1:1000 
FLAG M2 Mouse monoclonal Sigma-Aldrich (F3165) 1:2000 
GAPDH Rabbit polyclonal Abgent (AP7873b) 1:1000 
Actin Rabbit polyclonal Sigma-Aldrich (A2066) 1:1000 
α-Tubulin Mouse monoclonal Sigma-Aldrich (T5168) 1:2000 
Rabbit IgG - HRP Goat Jackson (111-035-003) 1:2000 
Mouse IgG - HRP Sheep GE Lifesciences (NA931vs) 1:2000 
 





2.6.3 Immunohistochemistry (IHC) 
Prior to IHC on prostate cancer tissue microarrays (TMA), antibodies were optimised on 
test TMA slides. Antigen retrieval was performed by pressure cooking the TMA in 10 mM 
citrate pH 6.0 followed by staining the tissues with serial antibody dilutions. Antibodies 
were validated using blocking peptides to determine specificity and rule out non-specific 
binding. Bound antibodies were visualised using biotinylated secondary antibodies and 
streptavidin horseradish peroxidase complex kit with DAB chromogen (Vectorlabs SK-
4100). Slides were counter-stained with haematoxylin (Sigma H9627) and dehydrated 
through graded alcohols and xylene (Sigma 296325) before mounting. Staining of a TMA 
containing 0.6 mm cores of benign prostatic hyperplasia (BPH) (n = 26), PCa (n = 72), 
and control tissues including breast, kidney, placenta, ovary, and liver was carried out 
by Dr Urszula McClurg at the Northern Institute of Cancer Research (NICR) and was 
scored using the 0-300 Histoscore score method 83. Briefly, percentage and intensity of 
positively stained cells was estimated on a 0-3 scale and used for calculating the H-score 
= (% of cells with 1 level positivity) + 2*(% of cells with 2 level positivity) + 3*(% of cells 
with 3 level positivity). 
 
 
Table 2.15: Basic clinical data for patient tissue samples used in TMA.  
Samples used in this study were collected between January 1989 and June 2003 from 
the Freeman Hospital patients. All samples were first analysed by a trained pathologist 
before selection of cores for TMA construction was performed. UK = unknown.  
 
































































2.6.4 Indirect immunofluorescence  
Confluent cells on cover-slips were washed with 1X PBS, followed by fixation of the cells 
with 4% paraformaldehyde (PFA) (Sigma P6148) for 20 minutes at room temperature or 
100% methanol (VWR Chemicals K977) for 10 minutes at -20°C. Cells were 
permeabilised by incubation in 0.1% Triton X-100 (Plusone 17-1315-01) detergent for 10 
minutes, and blocked in 10% horse serum (Sigma H0146) in 1X PBS for 1 hour. Cells 
were incubated in primary antibody diluted in 10% horse serum in 1X PBS for 1 hour at 
room temperature or overnight at 4°C. After three washes in 1X PBS for 5 minutes, the 
cells were incubated in fluorescent-conjugated secondary antibody diluted in 10% horse 
serum in 1X PBS for 1 hour at room temperature and protected from any light source 
with aluminium foil. After incubation, the cells were washed three times with 1X PBS for 
5 minutes. The coverslips were mounted onto glass slides using VectaShield Antifade 
Mounting Medium with 4’,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories H-
1200). Fluorescent images were obtained on an Axiovision microscope (Zeiss) and 
associated software. Primary and secondary antibodies used for indirect 
immunofluorescence are listed in Table 2.16.  
 
Antibody Species Supplier Dilution 
ST6GAL1 Rabbit polyclonal Abgent (AP19891c) 1:100 
Desmoplakin I & II Mouse monoclonal Abcam (ab16434) 1:100 
Relaxin 2 Mouse monoclonal Abcam (ab183505) 1:100 
FLAG M2 Mouse monoclonal Sigma-Aldrich (F3165) 1:100 
Rabbit 488 Alexa Fluor Donkey Abcam (ab150073) 1:100 
Mouse 488 Alexa Fluor Donkey Life Technologies (A21202) 1:100 





2.7 Cell culture 
2.7.1 Cell lines and culture conditions 
All cell lines were routinely cultured in the appropriate medium:  Dulbecco's Modified 
Eagle's Medium (DMEM) (Sigma D6429) or Gibco RPMI-1640 with L-Glutamine (Thermo 
Scientific 21875-034),  supplemented with 10% Heat Inactivated Fetal Bovine Serum 
(FBS) (Thermo Scientific 10270106), 1% Penicillin Streptomycin (Thermo Scientific 
15070063) and maintained at 37°C in a humidified atmosphere containing 5% carbon 
dioxide (CO2). For androgen treatment of LNCaP cells, culture medium was 
supplemented with 10% dextran charcoal stripped fetal bovine serum (Sigma F6765) to 
produce a medium stripped of steroids. Following culture for 72 hours, 10 nM synthetic 
androgen analogue methyltrienolone (R1881) (Sigma R0908) was added (Androgen +) 
or absent (Steroid deplete) for the times indicated. A list of cell lines and culture media 
used are listed in Table 2.17. 




Prostate cancer cell line derived from a 
needle aspiration biopsy of the left 
supraclavicular lymph node of a patient 
with metastatic prostate cancer (50 year old 








Prostate cancer cells derived from vertebral 
bone metastasis from a patient with 
hormone refractory prostate cancer (59 










Prostate cancer cells derived from brain 
metastasis from a patient with prostate 
adenocarcinoma (69 year old Caucasian 








Prostate cancer cells derived from bone 
metastasis from a patient with grade IV 
prostatic adenocarcinoma (62 year old 







A variant of the PC-3 cell line grown in 
nude mice with greater metastatic 
behaviour (Kozlowski et al., 1984). 






Prostate cancer cells derived from a 
xenograft that was serially propagated in 
mice after castration-induced regression 
and relapse of the parental, androgen 
dependent CWR22 xenograft. 
Androgen sensitive. 





LNCaP AI An androgen insensitive variant of LNCaP 
cells generated through continuous 






androgens for a period of 8 months 
(Halkidou et al., 2003). 
Androgen insensitive. 
LNCaP cdxR A Casodex resistant variant of LNCaP cells 
generated by exposing LNCaP cells to 
increasing concentrations of Casodex in 
normal growth medium over a 4-month 







A human embroyonic kidney cell line with 
high transfection efficiency (Graham et al., 
1977). 
D-MEM 




Cells contain a single stably integrated FRT 
site at a transcriptionally active genomic 
locus. Use to generate stable cell lines with 
high level protein of interest expression 
from Flp-In expression vectors. 
D-MEM 
 









2.7.2 Routine cell passage 
Cells were passaged every 3 to 5 days or at approximately 75% confluency. The culture 
medium was removed from the cells and the cells were washed in 1X PBS. 2nM Trypsin-
EDTA (Thermo Scientific 25300054) was added to the cells and incubated at 37°C for 2 
minutes or until the cells had detached from the surface. An equal volume of culture 
medium was added to the cells to inactivate the Trypsin and the cells were diluted for 
further culture. 
 
2.7.3 Cryopreservation  
Cell lines were routinely frozen to generate a stock of cells from early passage. 
Cryopreservation was performed in 500 μl aliquots of cryoprotective media containing 
10% dimethyl sulphoxide (DMSO) (Sigma D4540) and stored in cryovials at -80°C. When 
required, frozen stocks were rapidly thawed and re-suspended in complete culture 
medium and plated in sterile tissue culture flasks.  
 
2.7.4 Transfection 
  2.7.4.1  Lipofectamine 2000 transfection  
Cells were seeded in sterile 6 well culture plates 24 hours before transfection to be ~80% 
confluent upon transfection. Control cells were transfected with an empty vector at the 
same concentration. For each transfection, 12 μl Lipofectamine 2000 Reagent (Thermo 
Scientific 11668027) was diluted in 150 μl Opti-MEM Reduced Serum Media (Thermo 
Scientific 31985062) and 14 μg of plasmid or empty vector DNA was diluted in 700 μl 
Opti-MEM Media. The diluted Lipofectamine 2000 Reagent was added to the diluted 
DNA (1:1 ratio) and incubated for 5 minutes at room temperature. The resulting 
transfection complexes were added to the cells in a drop wise manner and incubated at 
37°C, 5% CO2 for 24 hours. Positive colonies were selected with appropriate antibiotics 
– Zeocin (Thermo Scientific R25001), Puromycin (Thermo Scientific A11138-03) or 
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Blasticidin (Thermo Scientific A11139-03). Tetracycline hydrochloride (Sigma T7660) 
was used to induce expression from Flp-In 293 T-Rex cells.  
 
2.7.4.2  Lipofectamine 3000 transfection  
Cells were seeded in sterile 6 well culture plates 24 hours before transfection to be ~80% 
confluent upon transfection. Control cells were transfected with an empty vector at the 
same concentration. For each transfection, 5 μl Lipofectamine 3000 Reagent (Thermo 
Scientific L3000001) was diluted in 125 μl Opti-MEM Reduced Serum Media (Thermo 
Scientific 31985062) and 5 μg of plasmid or empty vector DNA was diluted in 250 μl Opti-
MEM Media with 50 μl P3000 Reagent. The diluted Lipofectamine 3000 Reagent was 
added to the diluted DNA with P3000 reagent (1:1 ratio) and incubated for 15 minutes at 
room temperature. The resulting transfection complexes were added to the cells in a 
drop wise manner and incubated at 37°C, 5% CO2 for 24 hours. Positive colonies were 
selected with appropriate antibiotics – Zeocin (Thermo Scientific R25001), Puromycin 
(Thermo Scientific A11138-03) or Blasticidin (Thermo Scientific A11139-03). 
Tetracycline hydrochloride (Sigma T7660) was used to induce expression from Flp-In 
293 T-Rex cells.  
 
  2.7.4.3  GeneJammer transfection  
Cells were seeded in sterile 6 well culture plates 24 hours before transfection to be ~60% 
confluent upon transfection. Control cells were transfected with an empty vector at the 
same concentration. For each transfection, 3 μl GeneJammer Transfection Reagent 
(Agilent Technology 204132) was diluted in 100 μl Opti-MEM Reduced Serum Media 
(Thermo Scientific 31985062) and incubated at room temperature for 5 minutes. Plasmid 
or empty vector DNA was added and incubated for a further 15 minutes at room 
temperature. The resulting transfection complexes were added to the cells in a drop wise 
manner and incubated at 37°C, 5% CO2 for 24 hours. Positive colonies were selected 
with appropriate antibiotics – Zeocin (Thermo Scientific R25001), Puromycin (Thermo 
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Scientific A11138-03) or Blasticidin (Thermo Scientific A11139-03). Tetracycline 
hydrochloride (Sigma T7660) was used to induce expression from Flp-In 293 T-Rex cells.  
 
2.7.4.4  RNAiMAX transfection 
Depletion of the endogenous proteins was achieved by transfecting cells with pre-
designed siRNAs (Integrated DNA Technologies). siRNAs were transfected using 
RNAiMAX Transfection Agent (Thermo Scientific 13778030). Control cells were 
transfected with the same concentration of negative control siRNA (Integrated DNA 
Technologies 51-01-14-03). Cells were seeded in sterile 6 well culture plates 24 hours 
before transfection to be ~60% confluent upon transfection. For each transfection, 9 μl 
RNAiMAX Reagent was diluted in 150 μl Opti-MEM Reduced Serum Media (Thermo 
Scientific 31985062) and 3 μl of the appropriate siRNA (10 μM) was diluted in 150 μl 
Opti-MEM.  The diluted RNAiMAX Reagent was added to the diluted siRNA and 
incubated for 5 minutes at room temperature. The resulting transfection complexes were 
added to the cells in a drop wise manner and the cells were incubated at 37°C, 5% CO2 
for 72 hours and then harvested for both RNA extraction and Western Immunoblotting. 
 
2.8 Functional assays 
2.8.1 WST-1 cell proliferation assay 
Proliferation assays were carried out using a WST-1 Cell Proliferation Assay Kit (Cyman 
Chemical Company 10008883). Cells were seeded in sterile 96 well plates at 10,000 
cells per well and incubated at 37°C, 5% CO2 for 24 hours. After initial incubation, 10 μl 
reconstituted WST-1 mixture was added to each well and mixed gently on an orbital 
shaker for 1 minute. Plates were incubated for a further 2 hours at 37°C, 5% CO2 and 
mixed again for 1 minute to ensure homogeneous distribution of colour. The absorbance 
of each sample was measured against a background control using a Varioskan LUX 
(Thermo Fisher Scientific) microplate reader at a wavelength of 450 nm. This process 
was repeated over a 7day period. 
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2.8.2 Click-IT EdU proliferation assay 
Proliferation assay were carried out using a Click-iT EdU Alexa Fluor 594 Imaging Kit 
(Thermo Scientific C10339). Confluent cells on cover-slips were incubated in 10 μM EdU 
labelling solution and incubated for 2 hours at 37°C, 5% CO2. Cells were fixed with 4% 
PFA (Sigma P6148) for 20 minutes at room temperature and washed twice in 1 ml 3% 
bovine serum albumin (BSA) (Sigma A9418) in 1X PBS. Cells were permeabilised by 
incubation in 0.5% Triton X-100 detergent (Plusone 17-1315-01) for 20 minutes and 
washed twice in 1 ml 3% BSA in 1X PBS. Cells were incubated with 500 μl Click-IT EdU 
reaction cocktail (Table 12.18) for 30 minutes at room temperature and protected from 
any light source with aluminium foil. Cells were washed in 1 ml 3% BSA in 1X PBS and 
the coverslips were mounted onto glass slides using VectaShield Mounting Medium with 
4’,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories H-1200). Fluorescent images 
were obtained on an Axiovision microscope (Zeiss) and associated software and 
analysed using Image J software (National Institutes of Health, Bethesda, Maryland, 
USA). 
 
Reaction component Volume 
1X Click-IT EdU reaction buffer 4.3 ml 
CuSO4 200 μl 
Alexa Fluor azide 12.5 μl 
1X Click-IT EdU buffer additive 500 μl 
 






2.8.3 Calcein cell adhesion assay 
Cells suspended in serum free media were labelled with 5 μM Calcein AM (Sigma 17783) 
and incubated for 30 minutes at 37°C, 5% CO2. Labelled cells were washed twice in 1X 
PBS and seeded in sterile 96 wells plates; uncoated plates, human fibronectin coated 
plates (R&D Systems CWP001) and collagen I coated plates (Thermo Scientific 
A1142803) at 50,000 cells per well. After incubation for 2 hours at 37°C, 5% CO2 non-
adherent cells were removed by washing four times in 1X PBS. The fluorescence of each 
sample was measured against a background control using a Varioskan LUX (Thermo 
Fisher Scientific) microplate reader at an excitation of 400 nm, emission of 530 nm. The 
percentage adhesion was calculated by comparing with an identical unwashed plate. 
 
2.8.4 Crystal violet staining 
Cells were cultured under appropriate conditions as required then fixed and visualised 
using crystal violet staining. Cells were washed twice in cold PBS and fixed with 100% 
ice cold methanol (VWR Chemicals K977) for 10 minutes on ice. Cells were brought to 
room temperature and incubated for 10 minutes in 0.5% crystal violet solution (Sigma 
HT90132) in 25% methanol. Cells were washed in H2O until free of crystal violet stain 
and allowed to air dry at room temperature overnight.  
 
2.8.5 Scratch wound healing assay 
Scratch wound healing assays were carried out using a Cell Comb Scratch Assay (Merk 
Millipore 17-10191). Cells were grown to a confluent monolayer on 86mm x 12mm 
scratch assay cell culture plates. Scratches were made across the plate using the cell 
comb, applying sufficient force to create even scratches on the monolayer. The cells 
were washed three times in 1× PBS to remove floating cells, and wound closure was 
observed at indicated time points and photographed with a bright-field microscope. Ten 
images were taken for each plate at each time point and the mean average was 
calculated. Images were analysed using the Image J software (National Institutes of 
Health, Bethesda, Maryland, USA). Wound repair percentage was calculated as 
78 
 
following: (diameter of wound before migration - diameter of wound after migration) / 
diameter of wound before migration x 100. The mean value of wound repair in three 
duplicate wells was calculated for each group. 
 
2.8.6 Cell migration assay 
Cell migration assays were carried out using an Oris 96 well migration assay (Platypus 
Technologies PROCMACC1). Cells were seeded in 96 well collagen I coated plates at 
30,000 cells per well and incubated at 37°C, 5% CO2 for 2 hours. Seeding stoppers were 
removed and pre-migration images were taken. Migration of cells into the centre of the 
wells was observed at indicated time points and photographed with a bright-field 
microscope. Images were analysed using the Image J software (National Institutes of 
Health, Bethesda, Maryland, USA). Migration was calculated by comparing the open 
area of pre-migration cells to the open area of post migration cells at a set time point.  
 
2.8.7 Invasion assay 
Invasion assays were carried out using a Cultrex 96 well basement membrane extract 
(BME) cell invasion assay (R&D Systems 3455-096-K). Cells were cultured in serum free 
media for 24 hours and then added to the top chamber at 10,000 cells per well. Full 
culture meida was added to the bottom wells and plates were incubated at 37°C, 5% 
CO2 for 24 hours. Both chambers were washed in 1X wash buffer and incubated with 
Calcein AM / cell dissociation solution (final concentration: 0.8 μM) at 37°C, 5% CO2 for 
30 minutes. The fluorescence of each sample in the bottom chamber (invasive cells) was 
measured against a background control using a Varioskan LUX (Thermo Fisher Scientific) 




































Identifying clinically relevant androgen regulated gene 















Chapter 3 Results 
Identifying clinically relevant androgen regulated gene expression changes in 
prostate cancer 
3.1  Introduction 
Androgen receptor (AR) signalling remains the key driver in advanced and CRPC 
(Livermore et al., 2016). Over the past decade numerous genomic and transcriptomic 
studies have been carried out identifying AR binding sites and target genes. Until recently, 
the majority of these studies had focused on the use of a single cell line in vitro (Massie 
et al., 2007; Wang et al., 2007; Rajan et al., 2011), on genes with nearby AR genomic 
binding sites (Massie et al., 2011; Sharma et al., 2013), or had limited coverage on 
microarrays (Massie et al., 2007; Wang et al., 2009a; Massie et al., 2011; Rajan et al., 
2011). Hybridization-based microarrays were the technology of choice for large scale 
gene expression studies. They allowed interrogation of tens of thousands of transcripts 
simultaneously, but they were restricted by probe design. Microarrays only detect 
transcripts for which probes have been pre-designed, which requires existing genomic 
sequencing information. The probes can also differ considerably in their hybridisation 
properties and background hybridisation limits their accuracy.  
 
The development of RNA sequencing technology has allowed for transcriptome 
interrogation on a much larger scale. RNA sequencing, often termed RNA-Seq, generally 
involves total RNA samples which have been fragmented and converted into a library of 
cDNA fragments with adaptors. The fragments are then sequenced in a high-throughput 
manner, from either one end (single-end sequencing) or both ends (paired-end 
sequencing). RNA sequencing can detect known, novel and low level transcripts, as well 
as allele-specific expression, splice junctions, point mutations and gene fusion 
transcripts (Wang et al., 2009b; Ozsolak and Milos, 2011). This method can also be used 
to quantify small RNA molecules such as microRNAs (miRNAs), short interfering RNAs 
(siRNAs), small nucleolar RNA (snoRNAs) and Piwi-interacting RNA (piRNA).  
82 
 
Within the last decade, the emergence of RNA sequencing technologies has resulted in 
a number of published clinical PCa transcriptome datasets, providing an comprehensive  
profile of advanced, metastatic, castrate resistant and neuroendocrine prostate cancer 
(Fenner, 2011; Rajan et al., 2014; Robinson et al., 2015; Beltran et al., 2016; Kumar et 
al., 2016; Mo et al., 2017). More recently, technological advances have permitted single 
cell transcriptome sequencing (Guzvic et al., 2014; Lohr et al., 2014). Miyamoto et al 
confirmed the complex heterogeneity of individual tumours by profiling the transcriptome 
of circulating tumour cells (CTCs) (Miyamoto et al., 2016). CTCs are shed into blood 
from primary tumours and may provide a non-invasive means of identifying pathways 
contributing to cancer progression and metastasis.  
 
This advance in next generation sequencing technology has led to a greater 
understanding and characterisation of many cancers. The number of whole exome and 
transcriptome sequencing studies is ever increasing and has led to several large-scale 
cancer genome projects. The Cancer Genome Atlas project (TCGA; 
http://cancergenome.nih.gov), a collaboration between the National Cancer Institute 
(NCI) and the National Human Genome Research Institute (NHGRI) and the 
International Cancer Genome Consortium (ICGC; http://icgc.org) hold publically 
available genomic, transcriptomic and epigenomic data for a large number of different 
cancers and subtypes (Hudson et al., 2010; Weinstein et al., 2013). The cBioPortal for 
Cancer Genomics (http://cbioportal.org) provides a web-based portal which can be used 
to visualise and analyse these large cancer datasets (Cerami et al., 2012). Another web-
based platform, Oncomine (https://www.oncomine.org) contains gene expression data 
from 715 published cancer transcriptome datasets, including 60 PCa datasets (Rhodes 







3.2 Aims of chapter 
The majority of CRPC tumours remain dependent of AR signalling for growth (Crona and 
Whang, 2017). Detailed knowledge of their genetic and biological background is 
therefore essential for understanding drivers of disease progression, and will assist in 
the development of effective biomarkers and patient treatments. 
 
The aims of this chapter were to: 
 Use RNA sequencing technology to identify AR regulated transcriptome changes 
in prostate cancer cells. 
 Identify clinically relevant gene expression changes by correlating this dataset 
with a clinical PCa RNA sequencing dataset. 
 Carry out a meta-analysis of multiple PCa gene expression datasets using the 
Oncomine web-based platform to increase the statistical power of any identified 
changes. 
 Use Gene Ontology analysis to identify key AR regulated biological processes in 
clinical PCa.  
 
A comprehensive map of AR regulated genes, associated pathways and biological 
processes in clinical prostate cancer will help in our understanding of the development 










3.3.1 Identification of clinically relevant androgen responsive target genes in 
prostate cancer 
 
To analyse how the PCa transcriptome responds to androgens, paired-end RNA 
sequencing was carried out on six samples; three biological replicates of LNCaP cells 
grown in charcoal stripped steroid deplete media (SD), and three biological replicates 
from LNCaP cells grown in the presence of 10 nM synthetic androgen R1881 (A+) for 24 
hours using an Illumina HiSeq 2000. These RNA samples were prepared by Dr Jennifer 
Munkley and sequenced prior to the start of my PhD project.  
 
 
All bioinformatics analysis of the data was performed by Dr Daniel Vodak (Institute of 
Cancer Genetic and Informatics, Oslo, Norway). Initial analysis of the RNA sequencing 
data identified 3,339 genes which were significantly up-regulated by androgens, and 
2,760 genes which were significantly down-regulated (p <0.05). As previous studies have 
demonstrated differences between in vivo and in vitro AR-regulated genes (Sharma et 
al., 2013), we correlated our cell line data with a previously published clinical RNA 
sequencing dataset (Rajan et al., 2014). In this dataset, RNA was sequenced from seven 
patients with locally advanced metastatic prostate cancer before and around 22 weeks 
post ADT (patient information detailed in Table 3.1). Differential gene and transcript 
expression analysis was performed as follows: all reads were first mapped to human 
transcriptome/genome (build hg19) with TopHat / Bowtie, followed by per-sample 
transcript assembly with Cufflinks. Transcript assemblies derived from the clinical 
samples were merged together with Cuffmerge, and differential expression between the 
two conditions (prior and post ADT) was assessed with Cuffdiff. Genes and isoforms 
labelled by the software as significantly (p <0.05) differentially expressed were extracted 







Patient Age (years) Gleason sum score 
TNM stage  
T N M 
1 64.7 8 3b 0 0 
2 65.4 9 3b 0 0 
3 69.6 8 3b 1 0 
4 64.6 8 3a 0 1 
5 51.8 7 3a 0 0 
6 58.6 7 3b 1 0 
7 62.9 7 3b 1 0 
 
Table 3.1 Patient data for RNA sequencing clinical samples. Data and table 
taken from (Rajan et al., 2014). Clinical samples from 7 patients with locally advanced 
or metastatic PCa (Gleason sum score >7) were used for RNA sequencing. The patients 
were aged between 51.8 years and 69.6 years with an average age of 62.5 years. TNM 
stage: T (tumour), N (lymph node) and M (metastasis). The T stage shows how far the 
cancer has spread in and around the prostate: T3a - the cancer has broken through the 
outer layer of the prostate, but has not spread to the seminal vesicles (which produce 
and store some of the fluid in semen), T3b - the cancer has spread to the seminal 
vesicles. The N stage shows whether the cancer has spread to the lymph nodes near 
the prostate and the M stage shows whether the cancer has metastasised to other parts 
of the body. 
 
 
This process identified 660 potentially clinically relevant AR target genes with reciprocal 
expression signatures; androgen regulated in culture with reverse expression switches 
in patients in response to clinical ADT. A full gene list can be found in Appendix A. 
 
Two subsets of differentially expressed genes were identified: 
  
1) Genes up-regulated by androgens in LNCaP cells and down-regulated in all 7 patients 
following androgen-deprivation therapy, of which 548 genes were identified.  
2) Genes down-regulated by androgens in LNCaP cells and up-regulated in 7 patients 








Figure 3.1  Venn diagram of androgen regulated genes with reciprocal 
regulation patterns. Venn diagram showing the number of genes with significant 
differential expression (p <0.05). Comparison of the two RNA sequencing datasets 
identified 660 androgen-regulated genes with reciprocal regulation. (A) 548 genes were 
up-regulated in response to androgen treatment in LNCaP cells, but down-regulated in 
7 PCa patient samples post ADT. (B) 112 genes were down-regulated in response to 




Within the dataset were many established classes of AR target genes, including cell 
cycle regulators: zinc finger and BTB domain containing 16 (ZBTB16) (Jiang and Wang, 
2004); signalling molecules implicated in PCa including serine/threonine/tyrosine kinase 
1 (STYK1) (Chung et al., 2009); genes with roles in central metabolism, including cAMP 
responsive element binding protein 3 like 4 (CREB3L4) (Qi et al., 2002) and pyrroline-5-
carboxylate reductase 1 (PYCR1) (Jariwala et al., 2007); and biosynthetic pathway 
genes, including calcium/calmodulin dependent protein kinase kinase 2 (CAMKK2) 
(Racioppi, 2013); as well as many additional novel androgen-regulated genes. Although 
kallikrein related peptidase 3 (KLK3) was present in both the up-regulated by androgens 
in LNCaP cells and the down-regulated following androgen-deprivation therapy gene 
lists, it was surprisingly not listed in the merged differentially expressed gene list. This 
highlights to effect of setting optimal thresholds during the bioinformatic analysis. 
Although helpful when focusing large gene lists, setting such stringent thresholds can 
sometimes limit analysis.  
 
 
In order to validate the LNCaP RNA sequencing results, expression changes for several 
androgen-regulated genes were confirmed in an independent LNCaP sample set by real-









Figure 3.2 Differentially expressed genes in LNCaP cell line in response to 
androgens. Real-time quantitative reverse transcription PCR (qRT-PCR) analysis of 24 
differentially expressed genes in LNCaP cells in response to 10 nM synthetic androgen 
(R1881) stimulation (24 hours). Gene expression was calculated as the average (from 3 
biological replicates) fold change (log2) relative quantification of androgen treated 
LNCaP cells compared to steroid deplete cells (value set as 1). Samples were 
normalised using the average of three reference genes, GAPDH, β -tubulin and 
actin. Statistical significance was calculated using an independent two-sample t-test, 
where * p <0.05, ** p <0.01, *** p <0.0001, **** p <0.00001. All primer sequences are 







Several Wnt signalling pathway genes were analysed. Frizzled class receptor 8 and 5 
(FZD8 and FZD5) were significantly up-regulated (p <0.05) by androgens, whilst frizzled 
class receptor 7 (FZD7) was down-regulated. Ras homolog family member U (RHOU), 
a member of the Rho family of GTPases regulated by Wnt1 (Tao et al., 2001) showed 
the highest increase in expression. Other genes significantly up-regulated by androgens 
include, chromosome 1 open reading frame 116 (C1ORF116), also known as SARG, the 
RAP1 GTPase activating protein RAP1GAP, the epithelial splicing regulatory protein 
ESRP2, the nectin cell adhesion molecule PVRL2, the cAMP responsive element binding 
protein CREB3L4, the coronin actin binding protein CORO1B, the transmembrane 
protein TMEM8A, tetraspanin 1 (TSPAN1) and the long non-coding RNA (lncRNA) 
nuclear paraspeckle assembly transcript 1 (NEAT1).  
 
 
RHOU has recently shown potential as a biomarker to distinguish between metastatic 
PCa and localised PCa (Alinezhad et al., 2016). Knockdown of RHOU in both 2D and 
3D organotypic cell culture models resulted in reduced growth, tumour cell invasion, 
proliferation and cell-motility (Alinezhad et al., 2016). The lncRNA NEAT1 is regulated 
by the estrogen receptor alpha (ERα). NEAT1 is up-regulated PCa and can promote 
tumour progression and therapeutic resistance (Chakravarty et al., 2014). KLKP1 
(Kaushal et al., 2008), C1ORF116 (Steketee et al., 2004), CREB3L4 (Labrie et al., 2008) 
are known AR target genes.  
 
 
Genes confirmed as significantly down-regulated by androgens include SWI/SNF related, 
matrix associated, actin dependent regulator of chromatin, subfamily D, member 3 
(SMARCD3), the GLIS family zinc finger protein (GLIS2) and the lncRNA LOC283070. 
LOC283070 is frequently up-regulated in androgen insensitive PCa cell lines and is 
thought to mediate the transition of LNCaP cells into androgen independent cells via 




Androgen regulated expression of these genes was also analysed in another androgen 
responsive PCa cell line (VCaP) by real-time quantitative reverse transcription PCR 
(qRT-PCR) (Figure 3.3). Again, VCaP cells were treated with 10nM R1881 for 24 hours 
(A+) or without (steroid deplete, SD). 
 
 
Figure 3.3 Differentially expressed genes in VCaP cell line in response to 
androgens. Real-time quantitative reverse transcription PCR (qRT-PCR) analysis of 16 
differentially expressed genes in VCaP cells in response to 10 nM synthetic androgen 
(R1881) stimulation (24 hours). Gene expression was calculated as the average (from 3 
biological replicates) fold change (log2) relative quantification of androgen treated VCaP 
cells compared to steroid deplete cells (value set as 1). Samples were normalised using 
the average of three reference genes, GAPDH, β -tubulin and actin. Statistical 
significance was calculated using an independent two-sample t-test, where * p <0.05, ** 
p <0.01, *** p <0.0001, **** p <0.00001. All primer sequences are listed in Appendix B.  
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Five genes (FZD5, FZD8, RAP1GAP, RHOU and PVRL2) were significantly up-regulated 
by androgens in both the LNCaP and VCaP cell lines and four genes were down-
regulated (SMARCD3, FZD7, LOC283070 and GLIS2). Interestingly, ESRP2, TSPAN1 
and kallikrein pseudogene 1 (KLKP1) had opposing expression patterns in the VCaP 
cells compared to the LNCaP cells. Although both cell lines are androgen sensitive, they 
have different backgrounds, characteristics and each represents a distinct molecular 
subtype of prostate cancer. LNCaP cells were derived from a needle biopsy taken from 
the left supraclavicular lymph node of a 50-year old Caucasian male (Horoszewicz et al., 
1983), and harbour an AR ligand binding domain mutation. Whilst VCaP cells (vertebral 
cancer of the prostate) were derived from a vertebral metastatic lesion from a 59-year 
old Caucasian male (Korenchuk et al., 2001) and one harbour a AR gene amplification. 
Although proven invaluable for public health research, tumour derived cell lines can 
exhibit considerable genomic and transcriptomic diversity (Klijn et al., 2015) and do not 
fully represent individual clinical tumour samples.  
 
 
3.3.2 Meta-analysis of publically available datasets  
 
The growth of publicly available gene expression data is staggering. The availability of 
this data can be a powerful tool and has led to the discovery of disease biomarker and 
therapeutic targets. Meta-analysis across multiple datasets has greater statistical power 
and can overcome the biases of individual studies (Ramasamy et al., 2008). A meta-
analysis approach was used to analyse expression of each of the genes within the two 
subsets in clinical prostate cancer samples. Oncomine (www. oncomine.org) is a cancer-
profiling database containing published micro-array data that has been collected, 
standardised, annotated and analysed. This approach has been  
 
Five micro-array datasets were interrogated using the Oncomine database: 
 
 
1. Grasso et al: A 122 sample dataset containing 35 castrate resistant metastatic 
PCa, 59 localised PCa, and 28 benign prostate tissue specimens. Data was 
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generated on the Agilent Whole Human Genome 44k array (19,189 genes, 
41,000 reporters) (Grasso et al., 2012).  
 
2. Taylor et al: A 367 sample dataset containing 218 tumour samples (181 primary 
prostate tumours and 37 metastatic prostate) and 149 matched normal samples. 
Data was generated on the Affymetrix Human Exon 1.0 ST array (18,823 genes, 
19,084 reporters) (Taylor et al 2010).  
 
3. Varambally et al: A 19 samples dataset containing 6 castrate resistant 
metastatic PCa, 7 primary PCa and 6 normal prostate gland specimens. Data 
was generated using the Affymetrix Human Genome U133 plus 2.0 array (19,574 
genes, 54,675 reporters) (Varambally et al., 2005).  
 
4. Tomlins et al: A 101 sample dataset containing laser dissected cell populations 
from a progression of PCa cell types (benign, PIN, low-grade PCa, high-grade 
PCa, metastatic PCa) and normal adjacent tissue. Data was generated using a 
custom micro-array (10,656 genes, 19,928 reporters) (Tomlins et al., 2007).  
 
5. Lapointe et al: A 112 sample dataset containing 62 prostate carcinomas, 41 
matched normal prostate and 9 metastatic PCa (lymph node) specimens. Data 
was generated on a custom micro-array (10,166 genes, 19,116 reporters) 
(Lapointe et al., 2004).  
 
 
Gene expression in prostate cancer tissue was compared with that of normal or benign 
tissue (control) for each of the 660 genes in the gene set. The threshold criteria was set 
as: fold change >1, p value <0.05 in at least two of the studies analysed. Of the 548 
genes up-regulated by androgens in LNCaP cells and down-regulated in patients post 
ADT, 140 genes (26%) met the threshold criteria (Table 3.2). Of these, 51 genes met the 
threshold criteria in at least four of the five studies (genes highlighted blue in Table 3.2), 
and 43 genes meet the threshold criteria in all five studies (genes highlighted green in 
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Table 3.2). None of the 112 genes down-regulated by androgens in LNCaP cells and up-






fc p value fc p value fc p value fc p value fc p value 
ABAT 1.685 2.30E-04 1.225 0.008 1.453 0.011  -  - 1.151 0.031
ABHD2 1.613 2.68E-05 1.335 2.26E-05 1.834 5.48E-04 1.551 0.046 1.298 0.007
ACACA 1.181 3.41E-05 1.399 2.77E-05 1.239 0.043 2.083 6.24E-04 1.72 2.31E-13
ACLY 1.499 1.75E-05 1.356 2.10E-04 1.384 0.008 2.206 1.20E-02 1.292 5.12E-04
ACSM1 4.399 3.41E-09 2.736 1.90E-19 3.862 0.002 3.906 1.37E-04  -  - 
ADIPOR1 1.379 2.76E-09 1.144 0.002 1.157 0.16 1.902 9.47E-05 1.23 6.00E-06
ADRB1 1.768 2.45E-04 1.31 3.79E-07 3.015 1.71E-07 3.379 3.99E-04 1.843 2.32E-05
ADRBK1 1.325 1.24E-04 1.071 0.073 1.574 1.99E-05 1.997 0.091 1.291 3.96E-04
AGR2 2.711 7.12E-04 1.601 0.003 -1.429 0.873 9.533 1.85E-04 2.391 8.06E-06
AKR1A1 1.512 2.91E-07 1.123 0.007 1.233 0.027  -  -  -  - 
ALDH1A3 1.846 5.76E-05 1.517 1.77E-07 1.684 1.97E-04 2.136 0.026 1.354 0.006
ALG5 1.255 2.08E-04 1.043 0.141 -1.138 0.596 2.51 4.37E-05 -1.001 0.505
AMACR 13.502 4.57E-24 3.948 2.77E-21 10.451 6.75E-07 10.07 2.6E-13 7.228 4.11E-23
ARF4 1.23 4.62E-04 1.194 0.003 1.041 0.413 2.124 2.18E-04  -  - 
ARFIP2 1.455 2.44E-05 1.216 9.94E-05 1.118 0.182 -1.289 0.943 1.265 8.68E-04
ATP11B 1.662 3.03E-07 1.41 4.92E-05 1.708 2.00E-03 1.725 0.038 1.687 1.67E-10
B3GAT1 2.714 2.15E-04 1.309 1.33E-09 5.739 0.002 1.213 0.189 2.222 4.05E-09
BDH1 1.363 8.76E-06 1.14 5.05E-06 1.34 2.00E-03 1.51 0.033 1.344 1.79E-05
BEND4 1.923 1.30E-05 1.456 2.97E-09 2.455 2.00E-03  -  - 2.228 7.76E-09
C19orf48 2.25 4.97E-07 1.292 4.10E-09 2.187 6.71E-05 2.249 0.006  -  - 
C1orf116 1.773 5.57E-04 1.253 0.002 1.612 7.74E-04  -  - 1.437 1.10E-04
C9orf152  -  - 1.427 9.43E-05 1.594 0.007  -  -  -  - 
C9orf91 1.154 1.50E-02 1.135 8.06E-05 1.44 6.00E-03 1.996 9.46E-05 1.456 2.82E-10
CALR 1.304 0.006 1.14 0.002 1.552 0.033 1.008 0.487 1.167 0.051
CCDC167 1.305 0.043 1.476 4.76E-04 2.652 3.97E-05 6.476 0.031 1.281 0.055
CENPN 1.526 0.002 1.31 3.77E-04 -1.274 0.701 -3.137 1 1.743 2.12E-06
CLDN8 3.098 5.55E-11 1.743 2.22E-10 2.441 2.90E-02  -  - 2.73 3.18E-10
CORO1B 1.555 5.20E-05 1.086 0.029 1.228 0.059  -  -  -  - 
CREB3L4 1.941 5.88E-04 1.373 1.97E-04 1.548 0.014  -  - 1.47 3.02E-04
DCAF6 1.289 1.84E-04 1.191 0.003 1.477 0.23 2.14 2.45E-05 1.315 3.80E-07
DDAH1 1.474 3.42E-05 1.325 5.68E-05 1.751 6.31E-04 2.691 4.60E-05 1.372 1.54E-04
DEGS1 -1.063 0.707 1.113 0.011 -1.606 0.976 1.916 0.009 1.196 0.023
DHCR24 1.249 0.07 1.102 0.128 -1.137 0.744 1.614 0.046 1.197 0.04
DLX1 22.424 7.15E-27 1.406 3.84E-09 39.202 1.24E-05  -  -  -  - 
DNAJC10 1.706 3.59E-10 1.723 2.44E-08 1.674 5.36E-04 2.788 7.26E-05 1.823 4.48E-18
DUS1L 1.733 1.03E-09 1.262 1.13E-06 1.744 7.12E-05  -  - 1.538 4.09E-08
EDEM3 1.637 2.18E-10 1.506 6.77E-07 1.641 0.003  -  - 1.405 1.86E-07
ERGIC1 1.745 8.37E-07 1.426 3.74E-06 1.929 8.00E-03  -  - 1.442 0.00017
ESRP2 1.891 1.50E-04 1.267 4.76E-07 1.453 0.01 1.123 0.191 1.939 4.91E-17
F5 2.666 2.99E-07 1.403 9.62E-05 2.166 0.008 4.911 2.55E-06 3.986 3.21E-12
FAAH 1.599 0.003 1.162 0.007 1.151 0.228 -1.404 0.852 1.439 0.018
FASN 1.638 0.002 1.564 2.87E-06 1.852 0.007 -1.339 0.759 -2.001 1
FGFRL1 2.051 1.15E-08 1.238 3.83E-08 1.394 3.10E-02 1.756 0.0007 1.772 1.82E-11
FUT1 1.26 2.70E-02 1.062 3.00E-03 1.243 1.10E-01  -  -  -  -
FZD8 1.717 1.47E-05 1.132 5.84E-05 2.803 0.002 5.057 3.67E-06  -  - 
GABRB3 1.692 0.002 1.405 1.83E-06 1.369 0.06 3.803 0.014 2.118 1.51E-08
GALNT7 2.31 3.48E-07 1.764 1.12E-07 1.73 0.02  -  -  -  - 
GCNT1 3.455 5.53E-13 1.941 1.53E-14 4.771 0.006  -  - 2.555 1.72E-14
GLUD1 1.154 0.031 1.158 0.017 1.19 0.101 2.156 4.72E-07 1.121 0.04
GMDS 2.349 2.09E-13 1.535 5.86E-11 1.447 0.059  -  - 1.286 0.012
GNPNAT1 1.541 3.24E-08 1.251 1.52E-07 1.478 1.16E-04 1.931 0.002 1.409 2.54E-07
GOLM1 3.137 9.13E-09 2.062 1.86E-08 2.89 2.00E-03 3.799 0.000355 2.905 1.86E-13
GOLPH3 1.386 2.87E-06 1.182 9.37E-06 1.176 0.074 1.69 0.007 1.329 7.14E-07
GSKIP 1.331 1.42E-05 1.172 0.026 -1.133 0.708 1.053 0.393  -  - 
HGD 1.568 1.06E-07 1.531 2.65E-07 2.117 2.00E-03 2.518 0.000529 1.484 3.4E-07
HIPK2 1.378 1.00E-03 1.302 3.40E-05 1.499 8.54E-04 2.576 0.004 1.509 1.02E-06
HIST1H2BK 1.607 3.04E-04 1.131 2.75E-04 1.356 0.022 1.878 0.005  -  - 
HMG20B 1.539 8.67E-07 1.189 3.25E-04 1.358 0.031 1.562 0.034 1.372 2.42E-05
HPN 4.346 3.77E-09 1.683 2.19E-20 5.836 7.81E-05 3.323 0.004  -  - 
HSD17B4 1.792 1.19E-10 1.294 0.002 1.071 0.366 3.981 1.65E-05 1.474 1.37E-06
HSP90B1 1.235 0.002 1.334 5.97E-05 1.154 0.146 2.469 4.66E-04 1.28 3.45E-05
ICA1 3.072 2.56E-06 1.399 2.13E-05 1.295 1.30E-02 1.905 0.000327 1.659 1.72E-08
IQGAP2 2.052 2.40E-05 1.764 8.08E-08 2.901 2.84E-06 2.23 0.005 1.289 0.003
KDELR2 1.442 7.68E-05 1.394 8.16E-06 1.209 0.154 1.578 1.40E-04 1.284 2.43E-06
KIAA1244 1.475 7.89E-04 1.355 1.26E-04 1.376 0.059 2.837 3.66E-05 2.138 1.39E-09




fc p value fc p value fc p value fc p value fc p value 
KLK15 2.188 4.16E-07 1.282 2.01E-07 3.073 0.002  -  -  -  - 
KRT18 1.492 7.35E-04 1.261 1.16E-06 1.252 0.119 1.176 0.221 1.531 3.43E-06
LYPLA2 1.275 0.026 1.071 0.006  -  -  -  - 1.202 0.009
MAP7 1.806 2.13E-05 1.243 2.88E-04 1.215 0.201 1.7 0.016 1.669 6.31E-10
MBOAT2 1.681 8.51E-05 1.529 1.26E-07 1.504 4.00E-02 4.072 1.55E-05 1.837 4.80E-12
MCCC2 2.841 1.76E-11 1.357 5.92E-08 2.616 1.87E-04 1.789 0.061 2.607 6.97E-12
MICAL2 1.645 4.87E-06 1.233 2.07E-04 2.486 6.78E-04 1.84 0.006 1.161 0.035
MYBPC1 2.098 0.008 2.26 3.23E-06 5.041 0.016  -  -  -  - 
NAA35 1.29 9.49E-07 1.142 0.046 1.216 0.057 2.716 1.78E-05 1.372 1.64E-08
NANS 1.698 4.52E-05 1.228 1.70E-02 1.289 8.70E-02  -  - 1.15 6.10E-02
NDUFV2 1.451 6.28E-09 1.182 0.007 1.08 0.292 2.18 3.73E-05  -  - 
NEAT1 1.775 7.60E-09 1.011 0.386 1.173 0.161 2.756 8.77E-04 1.971 3.13E-10
P4HB 1.384 8.45E-04 1.222 4.68E-04 1.312 0.012 1.118 0.324 1.663 1.07E-06
PAOX 1.523 1.16E-05 1.15 1.09E-06 1.361 8.88E-04  -  -  -  - 
PCTP 1.788 2.49E-11 1.275 5.27E-07 1.906 0.001 1.825 7.55E-04 1.23 1.01E-05
PDIA5 1.753 1.26E-05 1.513 2.32E-06 1.656 1.60E-02 2.691 2.30E-02 1.604 1.60E-08
PDLIM5 3.035 1.71E-12 1.221 2.05E-04 2.529 2.00E-03 4.562 4.48E-05 2.883 4.64E-13
PEX10 1.51 4.58E-05 1.196 7.19E-07 1.117 0.291  -  -  -  - 
PLA1A 2.52 5.63E-10 1.768 3.59E-17 10.61 5.20E-07 2.857 4.00E-03 2.638 5.83E-10
PPP1CA 1.239 0.003 1.006 0.457 -1.108 0.077 2.624 0.012 1.245 5.92E-04
PRDX4 1.625 2.32E-06 1.31 3.25E-07 1.854 4.00E-04 2.938 8.21E-05 1.5 3.43E-05
PTPRN2 1.864 1.99E-04 1.552 3.01E-07 1.635 6.19E-04 1.693 0.052 1.637 2.01E-06
PVRL2 1.308 8.66E-04 1.205 5.79E-05 1.509 0.013 1.672 0.004 1.535 1.35E-05
PVRL3 1.326 7.00E-03 1.395 9.86E-07 2.17 2.01E-05 2.922 6.00E-03 1.603 2.21E-07
PXDN 1.626 1.50E-02 1.272 7.55E-06 1.602 5.64E-04 2.541 5.27E-05 1.531 2.23E-10
PYCR1 2.328 8.00E-08 1.366 1.67E-11 1.95 0.000347  -  -  -  - 
RAB11A 1.656 2.41E-07 1.177 0.009 1.136 0.241 3.839 4.28E-06 1.361 2.85E-08
RAB3B 2.297 0.002 1.659 1.45E-04 2.181 0.006 1.489 0.089 1.995 1.50E-07
RAB3IP 1.547 1.46E-04 1.289 2.92E-04 1.717 0.144 1.213 0.139 1.546 3.89E-10
RABEP2 1.62 1.90E-07 1.197 5.41E-08 1.323 0.014 1.828 0.001  -  - 
RAC3 1.31 1.22E-04 1.173 2.66E-06 2.577 0.039 1.728 0.036  -  - 
RAP1GAP 1.815 1.83E-10 1.471 5.65E-12 1.723 0.001 1.844 0.002 1.22 0.023
REPS2 2.815 3.63E-13 1.363 5.82E-14 3.099 4.77E-05 2.75 0.001 1.664 0.000248
RER1 1.234 0.00027 -1.058 0.848 1.627 0.136 1.733 0.01 1.704 5.71E-10
RPN2 1.435 1.67E-04 1.201 3.00E-03 1.213 1.12E-01  -  - 1.083 1.21E-01
SDK1 2.959 1.98E-13 1.596 7.77E-23 2.679 6.18E-05 2.445 3.85E-04  -  - 
SERINC2 1.246 0.04 1.094 0.015 1.093 0.301 -1.055 0.612 1.273 8.08E-04
SERP1 1.323 4.33E-04 1.221 4.51E-04 1.15 1.70E-01 3.597 1.06E-07 1.312 9.58E-07
SH3BP4 1.473 3.29E-04 1.159 4.00E-03 1.943 3.19E-04  -  - 1.18 0.015
SIM2 4.414 3.68E-07 1.788 1.54E-13 9.229 1.08E-05  -  - 2.8 2.92E-11
SLC25A16 1.275 0.004 1.049 0.059 -1.196 0.739 3.02 1.18E-05  -  - 
SLC25A33 1.475 8.55E-06 1.299 3.54E-06 1.233 0.124 2.241 0.001 1.303 0.0001
SLC43A1 2.423 6.32E-13 1.627 1.00E-15 2.049 1.27E-05 1.965 0.005 2.597 7.36E-15
SOAT1 1.516 4.98E-04 1.375 5.80E-04 1.12 1.314 -1.512 0.953 1.203 0.004
SPOCK1 1.671 1.00E-03 1.518 1.40E-04 1.739 2.10E-02 5.598 4.87E-05 2.144 5.92E-13
SPTBN2 1.512 2.53E-06 1.248 4.30E-06 2.27 0.014 1.611 0.187  -  - 
SRM 1.275 9.02E-05 1.153 6.24E-09 1.437 0.002 1.588 0.002 1.68 3.60E-09
SRPRB 1.372 1.87E-07 1.302 1.11E-04 1.311 2.70E-02 2.351 4.19E-05 1.324 3.28E-06
ST14 1.647 7.20E-05 1.264 2.99E-05 1.529 0.005 2.43 3.25E-06 1.513 1.13E-07
ST6GAL1 1.41 0.05 1.23 0.012 2.63 0.001 -3.906 1 1.32 0.003
ST6GALNAC1 2.951 5.18E-07 1.378 1.07E-09 4.049 1.99E-06  -  - 1.258 0.026
STRA13 1.419 5.53E-05 1.101 1.31E-05 1.156 0.138 1.255 0.205 1.589 1.72E-07
STT3A 1.263 4.02E-04 1.132 0.025  -  - 2.687 2.70E-05 1.278 1.68E-05
SYNGR2 1.629 0.001 1.138 8.29E-04 1.486 0.002  -  -  -  - 
TARP 3.456 9.20E-08 2.466 8.17E-07 2.047 1.90E-02 2.73 0.007 2.623 8.55E-09
TMED3 1.359 2.17E-04 1.144 0.003 1.644 1.78E-04  -  - 1.426 3.24E-06
TMEFF2 2.846 7.51E-04 2.178 1.20E-05 3.308 1.70E-02  -  - 1.676 0.004
TMEM125 1.5 0.024 1.112 0.009 1.023 0.455  -  - 1.371 2.74E-04
TMSB15A 3.215 2.11E-05 1.42 5.18E-13 3.389 4.31E-05  -  -  -  - 
TRIM36 2.37 7.28E-05 1.853 1.80E-07 3.454 2.21E-04 1.354 0.075 1.515 7.14E-04
TRPM4 3.059 7.08E-11 1.18 5.59E-04 3.622 3.94E-06  -  - -1.275 1.00E+00
TSPAN1 2.214 1.13E-06 1.844 1.72E-07 2.303 7.00E-03  -  - 1.59 4.19E-04
TSPAN13 2.486 4.48E-08 1.564 2.45E-09 -1.119 0.704 3.324 8.72E-08 2.462 2.30E-18
TTC39A 1.533 0.012 1.141 0.025 1.133 0.31 -1.588 0.998 1.114 0.106
TUSC3 1.312 1.00E-03 1.257 1.00E-03 1.507 4.70E-02 1.759 0.013 1.066 0.163
TWIST1 1.901 7.38E-06 1.157 4.97E-05 4.697 9.62E-05  -  - 1.639 2.18E-06
UAP1 2.439 1.50E-13 1.761 1.37E-12 2.606 1.34E-07 3.521 1.31E-07 2.387 1.07E-16
UBE2J1 1.476 2.93E-04 1.323 2.84E-04 1.518 1.22E-05 3.781 0.011 1.186 0.000809
UGGT1 1.44 8.02E-05 1.099 7.60E-02 1.11 3.11E-01 1.044 0.394 1.224 1.00E-03
VPS26B 1.197 7.13E-04 1.058 0.049 1.147 0.048 -1.099 0.683 1.338 1.31E-05
YIPF1 1.516 1.15E-04 1.334 4.34E-04  -  -  -  - 1.106 0.088
ZCCHC6 1.836 9.83E-07 1.452 5.41E-05 1.291 1.30E-02 3.155 3.13E-07 1.716 2.52E-09
ZDHHC9 1.474 2.23E-04 1.45 1.53E-07 1.45 7.91E-06 2.018 4.44E-05 1.661 4.73E-11
ZNF350 1.541 2.68E-04 1.232 0.007 1.073 0.385 2.117 0.002 1.771 3.84E-08
ZNF697 1.517 0.000309 1.086 4.00E-03 1.831 0.002 2.107 0.000226 1.445 9.19E-06
Gene
Grasso et al Taylor et al Varambally et al Tomlins et al Lapointe et al 
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Table 3.2 Meta-analysis using Oncomine online database of genes up-
regulated by androgens in LNCaP cells and down-regulated in patients post ADT. 
Five micro-array datasets were interrogated using the Oncomine database. For each 
study, gene expression in prostate cancer tissue was compared with that of normal 
tissue (control). The table shows genes which passed the threshold criteria (fold 
change >1, p value <0.05 in at least two of the five studies) with their associated fold 
change (fc) and p value for each of the five datasets (Lapointe et al., 2004; Varambally 
et al., 2005; Tomlins et al., 2007; Taylor et al., 2010; Grasso et al., 2012). Genes which 
meet the threshold criteria in at least four of the five studies are highlighted blue, and 




3.3.3 Gene ontology analysis identifies glycosylation as a key androgen 
regulated processed in prostate cancer 
 
To focus analysis of the dataset, Gene Ontology (GO) enrichment analysis was carried 
out by Dr Katherine James (Newcastle University). Briefly, GO analysis was used to 
investigate the pathways associated with biological processes as previously described 
(Young et al., 2010). Genes were considered significant at a p-value threshold of 0.05 
after adjustment using the Benjamini-Hochberg false discovery rate. 
 
 
GO analysis of the reciprocally regulated gene sets identified 72 terms with significant 
gene enrichment (p < 0.05). The top 30 significantly enriched terms from the up-regulated 
gene set are shown in Figure 3.4. Only one GO term was identified with significant gene 
enrichment within the down-regulated gene set. This was cell morphogenesis involved 






Figure 3.4 Gene Ontology (GO) analysis of the reciprocally regulated genes. 
GO analysis of the 660 reciprocally regulated gene set identified 72 terms with significant 
gene enrichment (p < 0.05). GO analysis was performed by Dr Katherine James 
(Newcastle University). The bar graph shows the –log10 (p values) for the top 30 
significantly enriched terms. Glycosylation related terms; glycoprotein biosynthetic 
process, protein N-linked glycosylation via asparagine, glycoprotein metabolic process, 
protein N-linked glycosylation, protein glycosylation, macromolecule glycosylation and 
glycosylation are highlighted within the blue boxes. 
 
 
GO investigation identified a number of known androgen regulated processes including 
lipid and cholesterol biosynthesis (Suburu and Chen, 2012; Wu et al., 2014), fatty acid 
metabolism (Swinnen et al., 2000; Li et al., 2016a), and response to ER stress (Sheng 
et al., 2015; Storm et al., 2016). Glycosylation was identified as a previously unidentified 
system-wide androgen-regulated process, involving 7 of the top 30 significantly enriched 
GO terms; glycoprotein biosynthetic process (GO:0009101), protein N-linked 
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glycosylation via asparagine (GO:0018279), glycoprotein metabolic process 
(GO:0009100), protein N-linked glycosylation (GO:0006487), protein glycosylation 
(GO:0006486), macromolecule glycosylation (GO:0043413) and glycosylation 
(GO:0070085) (highlighted within the blue boxes in Figure 3.4). 
 
 
There was an enrichment of genes encoding glycosylation enzymes within the dataset; 
a total of 31 genes involved in glycosylation were identified. Androgen regulation of these 
genes was confirmed in an independent LNCaP sample set by real-time quantitative 
reverse transcription PCR (qRT-PCR) (Figure 3.5). Further online GO software packages 
was used to confirm our findings, these included GOrilla (Gene Ontology enRIchment 
anaLysis and visuaLizAtion tool), available at http://cbl-gorilla.cs.technion.ac.il/ and The 











Figure 3.5 Expression of glycosylation related genes in LNCaP cell line in 
response to androgens. Real-time quantitative reverse transcription PCR (qRT-PCR) 
analysis of 31 glycosylation related genes in LNCaP cells in response to 10 nM synthetic 
androgen (R1881) stimulation (24 hours). Gene expression was calculated as the 
average (3 biological replicates) fold change (log2) relative quantification of androgen 
treated LNCaP cells compared to steroid deplete cells (value set as 1). Samples were 
normalised using the average of three reference genes, GAPDH, β -tubulin and 
actin. Statistical significance was calculated using an independent two-sample t-test. All 






Aberrant protein glycosylation is known to be associated with the development of many 
cancers. Changes in the glycan composition of PCa cells has been linked to disease 
progression: ST6 N-acetylgalactosaminide α-2,6-sialyltransferase 1 (ST6GALNAC1), 
UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1), glucosamine-phosphate N-
acetyltransferase 1 (GNPNAT1) and glucosaminyl (N-acetyl) transferase 1 (GCNT1), are 
all known AR target genes that have previously been linked with PCa progression. 
ST6GALNAC1 is a direct target of the AR and can affect cell adhesion (Munkley et al., 
2015b). UAP1 is over-expressed in PCa patients and its expression negatively correlates 
with Gleason score (Itkonen et al., 2015). GNPNAT1 is significantly decreased in CRPC 
and is linked to increased proliferation and aggressiveness (Kaushik et al., 2016), whilst 
GCNT1 expression correlates with the aggressive potential of PCa (Hagisawa et al., 
2005; Chen et al., 2014).  
 
 
Although not previously directly identified as androgen responsive genes, tumour 
suppressor candidate 3 (TUSC3) and α (1,6) fucosyltransferase (FUT8) have been 
linked to PCa. TUSC3 knockdown in PC3 and DU145 cell lines alters the ER stress 
response and accelerates proliferation and invasion (Horak et al., 2014). Although the 
function of TUSC3 has not yet been characterised, it shares homology with the S. 
cerevisiae oligosaccharyltransferase (OST) complex subunit Ost3p, implying a role in 
protein glycosylation. Over-expression of α (1,6) fucosyltransferase (FUT8) in LNCaP 
cells increases cell migration, while loss of FUT8 in PC3 cells decreased cell motility 
(Wang et al., 2014b).  
 
 
Androgen regulated expression of these glycosylation genes was also analysed in the 
VCaP cell line by real-time quantitative reverse transcription PCR (qRT-PCR) (Figure 
3.6). Again, VCaP cells were treated with 10nM R1881 for 24 hours (A+) or without 






Figure 3.6 Expression of glycosylation related genes in VCaP cell line in 
response to androgens. Real-time quantitative reverse transcription PCR (qRT-PCR) 
analysis of 31 glycosylation related genes in VCaP cells in response to 10 nM synthetic 
androgen (R1881) stimulation (24 hours). Gene expression was calculated as the 
average (3 biological replicates) fold change (log2) relative quantification of androgen 
treated LNCaP cells compared to steroid deplete cells (value set as 1). Samples were 
normalised using the average of three reference genes, GAPDH, β -tubulin and actin. 
Statistical significance was calculated using an independent two-sample t-test. All primer 





























































































































































































































































































































Of the 31 identified glycosylation genes, 17 meet the threshold criteria for our earlier 
meta-analysis (fold change >1, p value <0.05 in at least two of the studies analysed): 
dolichyl-phosphate beta-glucosyltransferase (ALG5), ADP ribosylation factor 4 (ARF4), 
calreticulin (CALR), ER degradation enhancing alpha-mannosidase like protein 3 
(EDEM3), fucosyltransferase 1 (FUT1), glucosaminyl (N-acetyl) transferase 1 (GCNT1), 
polypeptide N-acetylgalactosaminyltransferase 7 (GALNT7), glucosamine-phosphate N-
acetyltransferase 1 (GNPNAT1),  Nacetylneuraminate synthase (NANS), ribophorin 
II (RPN2), stress associated endoplasmic reticulum protein 1 (SERP1), catalytic subunit 
of the oligosaccharyltransferase complex (STT3A), ST6 N-acetylgalactosaminide α-2,6-
sialyltransferase 1 (ST6GALNAC1), ST6 beta-galactoside alpha-2,6-sialyltransferase 1 
(ST6GAL1), tumour suppressor candidate 3 (TUSC3), UDP-N-acetylglucosamine 
pyrophosphorylase 1 (UAP1), ubiquitin conjugating enzyme E2 J1 (UBE2J1) and UDP-
glucose glycoprotein glucosyltransferase 1 (UGGT1). Of these, 7 meet the threshold 
criteria in at least four of the five studies: EDEM3, GCNT1, SERP1, STT3A, 
ST6GALNAC1, ST6GAL1, and TUSC3 and 3 meet the criteria in all five of the studies: 
GNPNAT1, UBE2J1 and UAP1. ST6GALNAC1, UAP1, ST6GAL1 and UBE2J1 have the 
highest expression fold change in response to androgens in both the LNCaP and VCaP 
cell lines.  
 
 
To confirm androgen regulation of these genes, AR binding profiles created using 
chromatin immunoprecipitation with direct Solexa sequencing (ChIP-seq) were 
interrogated. Massie et al 2011 mapped AR binding profiles in LNCaP and VCaP cell 
lines, identifying 11,053 AR binding sites in LNCaP cells and 51,811 AR binding sites in 
VCaP cells (Massie et al., 2011). Annotations from the UCSC genome browser were 
used to calculate the distance to the transcription start sites for each of the identified 
glycosylation genes (Table 3.3).  
 
 
From the 10 genes which meet the threshold criteria in at least four of the five meta-
analysis studies, 9 had AR binding site within 50kb of the transcription start site: EDEM3 
(9.3kb), GCNT1 (29.6kb), SERP1 (48.5kb), STT3A (14.5kb), ST6GALNAC1 (2.6kb), 
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ST6GAL1 (7.2kb), TUSC3 (1.3kb), UBE2J1 (6.1kb) and UAP1 (9.3kb) suggesting that 






































Table 3.3 Distance in kilobases (kb) of androgen receptor binding sites from 
the transcriptional start site of the identified glycosylation genes. Published data 
from mapped AR binding profiles (Massie et al., 2011) were used to calculate the 
distance in kilobases (kb) of AR binding sites from the transcriptional start sites of the 
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glycosylation genes. AR binding site annotations were created by uploading the 
published data to the UCSC genome browser and calculations were made for each gene. 
Numbers in red indicate the presence of an AR binding site within 50kb of the 
transcription start site of the gene. Genes highlighted in blue represent genes which meet 































In this chapter, RNA sequencing has been used to identify reciprocal gene expression 
changes in response to acute androgen stimulation in cultured prostate cancer cells, and 
androgen deprivation in 7 patients with prostate cancer. This method highlighted a core 
set of 660 clinically relevant androgen-regulated genes: 548 genes whose expression 
was up-regulated by androgens in LNCaP cells and down-regulated in all 7 patients 
following ADT and 112 genes whose expression was down-regulated by androgens in 
LNCaP cells and up-regulated in 7 patients following ADT. This data provides a 
comprehensive map of AR-regulated genes in clinical prostate cancer. It offers a new 
window through which to understand the signalling pathways downstream of the AR and 
the role these pathways play in both the development of PCa and the response to ADT. 
 
Previous studies have looked at androgen regulation in vitro (Massie et al., 2007; Wang 
et al., 2007; Rajan et al., 2011) and somewhat fewer in vivo (Lohr et al., 2014; Rajan et 
al., 2014; Radtke et al., 2017). The correlation of androgen regulation in cell lines with 
PCa patient samples, coupled with a multiple dataset meta-analysis strategy presented 
here has identified a number of AR-regulated genes that have not previously been 
considered, such as the epithelial splicing regulatory protein ESRP2, the nectin cell 
adhesion molecule PVRL2 and cell migration protein TSPAN1. Further investigation has 
found that increased expression of TSPAN1 in prostate cancer cells controls the 
expression of key proteins involved in cell migration, and is important for cancer cell 
survival (Munkley et al., 2017b).] 
 
Although we have identified a number of individual genes as androgen regulated, further 
analysis of the dataset indicates a system wide regulation, with a significant enrichment 
in the cellular process glycosylation. A total of 31 genes were identified in the GO 
analysis, of these 10 also showed significant gene expression changes (fold change >1, 
p value <0.05) in at least four of the five meta-analysis studies: EDEM3, GCNT1, SERP1, 
STT3A, ST6GALNAC1, ST6GAL1, GNPNAT1, UBE2J1, TUSC3 and UAP1. Of these, 9 
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genes had an AR binding site within 50kb of the transcription start site, suggesting 
changes in expression were directly under AR control. 
 
Aberrant glycosylation, primarily caused by altered expression or the mislocalisation of 
glycoenzymes is a common feature of cancer cells (Pinho and Reis, 2015; Stowell et al., 
2015). Alterations in the expression of these glycoenzymes can lead to modifications 
which can alter many important biological processes such as cell-cell adhesion, 
migration, interactions with the cell matrix, immune surveillance, signalling and cellular 
metabolism (Munkley and Elliott, 2016). The enrichment of genes encoding glycosylation 
enzymes within our dataset suggests that these genes may play a role in modifying some 
of these processes in PCa and could therefore contribute to disease progression.  
 
 
From the genes identified, GCNT1, ST6GALNAC1, TUSC3 and UAP1 have previously 
been linked to PCa. Increased expression of GCNT1, which is involved in the formation 
of branched O-linked glycans, has been shown to positively correlate with the aggressive 
potential of PCa (Hagisawa et al., 2005; Chen et al., 2014). Increased expression of 
ST6GalNAc1 by androgens in prostate cancer cells can reduce prostate cancer cell 
adhesion (Munkley et al., 2015b; Munkley et al., 2016b). Knockdown of the novel tumour 
suppressor gene TUSC3 in PCa cell lines alters the ER stress response and accelerates 
proliferation and invasion (Horak et al., 2014). UAP1 is highly overexpressed in PCa and 
can protect cancer cells from ER stress by protecting against inhibitors (Itkonen et al., 
2014). Both SERP1 and UBE2J1 have been identified as androgen regulated in previous 
microarray profiling studies (Lin et al., 2013), however there has been no linked made to 
the prostate cancer progression. In fact, UBE2J1 expression has no impact on LNCaP 
androgen independent cell growth (Sun et al., 2014). As far as I am aware, this is the 
first time androgen regulation of EDEM3, STT3A, and ST6GAL1 has been described.  
 
 
The identification of glycosylation as an androgen regulated process in PCa could have 
important clinical implications both in patient diagnosis and therapeutic strategies. An 
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increased understanding of how these individual glycoenzmyes and glycosylation as a 
whole influences prostate cancer cell behaviour is required. This could assist in the 
development of new glyco-based specific biomarkers for use in the early detection and 
management of PCa. Glycans have been shown to play a role in all aspects of cancer 
progression and are therefore attractive targets for therapeutic intervention (Munkley and 
Elliott, 2016). Inhibiting glycosylation, even in conditions where the AR is active, can 












































Chapter 4 Results 
 
Characterisation of ST6Gal1 in prostate cancer  
4.1  Introduction 
4.1.1 Glycosylation is an androgen regulated process 
 
In the previous chapter I presented data that identified glycosylation as a global target 
for androgen control in prostate cancer cells. Understanding the role androgen-regulated 
pathways play in prostate cancer is important as it can have clinical implications in patient 
diagnosis and treatment. Analysis of our RNA sequencing data identified 31 individual 
glycosylation related genes with reciprocal expression patterns following androgen 
stimulation in vitro and ADT in patient samples. Meta-analysis of five individual PCa gene 
expression datasets (Lapointe et al., 2004; Varambally et al., 2005; Tomlins et al., 2007; 
Taylor et al., 2010; Grasso et al., 2012) identified a subset of 10 glycosylation genes with 
significant expression changes (p value <0.05) in PCa relative to normal prostate gland 
in at least four of the five datasets. These genes were: EDEM3, GCNT1, SERP1, STT3A, 
ST6GALNAC1, ST6GAL1, TUSC3, GNPNAT1, UBE2J1 and UAP1.     
 
EDEM3 stimulates mannose trimming of N-glycans and belongs to a group of proteins 
that are involved in the endoplasmic reticulum-associated degradation (ERAD) of 
misfolded glycoproteins (Hirao et al., 2006; Olivari and Molinari, 2007). ERAD is a highly 
controlled mechanism within the ER that degrades unwanted and misfolded 
glycoproteins. ERAD is especially important in cancer, where increased metabolic 
activity can lead to the accumulation of faulty proteins (Olzmann et al., 2013). The ERAD 
pathway is known to be androgen regulated; androgen treatment causes an up-
regulation of ERAD associated genes and increases the degradation rate of ERAD 
substrates (Erzurumlu and Ballar, 2017). Work within our laboratory has found that 
expression of EDEM3 is androgen regulated in PCa cells and is important for PCa cell 
viability and growth (Munkley et al., 2016b).  
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SERP1, a stress response protein which helps stabilises membrane proteins and 
facilitates N-linked glycosylation (Yamaguchi et al., 1999; Xiao et al., 2017) has recently 
been identified as a marker of poor prognosis in pancreatic ductal adenocarcinoma 
patients (Ma et al., 2017). UBE2J1 is another glyco-enzyme which functions within the 
ERAD pathway, catalysing the covalent attachment of ubiquitin to proteins for 
degradation. Androgen regulation of SERP1 and UBE2J1 has been described previously 
(Jin et al., 2013) but there are no currently reported links to prostate cancer.  
 
GCNT1 is a glycosyltransferase that is involved in the formation of core 2 branched O-
glycans. O-glycans are often altered in the early stages of cellular transformation and 
are important for initiation, invasion and metastasis (Pinho and Reis, 2015). GCNT1 
expression is regulated by androgens in PCa cells and has been associated with 
aggressive potential (Munkley et al., 2016b; Sato et al., 2016). Detection of GCNT1 in 
PCa patients urine has been used differentiate between extracapsular extension and 
localised disease (Kojima et al., 2015). Increased expression of GCNT1 has also been 
implicated in the synthesis of the cancer associated SLex antigen (Chen et al., 2014).  
 
STT3A encodes the catalytic subunit of the oligosaccharyltransferase (OST) complex 
(Yan and Lennarz, 2002; Nilsson et al., 2003). The OST complex functions in the 
endoplasmic reticulum to transfer complex glycan chains to asparagine residues of target 
proteins. The STT3A protein is present in the majority of OST complexes and is involved 
in the co-translational N-glycosylation of most sites on target proteins. Androgen 
regulation of STT3A expression has not previously been described and there no clear 
links to cancer have been reported. TUSC3 is another component of the OST complex. 
Localised to the ER, TUSC3 functions in final stages of N-glycosylation through its 
interaction with the STT3B subunit (Horak et al., 2014; Mohorko et al., 2014). TUSC3 
knockdown in PCa cells alters the ER stress response and accelerates proliferation and 




Previous work in our laboratory has found that expression of ST6GalNAc1, a 
sialytransferase that catalyses the transfer of sialic acid onto the Tn antigen, is regulated 
by androgens and can affect cell adhesion (Munkley et al., 2015b). Increased 
ST6GalNAc1 expression is found in primary prostate tumours, although this expression 
is down-regulated in metastatic tissue compared to non-malignant prostate tissue, 
suggesting a more transient role in tumour progression. An androgen regulated novel 
splice variant of the ST6GalNAc1 protein in PCa cells reduces adhesion, increases 
motility and promotes a transition towards a mesenchymal like phenotype (Munkley et 
al., 2015b).  
 
ST6Gal1 is another sialytransferase that catalyses the transfer of sialic acid from CMP-
sialic acid to N-terminus of galactose-containing substrates. Increased sialylation is 
already known to be associated with cancer cell progression and metastasis, affecting 
cell adhesion, migration and invasion (Seales et al., 2005; Bull et al., 2013; Pinho and 
Reis, 2015). Up-regulation of ST6Gal1 has been described in several cancers including 
colon cancer (Dall'Olio et al., 1989), breast cancer (Lin et al., 2002), choriocarcinoma 
(Fukushima et al., 1998), hepatocarcinoma (Dall'Olio et al., 2004; Poon et al., 2005), 
cervical cancer (Wang et al., 2001), and myeloid leukaemias (Skacel et al., 1991). Whilst 
there are many studies that support the oncogenic role of ST6Gal1 in cancer (Britain CM 
2017) (Swindall and Bellis, 2011) (Amano et al., 2003; Seales et al., 2005; Shaikh et al., 
2008; Liu et al., 2011; Park et al., 2012) (Lin et al., 2002) (Meng et al., 2015) (Zhu et al., 
2001) (Lu et al., 2014) (Liu et al., 2014b) (Hsieh et al., 2017) (Mondal et al., 2010), there 
is also contradictory evidence to suggest that ST6Gal1 may also have tumour 
suppressor potential (Park et al., 2012) (Wild et al., 2005) (Antony et al., 2014), and its 
role in PCa is yet to be established. 
 
The hexosamine biosynthetic pathway (HBP) pathway works to metabolise glucose to 
produce UDP- N-acetylglucosamine (GlcNAc). UDP-GlcNAc functions as the main sugar 
donor for N-linked and O-linked glycosylation. GNPNAT1 is an acyltransferases which is 
involved in the HBP. GNPNAT1 expression is regulated by androgens and elevated in 
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androgen dependant PCa cells. GNPNAT1 expression is significantly decreased in 
CRPC compared to localised PCa and it has been linked to increased proliferation and 
aggressiveness (Kaushik et al., 2016). UAP1 is the last enzyme in the HBP and is highly 
over-expressed in PCa patients (Itkonen et al., 2015). We have also shown that depletion 
of UAP1 in PCa cells reduces cell viability (Munkley et al., 2016b).  
 
4.1.2 The role of ST6Gal1 in prostate cancer 
Taken together, the above data suggests that glycosylation is an androgen regulated 
process and that the controlled expression of many glycosylation associated enzymes 
may help contribute towards PCa development and progression (Munkley et al., 2016b; 
Munkley, 2017). Of the identified genes, I decided to investigate the role of ST6Gal1 in 
PCa further. ST6Gal1 is a member of the ST6 sialytransferase family which catalyses 
the transfer of sialic acid from CMP-sialic acid to galactose containing acceptor 
substrates on N-glycans in the α-2,6 formation (Weijers et al., 2008). Sialic acids are 
often expressed as the terminal glycan of glycoconjugates and due to their terminal 
locality have associated with functions such as adhesion, recognition, immune defence 
and stability (Hedlund et al., 2008; Swindall and Bellis, 2011; Schultz et al., 2012). 
Elevated sialyltransferase activity can result in hypersialylation and an upregulation of 
sialylated glycans, which has been linked to cancer (Pearce and Laubli, 2016; Wang et 
al., 2016b). Hypersialylation is an established hallmark of cancer and has been 
associated with more malignant tumour phenotypes (Hauselmann and Borsig, 2014; 
Munkley and Elliott, 2016). 
 
ST6Gal1 has been shown to function as a regulator of cell survival; α-2,6 sialylation of 
the Fas death receptor (CD95), tumour necrosis receptor 1 (TNFR1) and the CD45 
receptor, protects against apoptosis (Amano et al., 2003; Liu et al., 2011; Swindall and 
Bellis, 2011). ST6Gal1 up-regulation promotes cell migration and invasion through its 
interaction with the β1 integrin and EGFR receptors (Seales et al., 2005; Shaikh et al., 
2008; Park et al., 2012), whilst knockdown of ST6Gal1 inhibits metastasis in breast 
cancer (Lin et al., 2002), osteosarcoma (Meng et al., 2015) and colon cancer (Zhu et al., 
113 
 
2001). In localised clear-cell renal carcinomas, ST6Gal1 expression is an adverse 
predictor of survival and recurrence (Liu et al., 2014b), whilst in pancreatic cancer, high 
ST6Gal1 expression predicted poorer patient prognosis (Hsieh et al., 2017). High 
ST6Gal1 expression also positively correlates with high risk of paediatric acute leukemia 
(Mondal et al., 2010).  
 
Whilst there are many studies that support the oncogenic role of ST6Gal1 in cancer, 
there is also contradictory evidence to suggest that ST6Gal1 may also have tumour 
suppressor potential. Down-regulation of ST6Gal1 in colorectal cancer (CRC) cell lines 
increased cell proliferation and tumour growth (Park et al., 2012). In CRC patient pair-
matched tumour/normal tissue ST6Gal1 expression was significantly higher in non-
metastatic tumours than that in metastatic tumours (Zhang et al., 2017). ST6Gal1 is also 
down-regulated in invasive bladder cancer when compared to normal urothelium, and 
expression loss correlates with high grade, invasive clinical tumours (Wild et al., 2005). 
This expression loss is caused by aberrant ST6Gal1 promoter methylation, suggesting 
repression of a possible tumour suppressive role for ST6Gal1 in advanced bladder 
cancer (Antony et al., 2014).  
 
4.1.3 The role of ST6GAL1 in epithelial to mesenchymal transition (EMT)  
Epithelial to mesenchymal transition (EMT) is a highly conserved trans-differentiation 
process in which epithelial cells lose their polarity and take on more migratory 
mesenchymal properties (Thiery and Sleeman, 2006). EMT involves the loss of tight 
junctions, adherens junctions and desmosomes, together with cytoskeleton changes, a 
transcriptional shift and increased cell migration and motility potential. EMT is 
characterised by decreased expression of cell adhesion molecules and epithelial 
markers such as actin, E-cadherin, β-catenin, claudins and desmosomal proteins, and 
increased expression of intermediate filament proteins and mesenchymal cell markers, 
including N-cadherin, α-smooth muscle actin (α-SMA), and vimentin. EMT can be 
induced by a number of different growth and transcription factors including transforming 
growth factor-β (TGF-β) (Xu et al., 2009). Increased expression of ST6Gal1 has been 
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shown to promote TGF- β induced EMT in the mouse epithelial cell line GE11, through 
the down-regulation of E-cadherin mediated cell adhesion and up-regulation of integrin 
mediated cell migration (Lu et al., 2014).  
 
EMT plays an important role in the invasiveness of cancer cells and understanding the 
process of EMT may help unravel the mechanisms that control cancer progression. In 
particular, cancer cells undergoing EMT often present aberrant glycan structures, fuelled 
by metabolic reprogramming (Carvalho-Cruz et al., 2017).  
 
4.2 Aims of the chapter  
Current evidence suggests a complex role for ST6Gal1 in cancer development and 
progression. The work in this thesis has so far shown that ST6Gal1 expression is up-
regulated in PCa cells in response to androgen stimulation, but the role ST6Gal1 plays 
in PCa requires further investigation.  
 
The aims of this chapter were to: 
 Use prostate cancer cells lines and clinical patient samples to identify ST6Gal1 
expression patterns. 
 Use molecular cloning techniques to create stable prostate cancer cell lines with 
either ST6Gal1 over-expression or knock-down. 
 Investigate the effect of these expression changes on the cellular functions of 
prostate cancer cells (proliferation, migration, invasion potential). 
 Use RNA sequencing techniques to identify ST6Gal1 regulated transcriptional 
changes in prostate cancer. 
 
Achieving these aims will help us to understand the role that ST6Gal1 plays in prostate 




4.3.1 Expression of ST6Gal1 is up-regulated by androgens 
 
Our RNA sequencing data of LNCaP cells showed that ST6Gal1 expression is up-
regulated by androgen stimulation. A UCSC Genome Browser snapshot of this result is 
shown in Figure 4.1.  
 
 
Figure 4.1  UCSC Genome Browser snapshot showing RNA sequencing reads 
aligned to ST6Gal1. RNAseq profiles are shown from three biological replicates of 
LNCaP cells grown in the presence of 10 nM synthetic androgen R1881 for 24 hours 
(LNCaP Androgen) and LNCaP cells grown in charcoal stripped steroid deplete media 




To confirm androgen regulated of ST6Gal1, a new triplicate sample set of LNCaP cells 
were grown in charcoal stripped steroid deplete media (SD) for 24 hours, then treated 
with 10 nM synthetic androgen R1881 (A+) for three different time periods prior to harvest: 
24 hours, 48 hours and 72 hours. Figure 4.2 confirms that androgen treatment increased 




Figure 4.2  Expression of ST6Gal1 in the PCa LNCaP cell line. 
(a) Real-time quantitative reverse transcription PCR (qRT-PCR) analysis of 
ST6Gal1 mRNA in LNCaP cells treated with androgens over a 72 hour time 
period. Samples were taken at 24 hours, 48 hours and 72 hours. Gene 
expression was calculated as the average (from 3 biological replicates) fold 
change relative quantification of androgen treated LNCaP (A+) cells compared 
to steroid deplete cells (SD) (SD value set as 1). Samples were normalised using 
the average of three reference genes, GAPDH, β-tubulin and actin. Statistical 
significance was calculated using an independent two-sample t-test, where * p 
<0.05, ** p <0.01, *** p <0.0001, **** p <0.00001. All primer sequences are listed 
in Appendix B.  
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(b) Representative Western blot - expression of ST6Gal1 protein was induced in 
LNCaP cells treated with androgens at 24 hours, 48 hours and 72 hours. GAPDH 
(N-terminal) was used as a loading control. 
(c) Expression of ST6Gal1 protein detected in LNCaP cell treated with androgen for 
24 hours by immunofluorescence.  
 
 
Using a 24 hour time course in which cells were harvested at three hour intervals and 
qRT-PCR we found that androgen mediated induction of the ST6Gal1 gene could be 
detected in LNCaP cells after 6 hours androgen exposure (Figure 4.3a). This is a similar 
pattern of expression to PSA (Kim and Coetzee, 2004). ST6Gal1 expression was also 
blocked by treatment with the AR antagonist Casodex (bicalutamide) (Figure 4.3b), 












Figure 4.3  ST6Gal1 expression is directly regulated by the androgen receptor. 
(a) Real-time quantitative reverse transcription PCR (qRT-PCR) analysis of 
ST6Gal1 mRNA in LNCaP cells treated with androgens (A+) over a 24 hour time 
period (samples were taken every 3 hours). Gene expression was calculated as 
the average (from 3 biological replicates) fold change of androgen treated LNCaP 
(A+) cells relative to steroid deplete cells (SD) (value set as 1). Samples were 
normalised using the average of three reference genes (GAPDH, β -tubulin and 
actin).  
(b) Induction of ST6Gal1 mRNA by the AR is inhibited in the presence of 10 μM of 
the anti-androgen Casodex (bicalutamide). Statistical significance was calculated 
using an independent two-sample t-test, where * p <0.05, ** p <0.01, *** p 







Depletion of ST6Gal1 in LNCaP cells by two different siRNAs reduces cell viability. 
ST6Gal1 knockdown was confirmed at transcript level by qRT-PCR (Figure 4.4a) and at 
the protein level by Western blot (Figure 4.4b). Crystal violet staining of LNCaP cells 92 
hours after siRNA transfection shows a significant reduction in cell numbers compared 
to cells transfected with non-targeted control siRNA, indicating an important biological 
role for ST6GAL1 in these cells. 
 
 
Figure 4.4 ST6Gal1 knockdown reduces LNCaP cell viability. ST6Gal1 
expression is needed for prostate cancer cell viability. 
(a) Real-time quantitative reverse transcription PCR (qRT-PCR) analysis of ST6Gal1 
mRNA expression in LNCaP cells following siRNA transfection with 2 different 
siRNAs. Gene expression was calculated as the average (from 3 biological 
replicates) fold change of siRNA transfected cells relative to non-targeting siRNA 
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control cells (value set as 1). Samples were normalised using the average of 
three reference genes (GAPDH, β -tubulin and actin).  
(b) Representative Western blot confirmation of ST6Gal1 depletion after 72 hours. 
GAPDH (N-terminal) was used as a loading control. 
(c) Representative crystal violet stained images. Crystal violet dye binds to proteins 
and DNA of attached viable cells. There was a significant reduction in cell 
numbers in the ST6Gal1 siRNA depleted cells compared to cells transfected with 
non-targeted control siRNA. 
 
 
4.3.2 ST6Gal1 expression in clinical prostate cancer patients 
 
To investigate ST6Gal1 mRNA expression levels in prostate cancer patients, two 
independent clinical RNA validation cohorts were analysed using qRT-PCR. The first 
cohort compared RNA samples of benign prostatic hyperplasia (BPH) versus prostate 
carcinoma obtained from 49 patients, and the second cohort compared carcinoma 
versus adjacent normal tissue within 9 patients. Clinical samples were provided with 
ethical approval through the Exeter NIHR Clinical Research Facility tissue bank (Ref: 
STB20). Written informed consent for the use of surgically obtained tissue was provided 
by all patients. All carcinoma samples provided contained a tumour cellularity of at least 
80% to ensure the presence of sufficient tumour tissue for the experiments.  
 
In the BPH versus PCa tumour sample set, ST6Gal1 mRNA expression was increased 
in the tumour samples compared to the BPH samples (p=0.050) (Figure 4.5a). In the 
matched patient cohort, 6 of the 9 analysed patients showed a clear significant down-
regulation (p = <0.05) of ST6Gal1 mRNA expression in prostate carcinoma tissue 
compared to adjacent normal tissue (patients 1, 3, 5, 7, 8 and 9). Only one patient 
showed a significant increase (p = <0.05) in ST6Gal1 expression in prostate carcinoma 
tissue compared to adjacent normal tissue (patient 4) and for 2 of the patients there was 




Figure 4.5 ST6GAL1 mRNA expression levels in prostate cancer patient 
samples. Real-time quantitative reverse transcription PCR (qRT-PCR) analysis of 
ST6Gal1 mRNA expression in two independent clinical RNA datasets.  
(a) RNA from patients with benign prostatic hyperplasia (BPH) (n=32) and malignant 
samples from transurethral resection of the prostate (TURP) samples (n=17). 
ST6Gal1 expression was increased in the malignant patient samples compared to 
the BPH samples (p = 0.050).  
(b) RNA from matched tumour tissue and adjacent normal tissue samples from 9 
patients (* p <0.05, ** p <0.01, *** p <0.0001, **** p <0.00001). Six patients showed 
a clear significant down-regulation (p = <0.05) of ST6Gal1 mRNA expression in 




ST6Gal1 protein expression in PCa tissue was further examined using a tissue 
microarray (TMA) and an extensively validated ST6Gal1 antibody (Appendix C). Staining 





















































































Figure 4.6 ST6Gal1 antibody validation. Representative 0.6mm cores of prostate 
cancer tissue samples stained with the ST6Gal1 antibody (1:6000 dilution) and following 
incubation with the immunising peptide. Staining with the ST6Gal1 antibody was blocked 
by the immunising peptide, confirming specificity of the antibody.  
Prostate cancer tissue 
stained with ST6Gal1 
antibody at 1:6000 dilution 
Prostate cancer tissue stained 
with ST6Gal1 antibody at 
1:6000 dilution following pre-





Figure 4.7 ST6Gal1 protein expression is down-regulated in prostate cancer 
tissue compared to benign prostate hyperplasia (BPH) tissue. Analysis of ST6Gal1 
protein levels in patients with BPH or prostate cancer by tissue microarray (TMA). The 
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TMA was kindly provided by Professor Craig Robson (NICR, Newcastle) and the tissue 
staining and analysis was performed by Dr Urszula McClurg (NICR, Newcastle). Images, 
and graphs in this figure were also generated by Dr Urszula McClurg (NICR, Newcastle). 
(a) Representative 0.6mm cores of BPH and prostate cancer tissue samples stained 
with the ST6Gal1 antibody (1:6000 dilution).  
(b) Beeswarm plot shows significantly higher ST6Gal1 expression in the BPH samples 
compared to the prostate cancer samples (p = 0.0015). The TMA was scored using 
the 0-300 Histoscore score method (detailed in the methods section).   
(c) Kaplan-Meier survival curve show that patients with lower ST6Gal1 expression had 
a significantly reduced probability of overall survival (p = 0.0054) than patients with 
higher ST6Gal1 expression. 
(d) Beeswarm plot shows there is no significant difference in ST6Gal1 expression levels 
between the TMA prostate cancer patients with known metastasis and those without 
(p = 0.5206).   
(e) Beeswarm plot shows that lower ST6Gal1 expression levels are linked to higher PSA 
levels at relapse in prostate cancer samples. 
 
 
The TMA contained 0.6mm tissue cores from patients with BPH (n=26), prostate cancer 
(n=72) together with control tissues including breast, kidney, placenta, ovary, and liver. 
The TMA was stained and scored by Dr Urszula McClurg (NICR, Newcastle). 
Representative cores of BPH and prostate cancer tissues from the TMA are shown in 
Figure 4.7a. ST6Gal1 protein is expressed at significantly higher levels in the non-
malignant BPH tissue compared to prostate cancer patient tissue (p = 0.0015) (Figure 
4.7b). Lower levels of ST6Gal1 protein expression predict poor overall survival in months 
compared with higher levels of expression (p = 0.0054) (Figure 4.7c). Whilst there was 
no link between ST6Gal1 expression and metastasis (p = 0.5206) (Figure 4.7d), low 
ST6Gal1 levels were linked to higher PSA levels at relapse (p = 0.0265) (Figure 4.7e). 
The TMA shows that ST6Gal1 protein expression is significantly higher in the non-
malignant BPH tissue compared to PCa patient tissue. Published data comparing PCa 
to BPH is limited. Tomlins et al compared 11 BPH tissue samples and 49 prostate 
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carcinoma tissue samples and found that ST6Gal1 expression is higher in the BPH tissue 
compared to PCa patient tissue (Tomlins et al., 2007), which supports our data. Whilst 
Grasso et al compared 35 castrate resistant metastatic PCa, 59 localised PCa, and 28 
BPH tissue samples and found that ST6Gal1 expression was increased in PCa samples 
compared to BPH (Grasso et al., 2012).  
 
 
4.3.3 Creation of prostate cancer cell lines with ST6Gal1 over-expression and 
knock-down properties 
 
To investigate the biologically significance of increased ST6Gal1 expression on prostate 
cancer cell aggressiveness, molecular cloning and transfection techniques were used to 
establish cell lines with ST6Gal1 over-expression and knock-down properties. An initial 
screen of endogenous ST6Gal1 mRNA expression levels in various prostate cancer cells 
lines was performed using qRT-PCR (Figure 4.8).  
 
To create a cell line with increased stable expression, the ST6Gal1 coding sequence 
from LNCaP cells was PCR amplified and digested with appropriate restriction enzymes. 
The resulting purified DNA fragment was inserted into the p3xFLAG CMV-10 expression 
vector (Figure 4.9a) and transformed into DU145 cells. DU145 cells were chosen for 
transformation as they exhibited the lowest levels of endogenous ST6Gal1 expression 
(and so over-expressing ST6Gal1 might have the strongest effect). Empty p3xFLAG 
CMV-10 vectors were also transformed as controls. Stable transformants were selected 
using 300µg/ml Geneticin antibiotic (G418) selection. ST6Gal1 expression levels were 
assessed for each clone using RT-PCR and Western blot. Clones with the highest 
ST6Gal1 expression were selected and grown up for further analysis.  
 
A prostate cancer cell line with silenced ST6Gal1 expression was also created. The 
pLKO.1 HIV based lentiviral vector (Figure 4.9b) containing an shRNA targeting the 
ST6Gal1 coding sequence (NM_003032.2-1363s1c1) was transformed into CW-22Rv1 
cells. PCM3 and CW-22Rv1 cells were chosen as they exhibited higher endogenous 
ST6Gal1 expression, however transfection was only successful in the CW-22RV1 cells. 
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pLKO.1 vectors containing a scrambled sequence (shNC) with no homology to any 
known human genes were also transformed as controls. Stable transformants were 
selected with 1µg/ml Puromycin antibiotic. ST6Gal1 expression levels were assessed for 
each clone using RT-PCR and Western blot. Clones with the lowest ST6Gal1 expression 





Figure 4.8 ST6Gal 1 mRNA expression in various prostate cancer cell lines. 
Real-time quantitative reverse transcription PCR (qRT-PCR) analysis of ST6Gal1 mRNA 
expression in human prostate cancer cell lines (LNCaP steroid deplete (SD) and 
androgen (R1881) treated (A+), CW-22RV1, DU145, PC3 and PC3M). ST6Gal1 
expression was calculated as the average (from 3 biological replicates) fold change 
relative quantification compared to LNCaP steroid deplete cells (SD) (value set as 1). 
Samples were normalised using the average of three reference genes, GAPDH, β -

































Figugre 4.9 Expression vector maps. Maps of the expression vectors used to create 
prostate cancer cell lines with ST6Gal1 over-expression and knock-down properties.  
a) The full length ST6Gal1 construct was cloned into the p3xFLAG CMV-10 
expression vector (Sigma E7658) using NotI and BamHI restriction enzymes. 
b) The pLKO.1 HIV based lentiviral vector containing shRNA targeting the ST6Gal1 
coding sequence (NM_003032.2-1363s1c1) was purchased from Sigma.  
 
 
As predicted, the DU145 stable cell line exhibited significantly higher levels of ST6Gal1 
mRNA and protein compared to the empty vector control cells, confirmed by RT-PCR 
(Figure 4.10a) and western blot (Figure 4.10c). For the knockdown cell line, ST6Gal1-
shRNA transfection significantly inhibited ST6Gal1 mRNA expression in CW-22Rv1 cells 
compared to cells transfected with negative control shRNA, confirmed by RT-PCR 
(Figure 4.10b). ST6Gal1 protein levels were also significantly suppressed in ST6Gal-I-





Figure 4.10 Validation of ST6Gal1 overexpression and knock-down by real-time 
PCR and western blot. Real-time quantitative reverse transcription PCR (qRT-PCR) 
validation of (a) ST6Gal1 overexpression in DU145 cells and (b) ST6Gal1 knock-down 
in CW-22Rv1 cells. ST6Gal1 expression was calculated as the average (from 3 biological 
replicates) fold change relative quantification compared to the empty vector control cells 
(EVC) (value set as 1). Samples were normalised using the average of three reference 
genes, GAPDH, β -tubulin and actin (* p <0.05, ** p <0.01, *** p <0.0001, **** p <0.00001). 
Representative Western blot protein level validation of (c) ST6Gal1 overexpression in 
DU145 cells, (d) ST6Gal1 knock-down in CW-22Rv1 cells. GAPDH (using an antibody 




4.3.4 Effect of ST6Gal1 over-expression on cellular properties 
 
The effect of increased ST6Gal1 expression on DU145 cell proliferation was investigated 
using two separate assays: the WST-1 proliferation assay kit and the Click-iT EdU Alexa 
Fluor 594 imaging kit. The WST-1 assay is a colorimetric assay based on the reduction 
of tetrazolium salt WST-1 to soluble form by electron transport across the plasma 
membrane of dividing cells. The Click-iT EdU assay uses a modified thymidine analogue 
(EdU) which is fluorescently labelled. Incorporation of EdU into DNA during active DNA 
synthesis produces a fluorescent signal which can be detected by fluorescent 
microscopy. Based on either assay, up-pregulated ST6Gal1 expression had no 









Figure 4.11 Increased ST6Gal1 expression has no effect on cell proliferation. 
Cell proliferation assays showed that increased ST6Gal1 had no significant effect on cell 
proliferation in DU145 cells. 
a) WST-1 assay: DU145 cells expressing increased ST6Gal1 and empty vector control 
cells were grown in the presence of WST-1 reagent. Viable, actively dividing cells 
cleave the tetrazolium salt WST-1 to produce a formazan dye allowing 
spectrophotometric quantification. Cell proliferation was measured over a 6 day 
period.  
b) Click-iT EdU assay: cells were grown on coverslips and labelled with EdU which is 
incorporated into newly synthesized DNA. Detection is based on click chemistry, a 
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covalent reaction between an alkyne (ethynyl moiety of EdU) and an azide coupled 
to a fluorescent dye (Alexa Fluor 594). Nuclei are counterstained with blue DAPI. 
Fluorescent microscopy was used to detect actively dividing cells (red) on non-diving 
cells (blue).  
c) The number of actively dividing cells was calculated as a percentage of the total 
number of cells in DU145 cells expressing increased ST6Gal1 and empty vector 
control cells (25 images from each condition).  
 
 
The effect of increased ST6Gal1 expression on cell adhesion was investigated using a 
calcein-AM based cell adhesion assay. Over-expression of ST6Gal1 significantly 
increased DU145 cell adhesion to uncoated plates, and also plates coated with 











Figure 4.12 ST6Gal1 increases cell adhesion in DU154 cells. DU145 cells 
expressing increased ST6Gal1 and empty vector control cells were labelled with calcein-
AM and allowed to adhere to (a) un-coated and (b) fibronectin coated plates. The 
percentage cell adhesion was calculated by comparing a washed plate (representative 
of adherent cells) to an identical unwashed plate (representative of the total number of 
cells seeded). DU145 cells with increased ST6Gal1 expression had a significantly 
greater adhesion to both the un-coated and fibronectin coated plates.  
 
 
Metastasis is associated with the poor prognosis and survival in PCa patients. The effect 
of increased ST6Gal1 expression on cell migration was investigated using a standard 
scratch assay using a non-coated culture plates and the Oris Pro cell migration assay 
using a collagen I coated plate. Increased ST6Gal1 expression significantly reduced the 
migration properties of DU145 cells grown on un-coated and collagen I coated plates 




Figure 4.13 ST6Gal1 decreases cell migration in DU154 cells. ST6Gal1 
significantly decreased cell migration in DU145 cells, as shown by standard scratch 






The invasion properties of DU145 cells with increased ST6Gal1 expression was 
investigated using a Cultrex 96 well basement membrane extract (BME) cell invasion 
assay. The assay was used to quantify the degree to which DU145 cells penetrate a 
barrier consisting of basement membrane components in response to chemo-attractants 




Figure 4.14 ST6Gal1 increases the invasion potential of DU145 cells.The cell 
invasion assay involves a 96 well tissue culture plate with two chambers which are 
separated by a filter coated with basement membrane components (a). Schematic of the 
Cultrex 96 well basement membrane extract (BME) cell invasion assay (Cultrex BME 
Cell Invasion Assay, 96 well, R&D Systems). Cells were cultured in serum free media for 
24 hours and then added to the top chamber. The bottom chamber contained full culture 
media. Cells migrate through the pores in the filter to the bottom chamber in response to 
the chemoattractant gradient. 
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The migrated cells are stained and fluorescently quantified.  (b) Percentage invasion was 
calculated by comparing the fluorescence of the cells that had migrated through the BME 
to the bottom chamber with the fluorescence of the total input cells. High ST6Gal1 
expression significantly increased the cell invasion potential of DU145 cells (p = 0.00202). 
 
 
To investigate the regulatory mechanism involved in ST6Gal1-dependent prostate 
cancer cell motility, the expression of genes with established roles in epithelial to 
mesenchymal transition (EMT) was analysed. In DU145 cells, 9 out of 12 EMT related 
genes showed significant changes in gene expression when ST6Gal1 was 
overexpressed (Figure 4.15). Seven of the genes that were up-regulated were VIM 
(vimentin), CTNNB1 (β-catenin), FN1 (fibronectin), CDH1 (E-cadherin), SNAI2 (slug), 
SNAI1 (snail) HLA-G (β2-microglobulin). Two of the genes that were down-regulated 








Figure 4.15 ST6Gal1 effects the expression of genes involved in epithelial to 
mesenchymal transition (EMT). Real-time quantitative reverse transcription PCR 
(qRT-PCR) analysis of a panel of genes involved in epithelial to mesenchymal transition 
(EMT) using mRNA from DU145 cells over expressing ST6Gal1. Gene expression was 
calculated as the average (from 3 biological replicates) fold change relative quantification 
of DU145 cells with increased ST6Gal1 expression compared to DU145 empty vector 
control cells (value set as 1). Samples were normalised using the average of three 
reference genes, GAPDH, β -tubulin and actin. Statistical significance was calculated 
using an independent two-sample t-test, where * p <0.05, ** p <0.01, *** p <0.0001, **** 








































































































































The most significant and dramatic change in expression was down-regulation and almost 
complete loss of desmoplakin in response to ST6Gal1 expression. Desmoplakin is an 
essential component of desmosomal plaques, structures involved in cell to cell adhesion. 
Expression analysis of other important desmosomal component genes was also carried 
out (Figure 4.16). In contrast to the down-regulation of desmoplakin, 5 of the 12 genes 
analysed were significantly up-regulated. These were JUP (junction plakoglobin), PKP2 
(plakophilin 2), PKP3 (plakophilin 3), PKP4 (plakophilin 4) and PNN (desmosome-





Figure 4.16 ST6Gal1 effects the expression of a number of desmosomal genes. 
Real-time quantitative reverse transcription PCR (qRT-PCR) analysis of a panel of 
desmosomal genes found within the desmosome junctional complex using mRNA from 
DU145 cells over expressing ST6Gal1. Gene expression was calculated as the average 



























































































increased ST6Gal1 expression compared to DU145 empty vector control cells (value set 
as 1). Samples were normalised using the average of three reference genes, GAPDH, β 
-tubulin and actin. Statistical significance was calculated using an independent two-
sample t-test, where * p <0.05, ** p <0.01, *** p <0.0001, **** p <0.00001. All primer 
sequences are listed in Appendix B. 
 
Western blot and immunofluorescence analysis confirmed that desmoplakin protein 
expression was significantly depleted when ST6Gal1 was overexpressed (western blot 










Figure 4.17 Desmoplakin protein expression in DU145 cells overexpressing 
ST6Gal1. 
(a) Representative Western blots showing decreased expression of the desmoplakin 
protein in DU145 cells over-expressing ST6Gal1 compared to the empty vector control 
(EVC) cells. GAPDH (N-terminal) was used as a loading control.  
(b) Decreased expression of the desmoplakin protein in DU145 cells over-expressing 
ST6Gal1 compared to the empty vector control (EVC) cells detected by 








4.3.5 Effect of ST6Gal1 overexpression on the prostate cancer transcriptome  
 
To evaluate the effect of increased ST6Gal1 on the PCa cell transcriptome, RNA-
sequencing was performed on total RNA from a single sample of the ST6Gal1 over-
expressing and empty vector DU145 cells. Figure 4.18 shows an MA plot of mean 
expression (log2 fold change) for all genes within the RNA sequencing data, genes with 
a log2fold change > 1 are coloured red. The plot clearly shows the over-expression of 
ST6Gal1 and the down-regulation of desmoplakin (labelled). Figure 4.19 shows a 
snapshot of the USCS Genome Browser with the RNA sequencing reads aligned to 





Figure 4.18  Expression MA plot of RNA sequencing data. An MA plot showing the 
mean expression (log2 fold change) for all genes within the RNA sequencing data 
(ST6Gal1 over-expressing vs empty vector DU145 cell line). Each gene is represented 
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with a dot, all genes with a log2fold change > 1 are coloured red. Dot representing 











Figure 4.19 UCSC Genome Bowser snapshot of ST6Gal1 aligned RNA 
sequencing reads. UCSC snapshot showing RNA sequencing reads aligned to 
ST6Gal1 to confirm over-expression in the DU145 cell line in comparison to the empty 
vector control.  
 
 
RNA sequencing profiles for 58,143 transcripts were obtained, out of which 90 were 
significant (p value <0.05). Of these, 74 genes showed >2 log2fold change. Table 4.1 
and Table 4.2 show the significant genes of which 39 were up-regulated and 35 were 





Table 4.1 Genes up-regulated in response to increased ST6Gal1 expression. 
NCBI reference sequence, gene symbol, gene name, log2fold change and p value of 
the 39 genes up-regulated in response to increased ST6Gal1 expression in DU145 
cells.  
 
RefSeq Gene symbol Gene name log2FoldChange pvalue
NM_001353 AKR1C1 Aldo-Keto Reductase Family 1, Member C1 2.58 0.009666981
NM_001547 IFIT2 Interferon Induced Protein With Tetratricopeptide Repeats 2 2.57 0.010015238
NM_001080512 BICC1 BicC Family RNA Binding Protein 1 2.52 0.0115535
NM_002977 SCN9A Sodium Voltage-Gated Channel Alpha Subunit 9 2.51 0.011922949
NM_001512 GSTA4 Glutathione S-Transferase Alpha 4 2.49 0.012768256
NM_005502 ABCA1 ATP Binding Cassette Subfamily A Member 1 2.48 0.012783312
NM_001785 CDA Cytidine Deaminase 2.48 0.013167699
NM_002167 ID3 Inhibitor Of DNA Binding 3, HLH Protein 2.48 0.013188004
NM_173653 SLC9A9 Solute Carrier Family 9 Member A9 2.46 0.01394595
NM_000127 EXT1 Exostosin Glycosyltransferase 1 2.45 0.01438023
NM_004334 BST1 Bone Marrow Stromal Cell Antigen 1 2.41 0.015759486
NM_021255 PELI2 Pellino E3 Ubiquitin Protein Ligase Family Member 2 2.41 0.015890456
NM_032827 ATOH8 Atonal BHLH Transcription Factor 8 2.40 0.016411824
NM_014322 OPN3 Opsin 3 2.39 0.016695099
NM_138420 AHNAK2 AHNAK Nucleoprotein 2 2.37 0.017950921
NM_001170820 IFITM10 Interferon Induced Transmembrane Protein 10 2.36 0.01827112
NM_015163 TRIM9 Tripartite Motif Containing 9 2.36 0.018495574
NM_020733 HEG1 Heart Development Protein With EGF Like Domains 1 2.34 0.019435972
NM_018094 GSPT2 G1 To S Phase Transition 2 2.33 0.019937334
NM_003658 BARX2 BARX Homeobox 2 2.32 0.020276372
NM_002775 HTRA1 HtrA Serine Peptidase 1 2.32 0.020455036
NR_034089 LOC100131564 2.31 0.021116672
NM_012081 ELL2 Elongation Factor For RNA Polymerase II 2 2.30 0.021586206
NM_212558 TMEM215 Transmembrane Protein 215 2.29 0.021818746
NM_015059 TLN2 Talin 2 2.29 0.02203411
NM_003713 PPAP2B Phospholipid Phosphatase 3 2.28 0.02250555
NM_144717 IL20RB Interleukin 20 Receptor Subunit Beta 2.27 0.023327958
NM_020704 STRIP2 Striatin Interacting Protein 2 2.26 0.023783739
NM_152486 SAMD11 Sterile Alpha Motif Domain Containing 11 2.26 0.023923235
NM_014705 DOCK4 Dedicator Of Cytokinesis 4 2.24 0.025383044
NM_145754 KIFC2 Kinesin Family Member C2 2.22 0.026252228
NM_001044 SLC6A3 Solute Carrier Family 6 Member 3 2.22 0.026275307
NM_001113547 LIMA1 LIM Domain And Actin Binding 1 2.22 0.026614099
NM_030641 APOL6 Apolipoprotein L6 2.17 0.030281343
NM_019593 GPCPD1 Glycerophosphocholine Phosphodiesterase 1 2.17 0.030290183
NM_024746 HHIPL2 HHIP Like 2 2.15 0.03153358
NM_001347 DGKQ Diacylglycerol Kinase Theta 2.13 0.033316611
NM_181501 ITGA1 Integrin Subunit Alpha 1 2.11 0.034690466
NM_052924 RHPN1 Rhophilin, Rho GTPase Binding Protein 1 2.10 0.035789229




Table 4.2 Genes down-regulated in response to increased ST6Gal1 expression. 
NCBI reference sequence, gene symbol, gene name, log2fold change and p value of the 




RefSeq Gene symbol Gene name log2FoldChange pvalue
NM_005960 MUC3A Mucin 3A, Cell Surface Associated -2.62 0.008882771
NM_001037160 CYS1 Cystin 1 -2.52 0.011745693
NM_006187 OAS3 2'-5'-Oligoadenylate Synthetase 3 -2.51 0.012035365
NM_006617 NES Nestin -2.50 0.012511812
NM_002334 LRP4 LDL Receptor Related Protein 4 -2.50 0.012569003
NM_053056 CCND1 Cyclin D1 -2.49 0.012848797
NM_003054 SLC18A2 Solute Carrier Family 18 Member A2 -2.46 0.013794193
NM_021020 LZTS1 Leucine Zipper, Putative Tumor Suppressor 1 -2.45 0.014267242
NM_004789 LHX2 LIM Homeobox 2 -2.41 0.015768056
NM_000435 NOTCH3 Notch 3 -2.39 0.016765884
NM_022725 FANCF Fanconi Anemia Complementation Group F -2.38 0.01741819
NM_015993 PLLP Plasmolipin -2.36 0.018515886
NM_001145176 SHISA7 Shisa Family Member 7 -2.35 0.018995548
NM_021954 GJA3 Gap Junction Protein Alpha 3 -2.32 0.02012836
NM_006547 IGF2BP3 Insulin Like Growth Factor 2 MRNA Binding Protein 3 -2.32 0.020460583
NM_019106 37865 Septin 3 -2.32 0.020572104
NM_173833 SCARA5 Scavenger Receptor Class A Member 5 -2.31 0.02087016
NM_032777 ADGRA2 Adhesion G Protein-Coupled Receptor A2 -2.31 0.021164784
NM_024690 MUC16 Mucin 16, Cell Surface Associated -2.30 0.021243248
NM_021939 FKBP10 FK506 Binding Protein 10 -2.30 0.021714765
NM_031271 TEX15 Testis Expressed 15 -2.25 0.024318551
NM_004454 ETV5 ETS Variant 5 -2.24 0.024914537
NM_198573 ENHO Energy Homeostasis Associated -2.23 0.025671322
NM_014431 PALD1 Phosphatase Domain Containing, Paladin 1 -2.21 0.026764474
NM_005252 FOS FBJ Murine Osteosarcoma Viral Oncogene Homolog -2.21 0.026992541
NM_207361 FREM2 FRAS1 Related Extracellular Matrix Protein 2 -2.19 0.028251663
NM_020645 NRIP3 Nuclear Receptor Interacting Protein 3 -2.19 0.028484391
NM_006329 FBLN5 Fibulin 5 -2.18 0.028920068
NM_001004354 NRARP NOTCH-Regulated Ankyrin Repeat Protein -2.16 0.030922823
NM_006486 FBLN1 Fibulin 1 -2.16 0.031023029
NM_018365 MNS1 Meiosis Specific Nuclear Structural 1 -2.13 0.033268195
NM_175737 KLB Klotho Beta -2.11 0.034745426
NM_001453 FOXC1 Forkhead Box C1 -2.11 0.035002858
NM_022658 HOXC8 Homeobox C8 -2.11 0.035043307
NM_002442 MSI1 Musashi RNA Binding Protein -2.07 0.038885024
Genes down-regulated in response to increased ST6Gal1 expression in DU145 cells 
144 
 
In order to validate the RNA sequencing results, expression changes for genes with the 
highest fold change were confirmed in triplicate in an independent sample set by real-









Figure 4.20 Differentially expressed genes in DU145 cell line in response to 
increased ST6Gal1 expression. Real-time quantitative reverse transcription PCR 
(qRT-PCR) analysis of 20 differentially expressed genes in response to increased 
ST6Gal1 expression in DU145 cells; (a) up-regulated genes, (b) down-regulated genes. 
Gene expression was calculated as the average (from 3 biological replicates) fold 
change (log2) relative quantification of DU145 cells over-expressing ST6Gal1 compared 
to empty vector DU145 cells (value set as 1). Samples were normalised using the 
average of three reference genes, GAPDH, β -tubulin and actin. Statistical significance 
was calculated using an independent two-sample t-test, where * p <0.05, ** p <0.01, *** 
p <0.0001, **** p <0.00001. All primer sequences are listed in Appendix B.  
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Gene Ontology (GO) enrichment analysis was carried out by Dr Katherine James 
(Newcastle University) with GOstat, a tool for identifying enriched GO terms in ranked 
gene lists (Beissbarth and Speed, 2004). GO analysis of the RNA sequencing gene lists 
identified 78 terms with significant gene enrichment (p < 0.05). There were 12 enriched 
GO terms within the up-regulated genes list, shown in Figure 4.21 and 66 enriched GO 




Figure 4.21 Gene ontology analysis of genes up-regulated in response to 
increased ST6Gal1 expression. Gene Ontology (GO) analysis of the genes up-






Figure 4.22 Gene ontology analysis of genes down-regulated in response to 
increased ST6Gal1 expression.  Gene Ontology (GO) analysis of the genes down-
regulated by ST6Gal1 identified 66 terms with significant gene enrichment (p < 0.05). 




The Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.jp/kegg/) 
database is used to link genomic information with higher order functional information 
(Kanehisa et al 2000). Analysis of our dataset using the KEGG metabolic pathway 
database identified 4 significant pathways from the up-regulated gene list and 68 
pathways from the down-regulated gene list (Appendix C). There was one pathway 







regulation of cellular component size
peptidyl-lysine deacetylation
RNA splicing, via transesterification reactions
neuron projection extension
regulation of protein binding
citrulline biosynthetic process
regulation of extent of cell growth
regulation of microvillus organization
mRNA splicing, via spliceosome
proteasome-mediated ubiquitin-dependent protein catabolic process
cellular response to topologically incorrect protein
protein autophosphorylation
microtubule cytoskeleton organization
regulation of protein catabolic process
mitotic spindle organization
intrinsic apoptotic signaling pathway in response to DNA damage
carboxylic acid biosynthetic process
response to drug
cellular response to external stimulus
stress-activated protein kinase signaling cascade
-log10 (p vaule)
p = 0.05 significant enrichment 
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4.3.6 Effect of ST6GAL1 knockdown on cellular properties 
 
The effect of ST6Gal1 knockdown on the cellular properties of prostate cancer cells was 
investigated using a CW22-Rv1 cell line with silenced ST6Gal1 expression (section 
4.4.3). The effect of ST6Gal1 knock-down on cell proliferation was investigated using the 
WST-1 proliferation assay kit. The results show that knockdown of ST6Gal1 in CW-
22RV1 cells significantly decreased cell proliferation (Figure 4.23a) when compared to 
negative control cells. 
 
 
The effect of ST6Gal1 knock-down on cell adhesion was investigated using a calcein-
AM based cell adhesion assay. The results show that knockdown of ST6Gal1 in CW-
22RV1 cells significantly decreased cell adhesion to fibronectin coated plates (Figure 










Figure 4.23 Knockdown of ST6Gal1 decreases cell proliferation and cell 
adhesion. The WST-1 cell proliferation assay and the calcein-AM based cell adhesion 
assay showed that ST6Gal1 knock-down significantly decreased cell proliferation and 
adhesion in CW-22Rv1 cells. 
(a) WST-1 assay: ST6Gal1 knockdown CW22-Rv1 cells and negative control cells were 
grown in the presence of WST-1 reagent. Viable, actively dividing cells cleave the 
tetrazolium salt WST-1 to produce a formazan dye allowing spectrophotometric 
quantification. Cell proliferation was measured over a 5 day period. 
(b)  ST6Gal1 knockdown CW22-Rv1 cells and negative control cells were labelled with 
calcein-AM and allowed to adhere to fibronectin coated plates. The percentage 
adhesion was calculated by comparing a washed plate (representative of adherent 










Together with decreased proliferation and adhesion, ST6Gal1 knock-down also 
significantly decreased cell migration in CW-22Rv1 cells. A basic scratch assay showed 
that ST6Gal1 knock-down significantly decreased cell migration in CW-22Rv1 cells. 
Following 13 days incubation, the negative control cells had migrated into the scratched 
area of the plate (100% closure), whilst the ST6Gal1 knock-down cells had migrated into 
50% of the scratched area (Figure 4.24a-b). The ST6Gal1 knock-down cells appeared 
to be growing on top of each other rather than migrating across the plate like the negative 
control cells. A major drawback of the scratch assay is that it relies on simply observing 
cells within the scratched zone and therefore cannot distinguish the effects of 
proliferation from migration. The assay was performed using RPMI-1640 full serum 
culture media, replacing this with serum free media or using a DNA synthesis inhibitor 
such as mitomycin C or hydroxyurea to inhibit proliferation would have allowed us to 
identify migrating cells.  
 
 
The invasion properties of CW-22Rv1 cells with reduced ST6Gal1 expression was 
investigated using a Cultrex 96 well basement membrane extract (BME) cell invasion 
assay. Decreased ST6Gal1 expression significantly decreased the cell invasion potential 








Figure 4.24 Knockdown of ST6Gal1 decreases cell migration and invasion. 
(a) A scratch assay showed that ST6Gal1 knock-down significantly decreased cell 
migration in CW-22Rv1 cells. Cells were grown in culture for 13 days to observe the 
migration of cells into a scratched area of the plate. After 13 days incubation, the 
negative control cells had migrated into the scratched area of the plate (100% 
closure), whilst the ST6Gal1 knock-down cells had migrated into 50% of the 
scratched area 
(b) The invasion properties of ST6Gal1 knock-down CW22-Rv1 cells was investigated 
using a Cultrex 96 well basement membrane extract (BME) cell invasion assay. 
Percentage invasion was calculated by comparing the fluorescence of the cells that 
had migrated through the BME to the bottom chamber with the fluorescence of the 
total input cells. Decreased ST6Gal1 expression significantly decreased the cell 




To investigate the effect of reduced ST6Gal1 expression on prostate cancer cell motility 
and explore any reciprocal changes with the ST6Gal1 over-expression cell line, 
expression of the EMT gene marker panel was analysed in the CW-22Rv1 ST6Gal1 
knock-down cells. In CW22-Rv1 cells, 4 EMT related genes showed significant changes 
in gene expression when ST6Gal1 expression was decreased (Figure 4.25). CDH2 (N-
cadherin), FN1 (fibronectin), SNAI1 (snail) and SNAI2 (slug) were all down-regulated 
when ST6Gal1 was reduced. There was no significant effect on DSP (desmoplakin) 





Figure 4.25 Effect of ST6Gal1 knock-down on the expression of genes involved 
in epithelial to mesenchymal transition (EMT). Real-time quantitative reverse 
transcription PCR (qRT-PCR) analysis of key genes involved in epithelial to 
mesenchymal transition (EMT) using mRNA from CW-22Rv1 cells with reduced ST6Gal1 
expression. Gene expression was calculated as the average (from 3 biological replicates) 
fold change relative quantification of CW-22RV1 cells with knocked-down ST6Gal1 
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expression compared to negative control CW-22Rv1 cells (value set as 1). Samples were 
normalised using the average of three reference genes, GAPDH, β -tubulin and 
actin. Statistical significance was calculated using an independent two-sample t-test, 
where * p <0.05, ** p <0.01, *** p <0.0001, **** p <0.00001. All primer sequences are 
listed in Appendix B. 
 
To help understand the role that ST6Gal1 may play in PCa progression and to identify 
genes whose expression is directly affected by ST6Gal1, RT-PCR was used to identify 
genes with reciprocal expression changes in the ST6Gal1 modified cell lines. Genes 
identified in the RNA sequencing dataset were analysed for reciprocal expression 
patterns between the DU145 ST6Gal1 over-expressing cells and the CW-22RV1 
ST6Gal1 knock-down cells (Table 4.3). The genes identified with reciprocal expression 
patterns are more likely to be an effect by ST6Gal1.  
 
 
Three independent sample sets of both ST6Gal1 modified cell lines were used to 
generate an average fold change (change in gene expression compared to the negative 
control cells). Of the 20 genes analysed, 13 showed reciprocal gene expression patterns 
in response to ST6Gal1 levels, i.e. increased expression in response to increased 
ST6Ga1 levels as well as decreased expression in response to decreased ST6Ga1 
levels and vice versa. Aldo-keto reductase family 1 member C1 (AKR1C1), interferon 
induced protein with tetratricopeptide repeats 2 (IFIT2), bicC family RNA binding protein 
1 (BICC1), glutathione s-transferase alpha 4 (GSTA4), ATP binding cassette subfamily 
A member 1 (ABCA1), cytidine deaminase (CDA), solute carrier family 9 member A9 
(SLC9A9), exostosin glycosyltransferase 1 (EXT1) and bone marrow stromal cell antigen 
1 (BST1) each have increased expression in response to increased ST6Gal1 levels and 
decreased expression in response to decreased ST6Gal1 levels. Reciprocally, cystin 1 
(CYS1),  2'-5'-oligoadenylate synthetase 3 (OAS3), solute carrier family 18 
member A2 (SLC18A2) and notch 3 (NOTCH3) have decreased expression in response 
to increased ST6Gal1 levels and increased expression in response to decreased 




A number of these gene are known to play important roles in cancer development & 
progression. AKR1C3 is involved in androgen biosynthesis and plays a role in the 
development of CRPC (Adeniji., et al 2013).  
 
  
 DU145 ST6Gal1 over expressing 
cells 
CW22 ST6Gal1 knock down 
cells 
 
Gene average fold 
change  
SE p value   average 
fold change  
SE p value   
AKR1C1 6.159 0.85 3.65E-03 ↑ 0.763 0.15 1.81E-01 ↓ 
IFIT2 3.023 0.31  0.00283 ↑ 0.336 0.02 5.21E-06 ↓ 
BICC1 96.157 10.83 9.30E-04 ↑ 0.407 0.06 6.60E-04 ↓ 
SCN9A 2.414 0.2  0.00229 ↑ 2.116 0.86  0.26386 ↑ 
GSTA4 1.995 0.23 1.19E-02 ↑ 0.598 0.04  0.00069 ↓ 
ABCA1 2.593 0.05 5.98E-06 ↑ 0.188 0.04 2.82E-05 ↓ 
CDA 2.362 0.22 3.26E-03 ↑ 0.379 0.04  0.00012 ↓ 
SLC9A9 5.547 0.46 5.80E-04 ↑ 0.932 0.13  0.62083 ↓ 
EXT1 1.953 0.24  0.01734 ↑ 0.335 0.05 1.20E-04 ↓ 
BST1 4.830 0.27 1.50E-04 ↑ 0.39 0.04 6.45E-05 ↓ 
MUC3A 0.200 0.07 3.40E-04 ↓ 0.734 0.09 5.07E-02 ↓ 
CYS1 0.223 0.07  0.00028 ↓ 1.068 0.39 8.73E-01 ↑ 
OAS3 0.665 0.16  0.10608 ↓ 1.368 0.18 1.09E-01 ↑ 
NES 0.537 0.08 4.73E-03 ↓ 0.253 0.03 1.63E-05 ↓ 
LRP4 0.338 0.08 1.02E-03 ↓ 0.324 0.04 9.32E-05 ↓ 
CCND1 0.626 0.11 2.29E-02 ↓ 0.811 0.12 0.1701 ↓ 
SLC18A2 0.278 0.01 1.32E-07 ↓ 1.496 0.64 4.82E-01 ↑ 
LZTS1 1.385 0.06 3.82E-03 ↑ 1.696 0.44 1.86E-01 ↑ 
LHX2 0.282 0.02 4.17E-06 ↓ 0.433 0.04  0.00013 ↓ 
NOTCH3 0.756 0.1 6.74E-02 ↓ 4.724 1.03 2.25E-02 ↑ 
 
Table 4.3 Reciprocal gene expression changes in response to ST6Gal1 
expression. Real-time quantitative reverse transcription PCR (qRT-PCR) analysis was 
carried out using mRNA from DU145 cells over-expressing ST6Gal1 and CW-22Rv1 
cells with reduced ST6Gal1 expression. Red arrows indicate up-regulated genes and 
blue arrows indicate down-regulated genes. Genes in bold show reciprocal expression 
changes in response to ST6Gal1. Gene expression levels were calculated as an average 
(3 biological replicates from 3 sample sets with standard error (SE)) fold change 
compared to negative control cells in each case (value set as 1). Samples were 
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normalised using the average of three reference genes, GAPDH, β -tubulin and 
actin. Statistical significance was calculated using an independent two-sample t-test. 
 
4.4 Discussion 
Although aberrant glycosylation has previously been linked to PCa progression (Munkley 
et al., 2016b), the role of ST6Gal1 a sialyltransferase which transfers sialic acid from 
CMP-sialic acid to galactose-containing substrates in PCa is unclear. While there are 
many studies which suggest an oncogenic role for ST6Gal1 (Zhu et al., 2001; Lin et al., 
2002; Liu et al., 2014b; Meng et al., 2015; Hsieh et al., 2017), there is also growing 
evidence that ST6Gal1 may also have tumour suppressor activity (Wild et al., 2005; Park 
et al., 2012; Antony et al., 2014; Zhang et al., 2017).  
 
 
I have shown that expression of ST6Gal1 is up-regulated in PCa cells in response to 
androgen stimulation and that ST6Gal1 is likely to be a direct target of the androgen 
receptor. Meta-analysis of five publically available clinical gene expression datasets 
indicated that ST6Gal1 was up-regulated in PCa (Lapointe et al., 2004; Varambally et 
al., 2005; Tomlins et al., 2007; Taylor et al., 2010; Grasso et al., 2012). The aim of this 
chapter was to identify ST6Gal1 expression patterns in clinical patient samples. I have 
found that ST6Gal1 expression was increased in 17 malignant tumour samples from 
transurethral resections of the prostate (TURP) compared with 32 non-malignant BPH 
tissue from our independent patient RNA cohort. A recent study supports this, that found 
ST6Gal1 expression was significantly upregulated in PCa tumour tissues compared with 
BPH and that elevated ST6Gal1 expression was correlated with higher Gleason scores 
(Wei et al., 2016).  
 
 
Contradictory to this, I also found that ST6Gal1 expression was down-regulated when 
compared with normal prostate tissue. Our matched tumour and adjacent normal tissue 
samples RNA dataset showed that 6 out of the 9 patients had a clear significant down-
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regulation of ST6Gal1 in the tumour tissue compared to the adjacent normal tissue. 
Tumour tissue can consist of not only tumour cells but also stromal cells, immune cells 
and vascular cells. This sample heterogeneity can often influence the investigation of 
clinical tumour samples using genomic approaches, such as gene expression analysis. 
Normal cells within the sample, such as stromal and immune cells can have a different 
gene expression profile to that of the tumour cells, therefore it is important to accurately 
determine the tumour cellularity of the sample prior to any further analysis.  
 
 
Analysis of our PCa tissue microarray (TMA) shows that ST6Gal1 protein expression 
was down-regulated in PCa patient tissue samples compared with BPH tissue samples. 
We also found no correlation with patient Gleason scores or links to metastasis, but lower 
levels of ST6Gal1 predicted poor overall survival in months. 
 
 
Advanced metastatic PCa is the leading cause of death in PCa patients, but the 
underlying mechanisms are poorly understood. I used stable cells lines as an in vitro 
model to investigate the mechanistic role of ST6Gal1. DU145 cells are representative of 
the earlier androgen depletion independent prostate cancers and had the lowest levels 
of endogenous ST6Gal1 expression. DU145 cells with increased ST6Gal1 expression 
exhibited increased cell to matrix adhesion and reduced migratory potential. This 
correlates with the increased expression we observed in a number of key adherens 
junction genes such as CTNNB1 (beta-catenin), FN1 (fibronectin) and CDH1 (E-
cadherin).   
 
 
High ST6Gal1 expression levels also increased the invasion potential in DU145 cells. 
Epithelial to mesenchymal transition (EMT) plays an important role in the invasiveness 
of cancer cells. We saw increased expression levels of a number of genes known to be 
up-regulated during the EMT process, including VIM (vimentin), SNAI1 (snail) and SNAI2 




Whilst the adhesion assay showed a significant increase in cell adhesion in response to 
ST6Gal1, analysis of the KEGG database highlighted a number of cellular adhesion 
pathways which were significantly down-regulated in response to increased ST6Gal1, 
these include pathway 4520 - adherens junction, 4530 – tight junctions, 4510 - focal 
adhesion and 4512 - extra-cellular matrix receptor interaction.  
 
 
The osteoclast differentiation pathway was significant in both the up-regulated and down-
regulated gene lists. Osteoclasts are specialised multinucleated cells derived from the 
monocyte/macrophage lineage which adhere to and degrade bone matrix (Boyle et al., 
2003). In advanced PCa, metastasis is often detectable in bone with tumours which are 
predominantly osteoblastic (Clarke et al., 1993). The sialylation of immune complexes 
such as immunglobulin G (IgG) is known to control osteoclast differentiation, with 
reduced IgG sialyation enhancing osteoclastogenesis (Harre et al., 2015). 
 
 
To investigate the opposing effect of ST6Gal1, a ST6Gal1 knock-down cell line was 
created in the androgen sensitive CW-22Rv1 cells. The reduction of ST6Gal1 expression 
significantly decreased cell proliferation, cell to matrix adhesion, migration and invasion 
capability. This correlates with what has previously been observed in PC3 and DU145 
knock-down cell lines. Wei et al reported that ST6Gal1 expression was upregulated in 
human PCa tissues compared to non-malignant prostate tissue and high expression 
positively correlated with Gleason scores. They also found that ST6Gal1 knockdown in 
PC3 and DU145 cells significantly inhibited the proliferation, growth, migration and 
invasion capability (Wei et al., 2016).  ST6Gal1 has previously been associated with the 
maintenance of the cell mesenchymal state in breast cancer cell lines (Lu et al., 2014). 
In line with this we observed a significant decrease in CDH2 (N-cadherin) expression, a 
mesenchymal cadherin associated with EMT (Whang et al 2015) as well as other EMT 





Using molecular cloning techniques in two different PCa cell lines I have shown that the 
role of ST6Gal1 is complex and depends on the cellular background. There is always 
the possibility that off-target effects can contribute to the observed experimental result 
when using this kind of genome editing techniques. When generating the stable cell lines, 
single clones were selected and grown up. Using an initial pool of siRNAs or selecting 
more clones and pooling them together may have helped to limit any off-target effects. 
Rescue experiments are a good way to show siRNA specificity. If by adding a shRNA 
rescue control, the knock down effects were regained you can be confident the effects 
are due to the target knockdown. Around 50% ST6Gal1 knock-down was achieved in 
the CW-22Rv1 cell line. At this level it is possible that sufficient function may still have 
been retained.   
 
 
Experiments performed on cells grown in culture can be limiting as they lack the 
heterogeneity that exists in clinical tumours. They have been grown in a particular culture 
media with specific oxygen and serum concentrations, an environment not 
representative of how cells exist within an organism. By creating stable cells line with 
artificial expression levels (over-expression/knock-down) of a given protein, you are 
generating an environment which does not reflect the physiological conditions within the 
tumour cell. It can therefore be difficult to interpret any downstream functional effects. 
Three-dimensional (3D) organoid cultures in which cells are grouped together and 
arranged as in the prostate gland would help to overcome some of the limitations of basic 
monolayer cell cultures (Gao et al., 2014).  
 
 
In this chapter I have used cells lines and clinical patient samples to identify ST6Gal1 
expression patterns in PCa. Stable ST6Gal1 prostate cancer cell lines have been used 
to investigate the effect of ST6Ga1l on the cellular functions of prostate cancer cells, 
whilst RNA sequencing has identified reciprocal transcriptional changes in prostate 
cancer in response to ST6Gal1. Our data suggests that although ST6Gal1 expression in 
prostate cancer is highly variable and most likely dependable on the other compensatory 
mechanism available within the tumour together with the collective expression of other 
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glyco-enzymes. I have shown that changes in ST6Gal1 expression can modify the 
expression of some key cancer associated genes such as AKR1C1 (Zeng et al., 2017), 
ABCA1 (Lee et al., 2013), SLC18A2 (Haldrup et al., 2016) and NOTCH3 (Carvalho et al., 
2014). The next step for this study would be to carry out glycopeptide analysis (liquid 
chromatography–mass spectrometry/lectin arrays) to look at the effect on glycosylation 







































Chapter 5 Results 
 
Androgen regulated Relaxin mRNA isoforms  
5.1  Introduction 
5.1.1 The relaxin peptide hormone family 
 
Relaxins are peptide hormones that belong to the insulin-like super family. In humans, 
the family consists of seven cystine-rich peptides; relaxin 1, 2 and 3 (RLN1, RLN2 and 
RLN3) and the insulin-like peptides INSL3, INSL4, INSL5 and INSL6. The RLN1 and 
RLN2 genes share 90% DNA sequence similarity and have 82% predicted sequence 
identity at amino acid level. In females, RLN2 is predominantly known for its roles in 
reproduction and pregnancy (reviewed in (Bathgate et al., 2013). In males, RLN2 is 
produced by the secretory epithelial cell of the prostate gland and secreted into the 
seminal fluid (Yki-Jarvinen et al., 1983; Ivell et al., 1989) where it is thought to play a role 
in prostate growth, development of the reproductive tract and sperm motility (Hsu et al., 
2002; Samuel et al., 2003; Ferlin et al., 2012). Although RLN1 mRNA is expressed in the 
prostate its function remains unknown. RLN3 has a low overall sequence identity to 
RLN1 (26%) and RLN2 (22%) and is more structurally like INSL5. RLN3 expression is 
highest in the central nervous system (Smith et al., 2011; Bathgate et al., 2013) and is 
thought to play a role in arousal, feeding, anxiety and stress and drug addiction (Ryan et 
al., 2013; Smith et al., 2014; Hosken et al., 2015; Zhang et al., 2015a; Shirahase et al., 
2016).    
 
 
RLN2 has been shown to promote cancer progression in multiple cancers including 
breast cancer (Binder et al., 2004; Cao et al., 2013), thyroid cancer (Hombach-Klonisch 
et al., 2006; Radestock et al., 2010; Bialek et al., 2011), endometrial cancer (Kamat et 
al., 2006), osteosarcoma (Ma et al., 2013; Ren et al., 2015) and prostate cancer 
(Silvertown et al., 2006; Thompson et al., 2006; Feng et al., 2007; Silvertown et al., 2007; 
Feng et al., 2009; Trapnell et al., 2010; Neschadim et al., 2015). The role of relaxins in 
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PCa is well characterised, RLN2 expression is elevated in PCa samples relative to BPH 
samples (Vinall et al., 2011). RLN2 expression is negatively regulated by androgens and 
increases during the progression of PCa to androgen independence by promoting 
tumour growth and vascularisation (Silvertown et al., 2006; Thompson et al., 2006). 
RLN2 expression is also increased in neuroendocrine PCa (Figueiredo et al., 2005). 
RNAi mediated RXFP1 knockdown and inhibition of RLN2/RXFP1 signalling impairs PCa 
tumour growth and invasion capabilities (Feng et al., 2007; Silvertown et al., 2007). A 
synthetic RLN2 antagonist (AT-001) has been shown to reduce the growth of human 
CRPC xenografts by up to 60% (Neschadim et al., 2014). Combined inhibition of the 
PKA and NF-κB signalling pathways, which are activated by RLN2, reduced PCa tumour 
growth and induced apoptosis (Vinall et al., 2011).   
 
 
5.1.2 Relaxin fusion protein  
 
The high sequence homology between RLN1 and RLN2 makes it difficult to accurately 
characterise their individual functions. In addition to this, an alternatively spliced larger 
variant of RLN2 has been described in the prostate (Gunnersen et al 1996). More 
recently, a novel fusion transcript comprising sequences from the both RLN1 and RLN2 
genes has been identified in normal and PCa tissue. Single molecule real time (SMRT) 
sequencing on LNCaP cells was performed using the PacBio platform which generates 
longer sequencing reads. This method detected a RLN1/RLN2 novel transcript which 
was abundantly expressed in LNCaPs (Tevz et al., 2016).  
The fusion transcript contains incomplete sequences from both RLN1 and RLN2 as well 
as a novel exon in the intronic region between the genes. Analysis of the new fusion 
sequence predicated a protein isoform which contained all the intact functional domains 
of RLN2 (A and B chains and C-peptide) but was missing the signal sequence, which is 
essential for secretion. Expression of RLN1 is increased by androgens (Tevz et al., 2016), 
whereas RLN2 is negatively regulated by androgens (Thompson et al., 2006). As with 





5.2  Aims 
 
This project has shown that the AR plays a key role in regulating gene expression in PCa 
cells. However, individual genes can produce multiple different mRNA isoforms, which 
can have quite different biological activities from each other. For example, alternative 
isoforms made by the same gene can make proteins which switch gene function between 
pro and anti-apoptotic isoforms, leading to cell death or survival, or from stable epithelial 
cells towards mesenchymal cells which move around the body (Rajan et al., 2009; Sette 
et al., 2013).  
 
There is mounting evidence to suggest that gene transcription and pre-mRNA processing 
are co-ordinated events (Cramer et al., 1997; Cramer et al., 1999; Cramer et al., 2001; 
Pagani et al., 2003; Dowhan et al., 2005). Androgens can control exon splicing through 
their control of regulators and coactivators (Dowhan et al., 2005). The AR can recruit the 
RNA binding proteins Sam68 and p68 which have been shown to influence alternative 
splicing of a subset of genes (Clark et al., 2008; Rajan et al., 2008; Munkley et al., 2017a). 
Androgens drive the production of a different mRNA isoform from the normally tumour 
suppressor TSC2 gene (Rajan et al., 2011). This novel TSC2 isoform activates instead 
of repressing cell proliferation, and is expressed in clinical prostate cancer so provides a 
new route through which these cells might proliferate (Munkley et al., 2014).  
 
Together with the androgen regulated transcriptional changes (detailed in Chapter 3 of 
this thesis), the RNA sequencing data from LNCaP cells also identified 73 androgen 
regulated alternative mRNA isoforms. These included 56 alternative promoters, 4 
alternative 3′ ends and 13 alternative spicing events (paper currently in preparation). This 
chapter will focus on the identified androgen regulated promoter switches for the RLN1 





The aims of this chapter were to: 
 Establish RLN1 and RLN2 isoform expression patterns in prostate cancer cells.  
 Establish if RLN1 and RLN2 protein expression is androgen regulated. 




















5.3  Results 
5.3.1. Novel mRNA isoforms of RLN1 and RLN2 are androgen regulated  
The RNA sequencing data identified androgen regulated promoter switches for the RLN1 
and RLN2 genes. For RLN1, there was a decrease in expression from a promoter 
(promoter 2) driving a non-coding transcript in the presence of androgens, compared to 
the expression from an up-stream promoter (promoter 1) driving the expression of a 
coding mRNA isoform (Figure 5.1a). Therefore androgens were found to repress the 
expression of a non-coding RLN1 isoform in prostate cancer cells. A promoter switch for 
the adjacent RLN2 gene was also observed. Here there was an increase in expression 
from the up-stream promoter (promoter 1) in the presence of androgens (Figure 5.1b). 




Figure 5.1 Androgen regulated alternative promoter switches for RLN1 and 
RLN2. RNAseq profiles for RLN1 and RLN2 from LNCaP cells grown in the presence of 
10 nM synthetic androgen R1881 for 24 hours (+ androgens) and LNCaP cells grown in 
charcoal stripped steroid deplete media (steroid deplete). Alternative promoter switches 
and predicted protein isoforms are highlighted within the red boxes.  
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Figure 5.2 Expression of RLN1 and RLN2 in LNCaP cell line in response to 
androgens. Real-time quantitative reverse transcription PCR (qRT-PCR) analysis of: 
(a) RLN1 (both isoforms) expression in LNCaP cells in response to 10 nM synthetic 
























RLN1 – both isoforms





SD A+ SD A+
24 hours                  48 hours















































SD A+ SD A+
RLN2




increase in RLN1 mRNA expression in response to androgens after 24 hours. 
This was detected using a primer set that amplifies both isoforms.  
(b) RLN2 (both isoforms) expression in LNCaP cells in response to 10 nM synthetic 
androgen (R1881) stimulation (24 hours and 48 hours). There was a decrease in 
RLN2 mRNA expression in response to androgens after 48 hours.  Detected 
using a primer set that amplifies both isoforms.  
(c) RLN1 isoform expression in LNCaP cells in response to 10 nM synthetic 
androgen (R1881) stimulation (24 hours). There was an increase in expression 
of RLN1 promoter 1 expression in response to 24 hours androgen stimulation. 
There was no change is promoter 2 expression. This was detected using an 
isoform specific primer set (Figure 5.3). 
(d) RLN2 isoform expression in LNCaP cells in response to 10 nM synthetic 
androgen (R1881) stimulation (24 hours). There was no change in expression of 
RLN2 promoter 1 expression and a decrease of RLN2 promoter 2 expression in 
response to 24 hours androgen stimulation. This was detected using an isoform 
specific primer set (Figure 5.3). 
 
Gene expression was calculated as the average (3 biological replicates) fold change 
(log2) relative quantification of androgen treated LNCaP cells compared to steroid 
deplete cells (value set as 1). Samples were normalised using the average of three 
















Figure 5.3  RLN1 and RLN2 transcript variants and qRT-PCR primers. RLN1 and 
RLN2 transcripts with isoform specific real-time quantitative reverse transcription PCR 
(qRT-PCR) primers. Pink star - forward primer location for isoform 1, blue star – forward 
primer location for isoform 2, purple star – common reverse primer location. 
 
5.3.2 Generation of the RLN1 antibody 
We next wanted to establish if RLN1 and RLN2 were androgen regulated at the protein 
level. A number of commercial available RLN1 antibodies were tested but none could be 
validated. Despite extensive optimisation, the antibodies tested did not produce a band 
at the predicted molecular weight nor did they recognise over-expressed protein.  
 
To allow further investigation into the expression of RLN1 protein, a specific RLN1 
antibody was raised. An antigenic peptide from amino acids 87-185 of the RLN1 protein 
sequence was chosen as an epitope that would identify expression of both isoforms. The 
sequence was checked for its similarity to other protein sequences in the databases by 
a BLAST protein search (http://www.ncbi.nlm.nih.gov/BLAST/). The cDNA encoding this 
peptide was amplified by PCR and subsequently cloned into pGEX-5X1 vector in frame 
with glutathione S-transferase (Figure 5.4) and the pET32a (+) vector in frame with 
histidine tags (Figure 5.5). 
RLN1 isoform 1 





RLN2 isoform 1 









Figure 5.4 pGEX-5X-1 glutathione S-transferase fusion vector. Map of the 
pGEX-5X-1 vector showing the reading frames and main features. The GST fusion 
protein expression is under the control of the tac promoter, which is induced by the 
lactose analog isopropyl b-D thiogalactoside (IPTG). The vector also contains a lacIq 
gene product, a repressor protein that binds to the operator region of the tac promoter, 
preventing expression until induction by IPTG. Primer sequences and restriction 
enzymes used to allow for directional cloning of the insert sequence into the vector are 






MfeI forward primer:  AAAAAAAAC’AATTGATGTTGGAATTCATTGCTAATTTGCC   
 





















Figure 5.5 pET-32a(+) histidine tagged fusion vector. Map of the pET-32a(+) 
vector showing the reading frames and main features. The pET-32a(+) vector is 
designed for cloning and high-level expression of peptide sequences fused with 
GAA TTG ATG TTG GAA TTC ATT GCT AAT TTG CCA CCG GAG CTG AAG GCA GCC CTA TCT GAG AGG CAA CCA 
TCA TTA CCA GAG CTA CAG CAG TAT GTA CCT GCA TTA AAG GAT TCC AAT CTT AGC TTT GAA GAA TTT AAG 
AAA CTT ATT CGC AAT AGG CAA AGT GAA GCC GCA GAC AGC AAT CCT TCA GAA TTA AAA TAC TTA GGC TTG 
GAT ACT CAT TCT CAA AAA AAG AGA CGA CCC TAC GTG GCA CTG TTT GAG AAA TGT TGC CTA ATT GGT TGT 
ACC AAA AGG TCT CTT GCT AAA TAT TGC TGA CTC GA  
MfeI forward primer:   AAAAAAAAC’AATTGATGTTGGAATTCATTGCTAATTTGCC  
 
XhoI reverse primer:   AAAAAAAACTCGAGTCAGCAATATTTAGCAAGAGACCTTTTGG  
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thioredoxin (Trx-Tag) histidine (His-Tag) and S-Tag proteins.  Histidine fusion protein 
expression is under the control of the T7 promoter, which is induced by the lactose 
analog isopropyl b-D thiogalactoside (IPTG). The vector also contains a lacI repressor 
protein that binds to the operator region of the T7 promoter, preventing expression until 
induction by IPTG. Primer sequences and restriction enzymes used to allow for 
directional cloning of the insert sequence into the vector are detailed in Appendix B. 
 
Plasmids encoding the fusion peptides were transformed into E. coli BL21 bacteria and 
expression was induced by addition of IPTG to the culture medium (Figure 5.6a). Three 
hours after induction the bacteria were harvested and cell lysates were prepared.  
 
The GST-tagged fusion peptide was purified and used for immunization. To purify the 
peptide under non-denaturing conditions, the solubility of the peptides was tested by 
comparing whole bacterial cell lysate with supernatant from the sample after 
centrifugation and checking for the presence of the fusion-peptide (Figure 5.6b). 
Purification of the GST-fusion peptide was carried out using glutathione agarose (Figure 
5.6c). The purified peptide was then resolved on a preparative SDS-PAGE gel. The gel 
was washed in 1X SDS-PAGE running buffer without SDS and the gel slice containing 





Figure 5.6 Preparation of the RLN1 antigenic peptide. 
(a) Bacterial expression of the RLN1 GST (pGEX-5X1) and histidine (pET-32a (+) 
fusion peptides. Plasmids containing amino acids from the RLN1 protein were 
transformed into E. coli BL21 bacteria. Transformed bacteria was cultured and 
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expression from the plasmids was induced with IPTG. Samples were taken 
before and after induction (before IPTG) and after 3 hours (after IPTG) and 
resolved by SDS_PAGE. Gels were stained with Coomassie Brilliant Blue.  
(b) Solubility of the GST_RLN1 fusion peptide. Following bacterial expression, the 
lysates were centrifuged and total lysate was compared to supernatant by SDS-
PAGE.  
(c) Purification of the GST_RLN1 fusion peptide. The bacterial lysate was purified 
using glutathione agarose.  
Black arrows indicated the predicted size of the expressed proteins. 
 
 
The GST fusion peptide was used for immunisation of a rabbit. The immunisation 
program was carried out by National Service Scotland, Pentlands Science Park, 
Midlothian. Serum from the immunised rabbit was collected and the RLN1 antibody was 
purified using the histidine tagged peptide.  
 
The histidine-tagged peptide was purified using nickel affinity resin. The peptide was 
eluted with imidazole, which displaces histidine. This elution process was repeated to 
recover as much of the purified peptide as possible (Figure 5.7a). The eluted peptide 
was desalted using a P10 column and then coupled to a SulfoLink immobilising column. 
The collected flow through was analysed for protein content using a Bradford assay 
(Figure 5.7b).  
 
IgG was isolated from the rabbit serum using caprylic acid. The IgG was dialysed against 
PBS overnight and affinity purified against the RLN1-histidine fusion coupled to the 
SulfoLink column. Both acidic and basic conditions were used for elution which were 
analysed for protein content using a Bradford assay (Figure 5.7c). The protein positive 
fraction (acidic conditions, elution 2) were dialysed against PBS overnight. For long term 





Figure 5.7 Affinity purification using RLN1-histidine fusion peptide 
(a) Purification of the RLN1-histidine fusion peptide. Following bacterial expression 
the lysate was purified using nickel affinity resin. The bound peptide was eluted 
in 3 fractions which were analysed by SDS-PAGE.  
(b) Bradford protein assay. The flow through from the P10 desalting and coupling to 
the SulfoLink column were analysed for protein. Protein was detected in the 
elution from the P10 column (well 2) and in the antibody elution from the SulfoLink 
column following affinity purification (well 5). No protein was detected in the initial 
flow though (well 1) or in the flow through from the wash stages (wells 3 and 4). 
(c) Bradford protein assay analysis of antibody fraction following affinity purification 
under acidic and basic conditions. Positive fraction (containing protein) was 





5.3.3 Characterisation of the RLN1 antibody  
The purified RLN1 antibody was tested by Western blotting using protein prepared from 
Human Embryonic Kidney 293 (HEK-293) cells over-expressing the N-terminal 3xFlag 
tagged fusion RLN1 promoter 1 and promoter 2 proteins. The predicted sequences for 
RLN1 promoter 1 (RLN1_p1) and RLN1 promoter 2 (RLN1-p2) were cloned into the 
p3XFLAG-CMV-10 expression vector using restriction enzymes and transfected into 
HEK293 cells. The predicted molecular weight of the RLN1 protein (isoform 1) is 28kDa, 
whilst the RLN1 (isoform 2) sequence has a predicted molecular weight of 11kDa. This 
was calculated using a protein molecular weight calculator tool available at 
https://www.bioinformatics.org/sms/prot_mw.html.  
 
Expression of the larger RLN1 protein isoform (that would be made using promoter 1) 
was detected at approximately 31kDa using a monoclonal anti-Flag M2 antibody. No 
band was detected for the RLN1 promoter 2 isoform_Flag fusion protein isoform (Figure 
5.8a). The RLN1 antibody detected a protein band at approximately 28kDa as predicted 
for the RLN1 promoter 1_Flag fusion protein isoform. No smaller bands were detected 
for the promoter 2 isoform predicted fusion protein, despite mRNA expression (Figure 
5.8b and c). These results suggest no short RLN1 protein isoform is made in HEK293 
cells, despite over-expression. A number of different conditions for the SDS-PAGE gel 























Figure 5.8  Validation of the RLN1 antibody. Detection of RLN1 protein (isoform 1) 
in human HEK-293 cells over-expressing N-Terminal 3XFlag tagged fusion proteins. No 
protein expression was detected for the non-coding isoform.   
(a) Representative Western blot showing isoform 1 protein expression was detected 
using a monoclonal anti-Flag M2 antibody. Actin was used as a loading control. 
(a) 































































(b) Representative Western blot showing RLN1 protein was detected using the RLN1 
antibody. Actin was used as a loading control. 
(c) Real-time quantitative reverse transcription PCR (qRT-PCR) confirmation of 
RLN1 isoform overexpression in HEK-293 cells. Expression was calculated as 
the average (from 3 biological replicates) fold change relative quantification 
compared to the empty vector control cells (EV) (value set as 1). Samples were 




5.3.4 Characterisation in prostate cancer cells 
Although an increase in RLN1 promoter 1 mRNA expression was detected in LNCaP 
cells in response to androgen stimulation (Figure 5.2a), there was no corresponding 
increase in full length RLN1 protein expression at 24 hours or 48 hours. A slight increase 
was overserved after 72 hours. Expression of RLN2 protein was reduced following 24 
hours androgen stimulation (Figure 5.2b). A smaller band was observed at ~15kDa, this 
is most likely non-specific. This could have been controlled for by using a RLN negative 
cell line, in which RLN1 is known to be absent such as Hela or MCF7 cells. If the band 























Figure 5.9 Androgen regulation of RLN1 and RLN2 protein expression  
(a) Representative Western blot showing expression of RLN1 protein (25kDa) in 
LNCaP cells in response to 10 nM synthetic androgen (R1881) stimulation (24 
hours, 48 hours and 72 hours). Actin was used as a loading control. 
(b) Representative Western blot showing expression of RLN2 protein (21kDa) in 
three replicate samples of LNCaP cells in response to 10 nM synthetic androgen 
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5.3.5 Relaxin expression in clinical prostate cancer patient samples  
 
Expression levels of RLN1 and RLN2 mRNA were analysed in prostate cancer patient 
RNA samples using qRT-PCR. The sample set contained RNA from carcinoma tissue 
and adjacent normal tissue from 9 patients. Clinical samples were provided with ethical 
approval through the Exeter NIHR Clinical Research Facility tissue bank (Ref: STB20). 
Written informed consent for the use of surgically obtained tissue was provided by all 
patients. 
 
3 of the 9 patients showed an increase in RLN1 promoter 1 mRNA expression in prostate 
carcinoma tissue compared to adjacent normal tissue (patients 1, 4 and 9), whilst the 
remaining 6 patients showed a decrease (patients 2,3,5,6,7 and 8) (Figure 5.10a). 2 of 
the 9 patients showed an increase in RLN1 promoter 2 mRNA expression in prostate 
carcinoma tissue compared to adjacent normal tissue (patients 8 and 9) (Figure 5.10b). 
Patients 1 and 4 had an increase in promoter 1 transcripts compared to promoter 2 
transcripts in the carcinoma tissue, whilst patients 8 and 9 had an increase in promoter 
2 transcripts compared to promoter 1 transcripts in the carcinoma tissue. Patients 2,3,5,6 
and 7 have lower levels of RLN1 (both isoforms) mRNA expression in prostate carcinoma 
tissue compared to adjacent normal tissue. For RLN2, 2 of the 9 patients showed an 
increase in promoter 1 mRNA expression in prostate carcinoma tissue compared to 
adjacent normal tissue (patients 4 and 9), whilst the remaining 7 patients showed a 
decrease (patients 1,2,3,5,6,7 and 8) (Figure 5.11a). 2 of the 9 patients showed an 
increase in RLN2 promoter 2 mRNA expression in prostate carcinoma tissue compared 
to adjacent normal tissue (patients 8 and 9) (Figure 5.11b). Patient 4 has an increase in 
promoter 1 transcripts compared to promoter 2 transcripts in the carcinoma tissue, whilst 
patients 8 and 9 had an increase in promoter 2 transcripts compared to promoter 1 
transcripts in the carcinoma tissue. Patients 2,3,5,6 and 7 have lower levels of RLN2 
(both isoforms) mRNA expression in prostate carcinoma tissue compared to adjacent 




The difference in expression observed for each patient was highly variable. All samples 
have been normalised to the normal tissue expression levels, but this was not consistent 




Figure 5.10 RLN1 mRNA expression levels in prostate cancer patient samples. 
Real-time quantitative reverse transcription PCR (qRT-PCR) analysis of RLN1 promoter 
1 and promoter 2 mRNA expression in RNA from matched tumour tissue and adjacent 
normal tissue samples from 9 patients.  
(a) 3 of the 9 patients showed an increase in RLN1 promoter 1 mRNA expression in 
prostate carcinoma tissue compared to adjacent normal tissue (patients 1, 4 and 
9), whilst the remaining 6 patients showed a decrease (patients 2,3,5,6,7 and 8). 
(b) 2 of the 9 patients showed an increase in RLN1 promoter 2 mRNA expression in 








Figure 5.11 RLN2 mRNA expression levels in prostate cancer patient samples. 
Real-time quantitative reverse transcription PCR (qRT-PCR) analysis of RLN2 promoter 
1 and promoter 2 mRNA expression in RNA from matched tumour tissue and adjacent 
normal tissue samples from 9 patients.  
(a) 2 of the 9 patients showed an increase in RLN2 promoter 1 mRNA expression in 
prostate carcinoma tissue compared to adjacent normal tissue (patients 4 and 9), 
whilst the remaining 7 patients showed a decrease (patients 1,2,3,5,6,7 and 8). 
(b) 2 of the 9 patients showed an increase in RLN2 promoter 2 mRNA expression in 











5.4 Discussion  
As well as transcriptional changes, androgens can also drive the expression of 
alternative mRNA isoforms. An individual gene can produce multiple different mRNA 
isoforms, vastly expanding the range of proteins within the cell. These protein variants 
can have different functions and sub-cellular locations from each other (Stamm et al., 
2005). Transcriptome exon microarray experiments have previously identified androgen 
regulated cassette exons: an exon within the ZNF121 gene was activated by androgens 
and an exon within the NDUFV3 gene was repressed by androgens (Rajan 2011). The 
same study also identified an androgen regulated alternative TSC2 mRNA isoform which 
encodes a protein promoting cell growth (Munkley et al. 2014). More recently RNA 
sequencing experiments have identified an androgen regulated ST6GalNac1 mRNA 
splice isoform encoding a shorter ST6GalNac1 protein which reduces cell adhesion, 
increases motility and promotes EMT in prostate cancer cells (Munkley et al., 2015b). 
 
The global RNA sequencing data from LNCaP cells reported here has identified 73 
androgen regulated alternative mRNA isoforms, the majority of which are generated 
through alternative promoter selection. This thus significantly increases the number of 
known AR regulated mRNA isoforms and implies a much greater level of complexity 
whereby androgens are able to simultaneously regulate transcriptional and alternative 
mRNA isoform expression changes in prostate cancer (paper currently in preparation).   
 
In this chapter I have particularly reported that the AR can induce expression of 
alternative mRNA isoforms of the RLN1 and RLN2 genes in prostate cancer cells. 
Androgen regulated promoter switches for the peptide hormones RLN1 and RLN2 were 
identified. Androgens were found to repress the expression of a non-coding RLN1 
isoform, increasing the expression of the protein coding isoform. For RLN2, there was 
an increase in expression from the up-stream promoter (promoter 1) in the presence of 
androgens. In both cases, androgen stimulation resulted in an overall decrease in the 
non-coding isoform.  
184 
 
Expression levels of RLN1 are known to be up-regulated in LNCaP cells in response to 
androgens (Tevz et al., 2016) and RLN1 is abundantly expressed in LNCaP cells, normal 
prostate tissue and prostate cancer tissue (Hansell et al., 1991; Gunnersen et al., 1996; 
Tevz et al., 2016). This supports my findings that androgens increase the expression of 
RLN1 mRNA, although I was not able to confirm this change at the protein level. A shorter 
RLN1 isoform was detected by western blot in androgen stimulated LNCaP cells, 
however this is likely to be a non-specific artefact, further investigation is required. RLN2 
expression is known to be negatively regulated by androgens and increases during the 
progression of prostate cancer to androgen independence by promoting tumour growth 
and vascularisation (Silvertown et al., 2006; Thompson et al., 2006). I also found that 
androgens decrease the expression of RLN2 mRNA and protein.  
 
Comparison of matched prostate carcinoma and adjacent normal tissue samples in a 9 
patient cohort identified significantly differentially expressed mRNA isoforms for RLN1 
and RLN2. 2 patients showed an increase in RLN1 promoter 1 mRNA expression and a 
decrease in promoter 2 expression in the prostate carcinoma tissue. Another patient 
showed an increase in RLN1 promoter 2 mRNA expression and a decrease in promoter 
1 expression in the prostate carcinoma tissue. The same pattern was observed for the 
RLN2 mRNA isoforms with one patient showing an increase in RLN2 promoter 1 mRNA 
expression and a decrease in promoter 2 expression and another patient showed an 
increase in RLN2 promoter 2 mRNA expression and a decrease in promoter 1 
expression in the prostate carcinoma tissue. This is a small cohort of patients and as the 
results between patients are highly variable, a larger cohort would be needed to 
understand true expression patterns.  
 
The novel fusion transcript which has recently been described contains incomplete 
sequences of both RLN1 and RLN2. This fusion transcript is expressed in LNCaP cells 
and normal prostate tissue and is down-regulated by androgens (Tevz et al., 2016). 
When the RNA transcripts were aligned to the human genome, the RLN1-RLN2 fusion 
showed a significant overlap with the annotated RLN1 and RLN2 genes. Overlapping 
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transcripts included the 3’ end of the first RLN1 exon and the 5’ end of the second RLN1 
exon, the 3’ end of the first RLN2 exon and all of the second RLN2 exon. As with earlier 
studies, my primers were designed near the exon junction and would therefore not be 
able to discriminate between RLN1/RLN2 and RLN1-RLN2 fusion transcripts. The 
abundant expression of this fusion transcript in LNCaP cells may have skewed my results, 
although no fusion protein (larger protein band) was detected using the RLN1 or RLN2 
specific antibodies and no reads were mapped between RLN1 and RLN2 in the analysis 
of our RNA sequencing.  
 
Further investigation of these androgen regulated mRNA isoforms is necessary to 
establish which isoforms encode proteins that may be clinically relevant. The generation 
of a RLN1 antibody will allow further functional investigations into the expression patterns 
and localisation of this protein. Although the identification of this novel RLN1-RLN2 fusion 


















































Chapter 6  
 
Concluding remarks and future direction 
 
Prostate cancer remains one of the leading causes of cancer-related death in men 
(Hassanipour-Azgomi et al., 2016). Androgens and the AR are key players in the 
development and progression of the disease and have been the main target of 
therapeutic treatments for many years (Livermore et al., 2016). Numerous genomic and 
transcriptomic studies have been carried out over the years, identifying AR binding sites 
and target genes (Massie et al., 2007; Wang et al., 2007; Wang et al., 2009a; Massie et 
al., 2011; Rajan et al., 2011; Sharma et al., 2013). The development of RNA sequencing 
technology has allowed for transcriptome interrogation on a much larger scale. Within 
the last decade, there have been a number of published clinical PCa transcriptome 
datasets, providing a comprehensive profile of advanced, metastatic, castrate resistant 
and neuroendocrine prostate cancer (Fenner, 2011; Rajan et al., 2014; Robinson et al., 
2015; Beltran et al., 2016; Kumar et al., 2016; Mo et al., 2017).  
 
 
The aim of this project was to use current RNA sequencing technology to identify 
clinically relevant androgen regulated transcriptional changes. By correlating RNA 
sequencing data from androgens stimulated LNCaP cells with RNA sequencing from 
advanced prostate cancer patients before and after ADT (Rajan et al., 2014), we 
identified over 600 potentially clinically relevant AR target genes. These genes had 
reciprocal expression signatures; androgen regulated in culture with reverse expression 
switches in the patients in response to clinical ADT. This dataset provides a 
comprehensive map of AR-regulated genes in clinical prostate cancer and has recently 
been published (Munkley et al., 2016b). It offers a new window through which to 
understand the signalling pathways downstream of the AR and the role that these 
pathways play in both the development of prostate cancer and the response to ADT.  
A meta-analysis approach was used to analyse the expression of these identified genes 
across multiple prostate cancer gene expression datasets.  Gene Ontology (GO) 
analysis of the dataset identified a number of key AR regulated biological processes, 
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including glycosylation as a previously unidentified system-wide androgen-regulated 
process. Aberrant glycosylation, primarily caused by the altered expression or mis-
localisation of glycoenzymes is a common feature of cancer cells (Pinho and Reis, 2015; 
Stowell et al., 2015). Alterations in the expression of these glycoenzymes can lead to 
aberrant modifications which can alter many important biological processes such as cell-
cell adhesion, migration, interactions with the cell matrix, immune surveillance, signalling 
and cellular metabolism (Munkley and Elliott, 2016). The enrichment of genes encoding 
glycosylation enzymes within our dataset suggests that these identified genes may play 
a role in modifying some of these processes in prostate cancer and could therefore 
contribute to disease progression.  
 
Meta-analysis highlighted a sub-set of 10 glycosylation enzymes with significant gene 
expression changes: EDEM3, GCNT1, SERP1, STT3A, ST6GALNAC1, ST6GAL1, 
GNPNAT1, UBE2J1, TUSC3 and UAP1. GCNT1, ST6GALNAC1, TUSC3 and UAP1 
have previously been linked to PCa. Increased expression of GCNT1, which is involved 
in the formation of branched O-linked glycans, has been shown to positively correlate 
with the aggressive potential of PCa (Hagisawa et al., 2005; Chen et al., 2014). Increased 
expression of ST6GalNAc1 by androgens in prostate cancer cells can reduce prostate 
cancer cell adhesion (Munkley et al., 2015b; Munkley et al., 2016b). Knockdown of the 
novel tumour suppressor gene TUSC3 in PCa cell lines alters the ER stress response 
and accelerates cell proliferation and invasion (Horak et al., 2014). UAP1 is highly 
overexpressed in prostate cancer and can protect cancer cells from ER stress by 
protecting against inhibitors (Itkonen et al., 2014). SERP1 and UBE2J1 expression has 
been identified as androgen regulated but this is the first time androgen regulation of 
EDEM3, STT3A, and ST6GAL1 has been described.  
 
These enzymes are essential for prostate cancer cell survival, control key steps in glycan 
synthesis, and synthesise several cancer-associated glycans (Munkley et al., 2016b). 
The identification of glycosylation as an androgen regulated process in prostate cancer 
could have important clinical implications both in patient diagnosis and therapeutic 
strategies. Glycans have been shown to play a role in all aspects of cancer progression 
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and are therefore attractive targets for therapeutic intervention (Munkley and Elliott, 
2016). Inhibiting glycosylation, even in conditions where the AR is active, can decrease 
prostate cancer cell viability and invasion potential (Itkonen and Mills, 2013; Itkonen et 
al., 2016). An increased understanding of how these individual glyco-enzmyes, and 
glycosylation as a whole, influences prostate cancer cell behaviour is required. This 
could assist in the development of new glyco-based specific biomarkers for use in the 
early detection and management of prostate cancer. Drugs targeting glycans have 
already been developed as therapies for other cancer types (Fuster and Esko, 2005; 
Rabu et al., 2012; Vankemmelbeke et al., 2016; Shimomura et al., 2018). Further 
investigation into the role of these glycosylation enzymes could enable existing therapies 
to be utilised to treat prostate cancer.  
 
Amongst the enzymes investigated further was ST6Gal1, a sialytransferase that 
catalyses the transfer of sialic acid from CMP-sialic acid to N-terminus of galactose-
containing substrates. Increased sialylation is already known to be associated with 
cancer cell progression and metastasis, affecting cell adhesion, migration and invasion 
(Seales et al., 2005; Bull et al., 2013; Pinho and Reis, 2015) and up-regulation of 
ST6Gal1 has been described in several cancers (Dall'Olio et al., 1989; Skacel et al., 
1991; Wang et al., 2001; Lin et al., 2002; Dall'Olio et al., 2004; Poon et al., 2005).  
 
To investigate the biological significance of increased ST6Gal1 expression on prostate 
cancer cell aggressiveness, molecular cloning techniques were used to establish 
prostate cancer cell lines with ST6Gal1 over-expression and knock-down properties. 
Increased ST6Gal1 expression increased cell to matrix adhesion and reduced migratory 
potential in DU145 cells. This correlates with the increased expression observed in a 
number of key adherens junction genes such as CTNNB1 (beta-catenin), FN1 
(fibronectin) and CDH1 (E-cadherin). High ST6Gal1 expression levels also increased the 
invasion potential in DU145 cells. Epithelial to mesenchymal transition (EMT) plays an 
important role in the invasiveness of cancer cells (Yeung and Yang, 2017). Increased 
expression of a number of genes known to be up-regulated during the EMT process, 
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including vimentin, snail and slug as well as a dramatic loss of the desmosome junctional 
complex component desmoplakin were observed in the ST6Gal1 over-expressing 
DU145 cells. RNA sequencing of these cells has identified ST6Gal1 regulated 
expression changes in a number of key cancer associated genes such as AKR1C1 (Zeng 
et al., 2017), ABCA1 (Lee et al., 2013), SLC18A2 (Haldrup et al., 2016) and NOTCH3 
(Carvalho et al., 2014) 
 
 
The reduction of ST6Gal1 expression significantly decreased cell proliferation, cell to 
matrix adhesion, migration and invasion capability in CW-22Rv1 cells. This correlates 
with what has previously been observed in other prostate cancer cell lines (Wei et al., 
2016). ST6Gal1 has previously been associated with the maintenance of the cell 
mesenchymal state in breast cancer cell lines (Lu et al., 2014). In line with this we 
observed a significant decrease in CDH2 (N-cadherin) expression, a mesenchymal 
cadherin associated with EMT (Whang et al 2015) as well as other EMT markers FN1 
(fibronectin), SNAI1 (snail) and SNAI2 (slug).  
 
 
The role of ST6Gal1 in clinical prostate cancer is less clear. ST6Gal1 expression was 
shown to be increased in our RNA sequencing dataset and the subsequent meta-
analysis. This was confirmed in our independent patient RNA cohort of 17 malignant 
tumour samples from transurethral resections of the prostate (TURP) and 32 non-
malignant BPH tissue from our independent patient RNA cohort. A recent study also 
supports this, that found ST6Gal1 expression was significantly upregulated in prostate 
cancer tumour tissues compared with BPH, and that elevated ST6Gal1 expression was 
correlated with higher Gleason scores (Wei et al., 2016). Contradictory to this, we found 
that ST6Gal1 expression was down-regulated when compared with normal prostate 
tissue. Our matched tumour and adjacent normal tissue samples RNA dataset showed 
that 6 out of the 9 patients had a clear significant down-regulation of ST6Gal1 in the 
tumour tissue compared to the adjacent normal tissue. In addition, analysis of our 
prostate cancer tissue microarray shows that ST6Gal1 protein expression was down-
regulated in the prostate cancer patient tissue samples compared with the BPH tissue 
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samples. Targeting ST6Gal1 therapeutically has shown potential, however globally 
targeting sialylation could have detrimental side effects for the patient. A targeted or pro-
drug approach would allow selective inhibition of sialylation in prostate cancer cells. The 
fluorinated sialic acid analogue P-3Fax-Neu5Ac selectively blocks sialylation in B16F10 
cells (Bull et al., 2013) and has shown potential for anticancer therapy. P-3Fax-Neu5Ac 
treatment blocks tumour cell adhesion to extra cellular matrix and migration in vitro and 
tumour engraftment in vivo (Bull et al., 2013).  
 
 
The findings of this project indicate that establishing the role of individual glyco-enzymes 
in prostate cancer is difficult. The role of ST6Gal1 in prostate cancer is complex and 
more than likely dependable on the other compensatory mechanisms available within 
the tumour, together with the collective expression of other glyco-enzymes. General two-
dimensional (2D) monolayer cell cultures fail to represent the complex behaviour of 
native tissue and lack the heterogeneity that exists within tumours. They are grown in a 
particular media supplemented with nutrients to support their growth, an environment not 
representative of how cells exist within an organism. The lack of cell-cell and tissue-
matrix interactions can alter gene and protein expression levels. Cells grown on flat, 
ridged plastic surfaces are often stressed, which can trigger abnormally high cell 
proliferation rates, impacting on results (Breslin and O'Driscoll, 2013).  
 
 
Over the past decade, there has been a surge in the development of platforms that 
enable the growth of three-dimensional (3D) spheroid cultures. These cultures can 
provide a more realistic environment, better replicating the natural morphology and 
physiology found in vivo (Edmondson et al., 2014). Recent platforms include hydrogels 
(Drury and Mooney, 2003), porous scaffolds (Fischbach et al., 2007), hanging drops 
(Aijian and Garrell, 2015) and microwell-mesh (Mosaad et al., 2018). Further functional 
experiments using 3D spheroid cultures could be useful to fully understand the role each 
of these individual enzymes plays in prostate cancer.  Together with the androgen 
regulated transcriptional changes, the RNA sequencing data also identified 73 androgen 
regulated alternative mRNA isoforms. These included 56 alternative promoters, 4 
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alternative 3′ ends and 13 alternative spicing events. 64  of  these  events  are  novel  to 
this project and  26  involve  previously  unannotated  isoforms. This significantly 
increases the number of known AR regulated mRNA isoforms and implies a much 
greater level of complexity whereby androgens are able to simultaneously regulate 
transcriptional and alternative mRNA isoform expression changes in prostate cancer.  
Never the less, further investigation is necessary to establish which isoforms encode 
proteins that may be clinically relevant. It will also be important  to  define  the  role  of  
specific  AR  co-regulators  in  AR  mediated  isoform  selection.    
 
Androgen regulated promoter switches for the peptide hormones RLN1 and RLN2 were 
identified. Alternative  promoter  use  can  generate  mRNA  isoforms  with  distinct  
functional  activities  from  the  same  gene,  which can sometimes  having  opposing  
functions (Munkley et al., 2017a). Androgens were found to repress the expression of a 
non-coding RLN1 isoform, increasing the expression of the protein coding isoform. For 
RLN2, there was an increase in expression from the up-stream promoter in the presence 
of androgens. In both cases, androgen stimulation resulted in an overall decrease in the 
non-coding isoform. However, the recent discovery of a novel RLN1-RLN2 fusion 
transcript has made it difficult to accurately characterise their independent expression.  
 
In conclusion, this project has identified a new panel of androgen regulated genes and 
novel mRNA isoforms. Analysis of this panel has demonstrated important androgen 
control over glycosylation modifications that has important implications for prostate 
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Genes up-regulated in response to androgen treatment in LNCaP cells, but down-
regulated in 7 PCa patient samples post ADT. 
Gene Information  
AACS Fatty acid synthesis 
ABAT GABA catabolism 
ABCC4 May be an organic anion pump relevant to cellular detoxification 
ABHD11 Protein containing an alpha/beta hydrolase fold domain. Lung cancer 
ABHD2 Migration. Enzyme alpha/beta hydrolase fold 
ACAA1 Acetyl-CoA acyltransferase 1. Beta-oxidation system of the peroxisomes 
ACACA Acetyl-CoA carboxylase. Long chain fatty acid biogenesis 
ACAD8 Acyl-CoA dehydrogenase family member 8 mitochondrial enzyme  
ACLY Enzyme responsible for the synthesis of cytosolic acetyl-CoA 
ACP2 Lysosomal acid phosphatase 
ACSL1 Activation of long-chain fatty acids 
ACSL3 Acyl-CoA synthetases (ACSL) activates long-chain fatty acids 
ACSM1 Fatty acid:CoA ligase activity. Acyl-CoA Synthetase2 
ACSM3 Fatty acid:CoA ligase activity 
ADAM9 Probable zinc protease. May mediate cell-cell or cell-matrix interactions 
ADI1 Aci-reductone dioxygenase. mRNA processing 
ADIPOR1 Fatty acid catabolism and glucose levels 
ADM2 Calcitonin-related hormones. Homeostasis. CRLR/RAMP receptor 
ADRB1 Activation of adenylate cyclase 
ADRBK1 Key regulator of LPAR1 signaling 
AFF3 Putative transcription activator 
AGR2 Proto-oncogene that may play a role in cell migration, cell differentiation and cell growth 
AGTRAP Negative regulator of type-1 angiotensin II 
AK4 Adenylate Kinase 4. Protein is localised to the mitochondrial matrix. 
AKR1A1 Catalyzes the NADPH-dependent reduction 
ALDH1A3 Aldehyde dehydrogenase 
ALDH4A1 Mitochondrial matrix NAD-dependent dehydrogenase 
ALG2 Glycosyltransferase 
ALG5 N-linked glycosylation 
ALOX15 Metabolism of fatty acid hydroperoxidases 
AMACR Alpha-methylacyl-CoA racemase  
AMD1 Intermediate enzyme in polyamine biosynthesis. Proliferation 
ANO7 Prostate specific may play a role in cell-cellinteractions 
AP1B1 Role in protein sorting in the late-Golgi/trans-Golgi network (TGN) and/or endosomes 
AP2S1 Protein transport. Vescicles.  Component of the adaptor protein complex 2 (AP-2) 
APLN Endogenous ligand for the G protein coupled receptor APJ 
ARF4 GTP-binding protein. Protein trafficking vesicle budding and uncoating within the golgi 
ARFGAP3 GTPase-activating protein (GAP) for ADP ribosylation factor 
ARFIP2 Involved in membrane ruffling 
ARHGEF26 Rho-guanine nucleotide exchange factor 
ARSD Sulfatase localized to the lysosome 
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ASRGL1 L-asparaginase and beta-aspartyl peptidase 
ATG101 Autophagy 
ATP10A P-type cation transport ATPases 
ATP11B P-type ATPases. Transport of ions across membranes 
ATP6V0B V-ATPase dependent organelle acidification 
ATP6V1G1 Component of vacuolar ATPase (V-ATPase) 
ATXN1 Chromatin-binding factor that repress Notch signaling 
AZGP1 Lipd degradation. May bind polyunsaturated fatty acids 
AZGP1P1 Pseudogene, and is affiliated with the lncRNA class 
B3GAT1 Glucuronyltransferase 
B4GALT1 One of seven beta-1,4-galactosyltransferase (beta4GalT) genes 
BAIAP2 
CDC42-mediated reorganization of the actin cytoskeleton and for RAC1-mediated 
membrane ruffling 
BDH1 Homotetrameric lipid-requiring enzyme of the mitochondrial membrane  
BEND4 BEN domain containing 4 
BHLHA15 
Plays a role in controlling the transcriptional activity of MYOD1. Gene expression. 
mitochondrial calcium ion transport 
BLOC1S5 Component of biogenesis of lysosome-related organelles complex 1 
BMPR1B 
Bone morphogenetic protein (BMP) receptor family of transmembrane serine/threonine 
kinases. TGF-beta 
BNIP3 Mitochondrial protein. Pro-apoptotic factor 
BZW1 Enhances histone H4 gene transcription 
C14orf1 Probable ergosterol biosynthetic protein 
C19orf10 Not characterised 
C19orf48 Not characterised 
C1orf116 Putative androgen-specific receptor 
C1orf210 May be involved in membrane trafficking between endosomes and plasma membrane 
C1orf85 GLMP glycosylated lysosomal membrane protein 
C1QTNF3 C1q And tumor necrosis factor related protein 3 
C9orf152 Not characterised 
C9orf91 Transmembrane protein  
CALR Calcium-binding chaperone. Lectin that interacts with glycoproteins in ER 
CAMK1 Calcium/calmodulin-dependent protein kinase I 
CAMKK2 Calcium/calmodulin-dependent protein kinase 
CANT1 Calcium-dependent nucleotidase 
CCDC167 Transmembrane and coiled-coil domain-containing protein 
CD320 Uptake of transcobalamin bound cobalamin (vitamin B12 
CDYL2 Linked to prostate cancer. Methylated histone residue binding 
CECR6 Cat Eye Syndrome chromosome region, candidate 61  
CENPN Mitosis 
CHCHD1 mitochondrial protein  
CHP1 




Nicotinic acetylcholine receptors. Opening of an ion-conducting channel across the 
plasma membrane 
CKAP4 Anchoring of ER  to microtubules. Golgi. Cytoskelton 
CLDN3 Role in tight junctions. Calcium dependent adhesion 
CLDN8 Plays a major role in tight junction-specific obliteration of the intercellular space 
CLGN Calmegin is a testis-specific endoplasmic reticulum chaperone protein. Spermatogenesis 
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CLPP Mitochondrial protein 
CLPTM1L Enhances cisplatin-mediated apoptosis when overexpressed. Breast cancer 
CLTC Clathrin is the major protein of the polyhedral coat of coated pits and vesicles 
CMC2 Mitochondrial protein 
CNDP2 Non-specific dipeptidase. Tumor suppressor in hepatocellular carcinoma  
CNTNAP2 Saltatory conduction of nerve impulses in myelinated nerve fibres 
COA3 Mitochondrial protein 
COPB1 p53, AKT activation and promotion of cell survival 
COPB2 
Reversibly associates with Golgi non-clathrin-coated vesicles. Mediate biosynthetic 
protein transport from the ER 
COPE Subunit of coatomer protein complex. Golgi. Vesicles 
COPG1 
Reversibly associates with Golgi non-clathrin-coated vesicles. Mediate biosynthetic 
protein transport from the ER 
CORO1B Cell motility 
CORO2A Member of the WD repeat protein family. Cell cycle? 
COX7A2 
Nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in 
mitochondrial electron transport 
COX7B 
Cytochrome c oxidase (COX), the terminal component of the mitochondrial respiratory 
chain 
COX8A Mitochondrial protein 
CPT1A Mitochondrial protein 
CREB3L4 Transcriptional activator 
CRELD2 May regulate transport of alpha4-beta2 neuronal acetylcholine receptor 
CRISP3 Cysteine-rich secretory protein 3 
CRLS1 Cardiolipin Synthase  
CSGALNACT1 Chondroitin sulfate N-acetylgalactosaminyltransferase 
CTBS Lysosomal glycosidase 
CYB561 Transmembrane electron transfer carrier and ferric-chelate reductase activity 
CYP51A1 
ER protein. member of the cytochrome P450 superfamily of enzymes. Synthesis of 
cholesterol, sterods and other lipds 
DAP Mediator of programmed cell death induced by interferon gamma 
DBI Binds medium- and long-chain acyl-CoA esters. GABA receptor 
DCAF6 Transcriptional activity of NR3C1 and AR 
DCXR Uronate cycle of glucose metabolism 
DDAH1 Role in nitric oxide generation 
DEGS1 Migration, membrane fatty acids 
DGKD Diacylglycerol kinases 
DHCR24 Oxidoreductase 
DHCR7 Production of cholesterol 
DLX1 Regulator of signals from multiple TGFB superfamily members 
DNAJB11 
Soluble glycoprotein of the ER lumen required for the proper folding and assembly of 
proteins 
DNAJC10 ER disulfide reductase. Protein folding and degradation. ER quality control 
DNAJC3 Unfolded protein response (UPR) during ER stress. May inhibit EIF2AK3/PERK activity 
DSC2 Glycoprotein. Adhesion 
DUS1L Catalyzes the synthesis of dihydrouridine in D-loop of most tRNAs 
EAF2 Testosterone-regulated apoptosis inducer. Transcriptional transactivator 
EBP Integral membrane protein of the endoplasmic reticulum 




EEF1E1 Eukaryotic translation elongation factor 1 epsilon 1 
EGF 





RNA Polymerase II Elongation Factor ELL22.  Increase the catalytic rate of RNA 
polymerase II transcription  
ELOVL1 Fatty acid metabolism 
ELOVL2 Catalyzes the synthesis of polyunsaturated very long chain fatty 
ELOVL5 Role in elongation of long-chain polyunsaturated fatty acids 
ELOVL7 
Enzyme that catalyzes the synthesis of saturated and polyunsaturated very long chain 
fatty acids 
ELP6 Transcriptional elongation 
EMC7 ER membrane comples protein 
ENDOD1 May act as a DNase and a RNase 
ENTPD2 E-NTPDases are a family of ecto-nucleosidases that hydrolyze 5'-triphosphates 
ENTPD6 Might support glycosylation reactions in the Golgi apparatus 
EPHX2 Binds to specific epoxides and converts them to the corresponding dihydrodiols 
ERBB3 Over expressed in prostate cancer. EGFR family  
ERGIC1 Possible role in transport between endoplasmic reticulum and Golgi 
ERLEC1 Probable lectin that binds selectively to improperly folded lumenal proteins 
ERP44 ER protein. role in the control of oxidative protein folding in the endoplasmic reticulum 
ESRP2 mRNA splicing factor. EMT isoforms. CD44. catenin 
F2RL1 Coagulation factor II (thrombin) receptor-like 1.  Inflammatory responses  
F5 Hemostasis 
FAAH Fatty acid metabolism 
FADS1 Fatty acid desaturase 
FADS2 Fatty acid desaturase  
FAM111B Cancer-associated nucleoprotein 
FAM174B Membrane protein 
FAM189A2 Family with sequence similarity 189, member A21  
FAR2P1 Fatty Acyl CoA reductase 2 pseudogene  
FAR2P2 lncRNA.  Fatty Acyl CoA reductase 2 pseudogene 21 
FASN Fatty acid synthetase 
FDFT1 First specific enzyme in cholesterol biosynthesis 
FECH Mitochondrial protein 
FGFR3 
Tyrosine-protein kinase. Cell-surface receptor for fibroblast growth factors. Cell 
proliferation and apoptosis 
FGFRL1 Fibroblast growth factor receptor 
FICD Adenylyltransferase 
FKBP2 Protein folding and trafficking 
FKBP5 
Protein folding and trafficking.  Intracellular trafficking of heterooligomeric forms of steroid 
hormone receptors  
FLJ20021 Not characterised 
FURIN Protease process protein and peptide precursors trafficking 
FUT1 Galactoside 2-L-fucosyltransferase enzyme 
FXYD3 FXYD-domain containing regulators of Na+/K+ ATPases 
FZD5 Receptor for Wnt proteins 
FZD8 Receptor for Wnt proteins 
G3BP2 mRNA transport? GTPase-activating protein 
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GABRB3 GABA.  Ligand-gated ionic channel family 
GABRG3 Gamma-aminobutyric acid (GABA) receptor 
GALNT7 Glycopeptide transferase involved in O-linked oligosaccharide biosynthesis 
GCAT Glycine C-acetyltransferase 
GCNT1 Glycosyltransferase 
GCNT2 Branching enzyme that converts linear into branched poly-N-acetyllactosaminoglycans 
GGT1 Type I gamma-glutamyltransferase. Metabolism 
GLB1L2 Galactosidase, beta 1-like 2 
GLUD1 Mitochondrial protein 
GMDS Catalyzes the conversion of GDP-D-mannose to GDP-4-dehydro-6-deoxy-D-mannose 
GNB2 Guanine nucleotide-binding proteins (G proteins). Transmembrane signalling 
GNPNAT1 Metabolism. Glucosamine-phosphate N-acetyltransferase  
GOLM1 Golgi membrane protein 1 
GOLPH3 
Role in golgi membrane trafficking and could indirectly give its flattened shape to the 
Golgi apparatus 
GOT2 Mitochondrial protein. Long chain fatty acids 
GPT2 Amino acid metabolism and gluconeogenesis 
GREB1 May play a role in estrogen-stimulated cell proliferation 
GRHL2 May function as a transcription factor 
GRIN3A Subunit of the N-methyl-D-aspartate (NMDA) receptors 
GSKIP Wnt signaling pathway. Retinoic acid 
GSTZ1 Metabolism. Glutathione S-transferase  
GTF3C6 Involved in RNA polymerase III-mediated transcription. General transcription factor 
GUCY1A3 Guanylate cyclases conversion of GTP to 3',5'-cyclic GMP and pyrophosphate 
H1F0 
Histones H1 are necessary for the condensation of nucleosome chains into higher-order 
structures 
H2AFJ Core component of nucleosome 
HEBP2 
Can promote mitochondrial permeability transition and facilitate necrotic cell death under 
stress conditions 
HERPUD1 ER quality control 
HGD 
Enzyme homogentisate 1,2 dioxygenase. This enzyme is involved in the catabolism  
amino acids 
HID1 Downregulated in cancer 
HINT1 Hydrolyze substrates such as AMP-morpholidate. Transcription. P53 
HIPK2 
Serine/threonine-protein kinase. Transcription regulation, p53 mediated cellular 
apoptosis. Cell cycle 
HIST1H1C Histone cluster 1, H1c. Gene expression 
HIST1H2BJ Histone cluster 1, H2bj. Core component of nucleosome. Gene expression 
HIST1H2BK Histone cluster 1, H2bk. Core component of nucleosome. Gene expression 
HIST2H2BE Transcription regulation 
HM13 Catalyzes intramembrane proteolysis of some signal peptides 
HMG20B Mitosis 
HMGCR Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis 
HMGCS1 This enzyme condenses acetyl-CoA with acetoacetyl-CoA to form HMG-CoA 
HMGCS2 Mitochondrial enzyme 
HMGXB3 HMG box domain containing 3. Transcription factor? 
HN1L Hematological and neurological expressed 1-like protein2 
HOMER2 Postsynaptic density scaffolding protein. Calcium. PIK3 
HPN Prostate cancer. Cell growth.  Transmembrane serine protease  
HSD17B4 Bifunctional enzyme acting on the peroxisomal beta-oxidation pathway for fatty acids 
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HSP90B1 Processing  transport of secreted proteins. Tumour formation 
HSPA5 Involved in the folding and assembly of proteins in the ER 
HYOU1 Protein folding and secretion in the ER. Invasiveness 
ICA1 May play a role in neurotransmitter secretion. Membrane bound in golgi 
IDE Peptide signaling 
IDH1 
Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-
oxoglutarate 
IDH2 Metabolism and energy production 
IDI1 Cholesterol 
IER3IP1 Apoptosis. Golgi. ER. Protein transport 
IMPDH1 Cell growth. de novo synthesis of guanine nucleotides 
INSIG1 Oxysterols regulate cholesterol homeostasis. Insulin induced. ER membrane protein 
IQGAP2 IQGAP family. Cytoskeleton, cell adhesion 
JAM3 Adhesion, migration 
KCNN2 Forms a voltage-independent potassium channel activated by intracellular calcium 
KCTD1 May repress the transcriptional activity of AP-2 family members 
KDELR2 Luminal ER protein retention system required for normal vesicular traffic through the Golgi 
KDM4B Histone demethylase 
KIAA1244 Not characterised 
KIF22 Mitosis 
KIF5C Mediates dendritic trafficking of mRNAs. Organnelle transport 
KLK15 Protease whose physiological substrate is not yet known 
KLK4 Kallikrein 4 
KLKP1 lncRNA. Kallikrein pseudogene  
KRT18 Filament reorganization 
KRT8 Intermediate filament 
LCP1 Processing of triglyceride rich proteins 
LDLR Binds LDL, and transports it into cells by endocytosis. Cholesterol 
LEAP2 Liver expressed antimicrobial peptide 2 
LIFR Signal-transducing molecule. benign epithelial tumor of the salivary gland. Proliferation 




Type I transmembrane lectin. shuttles between ER, Golgi and plasma membrane. Binds 
O-glycans 
LOC100294145 ncRNA 
LOC101927482 antisense RNA lncRNA? 
LOC440910 lncRNA 
LOC81691 Putative RNA exonuclease 
LPAR2 Lysophosphatidic acid (LPA) receptor and contributes to Ca2+ mobilization 
LPAR3 Calcium-mobilizing lysophosphatidic 
LRFN4 Leucine rich repeat and fibronectin type III domain containing 41  
LRIG1 Acts as a feedback negative regulator of signaling by receptor tyrosine kinases 
LRRC59 Required for nuclear import of FGF1 
LRRC75B Leucine Rich Repeat Containing 75B1 
LSR Clearance of triglyceride-rich lipoprotein from blood. Fatty acids 
LSS 
Catalyzes the first step in the biosynthesis of cholesterol, steroid hormones, and vitamin 
D 
LYPLA2 Lysophospholipase acts on membrane 




Involved in the apoptotic response after nerve growth factor (NGF) binding in neuronal 
cells. P53. Tumour specific antigen 
MAGED2 Melanoma antigen family D, 2 
MANF Golgi. susceptibility to ER stress-induced death. Cell proliferation. GABA 
MAOA Mitochondrial enzymes 
MAP7 Polarization and differentiation of epithelial cells during polorisation of epithelial cells 
MARVELD3 As a component of tight junctions, plays a role in paracellular ion conductivity 
MBOAT2 Membrane bound O-acyltransferase domain containing 2 
MCCC2 
Carboxyltransferase subunit of the 3-methylcrotonyl-CoA carboxylase. leucine and 
isovaleric acid catabolism 
MESP1 Transcription factor. Mesoderm. Notch signalling 
MFSD3 Major facilitator superfamily domain-containing protein 
MGST3 Inflammation 
MICAL2 Monooxygenase 
MIEN1 Migration and invasion enhancer 
MIF Glycosylation-inhibiting factor 3 macrophage migration inhibitory factor2  
MIR141 Metastatic prostate cancer 
MLEC N-glycosylation 
MLPH Melanophilin. Rab effector protein involved in melanosome transport 
MMAB Conversion of vitamin B(12) into AdoCbl 
MPC2 Mitochondrial protein 
MRPL36 Component of the large subunit of the mitochondrial ribosome 
MRPL41 Component of the mitochondrial ribosome large subunit. Apoptosis. Cell cycle p53 
MRPS18A Mitochondrial ribosomal proteins 
MRPS23 Mitochondrial protein 
MRPS28 Mitochondrial ribosomal protein S28 
MSMO1 Sterol-C4-mehtyl oxidase-like protein. ER localised. Cholesterol biosynthesis 
MT1F Metallothioneins have a high content of cysteine residues that bind various heavy metals 
MT1X Metallothionein 
MTCH2 Mitochondrial protein  
MTFP1 Mitochondia division 
MTMR2 Phosphoinositide lipid phosphatase 
MVD Cholesterol biosynthesis 
MYBPC1 Thick filament-associated protein 
NAA35 N(alpha)-acetyltransferase. Acetylation of N-terminal methionine residues 
NAAA Degrades bioactive fatty acid amides to their corresponding acids 
NAMPT Nicotinic acid phosphoribosyltransferase. Metabolism, stress, ageing 
NANS Biosynthetic pathways of sialic acids 
NCAPD3 Mitosis 
NDRG1 
Stress-responsive protein involved in hormone responses, cell growth, and differentiation. 
P53 
NDUFA2 
Accessory subunit of the mitochondrial membrane respiratory chain NADH 
dehydrogenase 
NDUFB10 Mitochondrial protein 
NDUFS6 Mitochondrial protein 
NDUFV2 Mitochondrial protein 
NEAT1 lncRNA 
NEDD4L E3 ubiquitin-protein ligase. Inhibits TGF-beta signaling  
NEU1 




NKX3-1 Transcription factor. Role in prostate development. Tumour suppressor in PC3 cells 
NOP10 Ribosome biogenesis and telomere maintenance 
NPDC1 
May be involved in transcriptional regulation.  Suppresses oncogenic transformation in 
neural and non-neural cells  
NUDT9 Nudix hydrolase family. ADP-ribosepyrophosphatase 
ODC1 Polyamine biosynthesis 
OR7E47P lncRNA. Olfactory receptor 
ORC5 DNA replication 
OSTC Oligosaccharyltransferase complex subunit 
P4HB Disulfide bonds 
PACSIN2 Intracellular vesicle-mediated transport. Endocytosis of cell surface receptors 
PAK1IP1 Negatively regulates the PAK1 kinase 
PANK3 Pantothenate kinase is a key regulatory enzyme in he biosynthesis of coenzyme A 
PAOX Oxidation of N(1)-acetylspermine to spermidine 
PAQR4 Progestin And AdipoQ Receptor Family Member 42  
PART1 Prostate androgen-regulated transcript 1. Antisense RNA 
PASK Serine/threonine-protein kinase involved in energy homeostasis and protein translation 
PC Mitochondrial protein  
PCCA Mitochondrial protein  
PCDH1 Cadherin superfamily. Cell-cell interaction processes and in cell adhesion 
PCTP 
Catalyzes the transfer of phosphatidylcholine between membranes. Binds a single lipid 
molecule 
PDE9A Catalyzes the hydrolysis of cAMP and cGMP to their corresponding monophosphates 
PDIA4 ER protein 
PDIA5 Protein disulfide isomerase family A, member 5 
PDIA6 Chaperone that inhibits aggregation of misfolded proteins. ER resident 
PDLIM5 PDZ and LIM domains protein 2 
PEBP4 
Promote cellular resistance to TNF-induced apoptosis by inhibiting activation of ERK1/2 
pathway 
PEMT Phosphatidylcholine (PC) is the most abundant mammalian phospholipid 
PEX10 Biogenesis of peroxisomes 
PGM3 Interconverts GlcNAc-6-P and GlcNAc-1-P 
PHPT1 Catalyzes the reversible dephosphorylation of histidine residues in proteins 
PIGH Phosphatidylinositol glycan anchor biosynthesis 
PITPNA Phospholipase C signaling. PIK3 
PLA1A Phospholipase that hydrolyzes fatty acids 
PLA2G12A 
Secreted phospholipase A2 (sPLA2) enzymes liberate arachidonic acid from 
phospholipids 
PLA2G4F Hydrolyze phospholipids into fatty acids 
PLEKHB2 Involved in retrograde transport of recycling endosomes 
PMEPA1 
Down-regulation of AR. Enhances ubiquitination and proteasome-mediated degradation 
of AR 
POLR2L Subunit of RNA polymerase II 
PPAP2A 
Membrane glycoprotein function in synthesis of glycerolipids and in phospholipase D-
mediated signal transduction 
PPAPDC2 Phosphatidic Acid Phosphatase. Immunity. Lipid 
PPIB PPIases accelerate the folding of proteins. ER. Secretion 
PPP1CA Serine/threonine phosphatase. 100s targets. Cell cycle 




PRDX4 Peroxidase. Probably involved in redox regulation of the cell 
PREB Probable role in the regulation of pituitary gene transcription 
PRSS8 Trypsinogen, serine protease, seminal fluid 
PSMA2 Processing of class I MHC peptides. Proteosome subunit 
PSMD8 Ptoteosome. Antigen processing 
PTPLB Protein tyrosine phosphatase like. Long chin fatty acid synthesis 
PTPRJ deP PIK3R1 
PTPRN2 Protein tyrosine phosphatase. Nervous system development 
PVR 
Transmembrane glycoprotein. Mediates NK cell adhesion and triggers NK cell effector 
functions 
PVRL2 Membrane glycoprotein. Cell adhesion 
PVRL3 Adhesion molecules at adherens junctions 
PXDN Extracellular matrix-associated peroxidase 
PYCR1 Proline biosynthesis. Oxidative stress 
RAB11A GTPase. Intracellular membrane trafficking 
RAB1B Transport between ER and golgi 
RAB27A Cytotoxic granule exocytosis 
RAB3B Protein transport, vesicle trafficing 
RAB3D Protein transport. Exocytosis 
RAB3IP Guanine nucleotide exchange factor 
RABEP2 Membrane trafficking. Endosome fusion 
RAC3 GTPase which belongs to the RAS superfamily. Cell growth and spreading 
RAP1GAP GTPase-activating-protein 
REPS2 
Regulates the endocytosis of growth factor receptors. Influence on the Ral signaling 
pathway 
RER1 Golgi 
RFPL2 Ret finger protein-like 21 
RHBDD2 Rhomboid domain containing 2 
RHOU Wnt signalling, adhesion, migration 
RHPN2 Rho pathway. Limit stress fiber formation. Increase turnover F actin 
RNF41 Acts as E3 ubiquitin-protein ligase and regulates the degradation of target proteins 
RPN1 Essential subunit of the N-oligosaccharyl transferase (OST) complex 
RPN2 Essential subunit of the N-oligosaccharyl transferase (OST) complex 
RWDD2A RWD domain containing 2A 
SAPCD2 Tumor specificity and mitosis phase-dependent expression protein 2  
SAR1B Involved in transport from the endoplasmic reticulum to the Golgi apparatus 
SAT1 Acetyltransferase family catalyzes the acetylation of spermidine and spermine 
SCAND1 May regulate the function of the transcription factor myeloid zinc finger 1B. SCAN domain 
SCD Fatty acid biosynthesis 
SDK1 
Cell adhesion protein that guides axonal terminals to specific synapses in developing 
neurons 
SEC11C Component of the microsomal signal peptidase complex 
SEC14L2 Cholesterol biosynthetic pathway 
SEC23B Vesicle trafficking. Golgi to ER 
SEC61A1 Plays a crucial role in the insertion of secretory and membrane polypeptides into the ER 
SEC61B 
The Sec61 complex is the central component of the protein translocation apparatus of the 
ER 
SERINC2 Lung cancer 




Interacts with target proteins during translocation to the ER lumen. Protects unfolded 
target proteinsduring ER stress 
SETD7 Histone methyltransferase. Transcriptional activation of insulin 
SFXN2 Potential iron transporter 
SFXN5 Transports citrate. Potential iron transporter 
SH3BP4 Endocytosis. mTOR signalling 
SHC2 
Signaling adapter that couples activated growth factor receptors to signaling pathway in 
neurons 
SHROOM2 May be involved in endothelial cell morphology changes during cell spreading 
SIL1 Required for protein translocation and folding in the endoplasmic reticulum (ER). 
SIM2 
Transcription factor that may be a master gene of CNS development in cooperation with 
Arnt 
SLC15A2 Solute Carrier Family 15 (H+/Peptide Transporter 
SLC1A5 Sodium-dependent neutral amino acid transporter 
SLC22A23 Transport organic ions across cell membranes 
SLC22A3 Mediates potential-dependent transport of a variety of organic cations 
SLC25A16 Mitochondrial protein 
SLC25A20 Mitochondrial protein 
SLC25A33 Mitochondrial protein 
SLC26A2 Sulfate transporter. Transmembrane glycoprotein 
SLC27A4 
Member of a family of fatty acid transport proteins, which are involved in translocation of 
long chain fatty acids 
SLC35B1 Probable sugar transporter 
SLC35E1 Putative transporter 
SLC35F2 Putative solute transporter. Lung cancer 
SLC39A1 Zinc uptake 
SLC39A10 May act as a zinc-influx transporter 
SLC39A6 May act as a zinc-influx transporter 
SLC39A7 
Transports zinc from the Golgi and endoplasmic reticulum to the cytoplasm. Activation of 
tyrosine kinases 
SLC43A1 Prostate cancer associated. Transport of large neutral amino acids 
SLC45A3 Prostate cancer associated 
SLC50A1 Sugar transport across membranes 
SLC52A2 Riboflavin transporter 
SLC5A4 Sodium-dependent glucose transporter 
SLC9A3R1 Scaffold protein . Wnt signalling 
SLC9A3R2 
Scaffold protein connects plasma membrane proteins with members of the 
ezrin/moesin/radixin family 
SMCO4 Single-pass membrane protein 
SMDT1 Essential regulatory subunit of the mitochondrial calcium uniporter complex 
SMPD1 Sphingomyelin phosphodiesterase 1, acid lysosomal 
SMS 
Catalyzes the production of spermine from spermidine and decarboxylated S-
adenosylmethionine (dcSAM) 
SNAP91 
Adaptins are components of the adapter complexes which link clathrin to receptors in 
coated vesicles 
SND1 Functions as a bridging factor between STAT6 and the basal transcription factor 
SNN Plays a role in the toxic effects of organotins 
SNX25 Sorting nexin. May be involved in several stages of intracellular trafficking 
SOAT1 Catalyzes the formation of fatty acid-cholesterol esters 
SOCS2 Cytokine signal transduction 
SOCS2-AS1 JAK/STAT pathway. cytokine signaling (SOCS) family 
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SORD Converts sorbitol to fructose. Sperm motility 
SPDEF 
ETS family of transcription factors. androgen-independent transactivator of PSA 
promoter. Prostate cancer  
SPOCK1 May play a role in cell-cell and cell-matrix interactions 
SPON2 
Cell adhesion protein that promotes adhesion and outgrowth of hippocampal embryonic 
neurons 
SPTBN2 Glutamate signaling 
SQLE Catalyzes the first oxygenation step in sterol biosynthesis 
SREBF2 Transcriptional activator required for lipid homeostasis 
SRM Spermidine synthase 
SRPR Targeting and translocation across ER 
SRPRB Correct targeting of the nascent secretory proteins to the ER 
SSR3 TRAP proteins regulates retention or ER resident proteins 
SSR4 Translocating protein across the ER 
ST14 Protease.  Degrades extracellular matrix. 
ST6GAL1 Siayltransferase. Generation cell surface carbohydrates 
ST6GALNAC1 Metastasis, syltransferase, sialyl-Tn 
STARD10 Phospholipid transfer protein 
STARD3NL Endosomal protein. Binds cholesterol 
STEAP4 Metalloreductase. Metabolic homeostasis 
STK39 Serine/threonine kinase, cellular stress response pathway, p38 MAPK 
STPG1 Sperm-tail PG-rich repeat containing 1, apoptosis 
STRA13 DNA damage repair. Mitosis 
STT3A N-glycosylation 
STXBP2 Intracellular vesicle trafficking and vesicle fusion with membranes 
STYK1 Tyrosine protein-kinase. Tumour cell invasion, metastasis, PIK3 signalling 
SUOX Mitochondrial protein 
SURF4 
Maintenance of the architecture of the endoplasmic reticulum-Golgi intermediate 
compartment and the golgi 
SYAP1 Synapse associated protein 1 
SYNGR2 Synaptogyrin family. may play a role in regulating membrane traffic 
SYT7 Prostate cancer associated. Ca(2+)-dependent exocytosis of secretory vesicles 
SYTL1 Vesicle trafficking 
TALDO1 Transaldolase: metabolites in pentose-phosphate pathway 
TARP Regulates the trafficking and gating properties of AMPA-selective glutamate receptors 
TARS 
Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino 
acid 
TBC1D16 May act as a GTPase-activating protein for Rab family protein 
TBC1D30 Rab GTPase activator activity 
TECPR1 Tethering factor involved in autophagy 
TIGD6 Tigger transposable element derived 6 
TIMM10B Mitochondrial protein 
TIMM13 Mitochondrial protein 
TIMM23 Mitochondrial protein 
TM9SF1 Transmembrane protein. Autophagy 
TMED10 Vesicular protein trafficking 
TMED2 Vesicular protein trafficking. Maintainance golgi 
TMED3 Vesicular protein trafficking. Golgi 
TMED9 Vesicular protein trafficking. Organization of intracellular membranes 
TMEFF2 Up-regulates cancer cell proliferation, probably by promoting ERK1/2 phosphorylation 
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TMEM125 Breast colorectal cancer 
TMEM134 Transmembrane protein 
TMEM141 Transmembrane protein  
TMEM251 Transmembrane protein 
TMEM258 Transmembrane Protein 258  
TMEM33 Transmembrane protein 33 
TMEM79 Epidermal integrity 
TMEM79 Transmembrane protein  
TMEM87B Transmembrane protein 
TMEM8A Cell surface adhesion 
TMPRSS2 Transmembrane protease, serine 2 
TMSB15A Plays an important role in the organization of the cytoskeleton 
TP53TG1 TP53 target.  lncRNA  
TPD52 Tumor protein D52 
TRAPPC5 May play a role in vesicular transport from endoplasmic reticulum to Golgi 
TRIM36 
E3 ubiquitin-protein ligase. mediates ubiquitination and  proteasomal degradation of 
proteins. Cell cycle 
TRPM2 calcium-permeable cation channel regulated by free intracellular ADP ribose 
TRPM4 
Calcium-activated non selective (CAN) cation channel that mediates membrane 
depolarization 
TRPM8 Transient receptor potential (TRP) superfamily of ion channels 
TSPAN1 Signal transduction, cell growth, motility 
TSPAN13 Transmembrane 4 superfamily 
TSPO 
Manifestation of peripheral-type benzodiazepine recognition sites. Mitochondria. 
Cholesterol 
TSTA3 NADP(H)-binding protein 
TTC39A Not characterised 
TUBA1C Microtubules 
TUBB4B Tubulin, beta 4B class IVb 
TUSC3 Magnesium transporter. May be involved in N-glycosylation 
TWIST1 
Basic helix-loop-helix (bHLH) transcription factors have been implicated in cell lineage 
determination 
TXNDC11 May act as a redox regulator involved in DUOX proteins folding 
TXNDC16 Thioredoxin domain-containing protein 
TXNDC5 Protects hypoxic cells from apoptosis 
UAP1 UDP-N-acteylglucosamine pyrophosphorylase 1 
UBE2J1 
Catalyzes the covalent attachment of ubiquitin to other proteins. Degradation of misfolded 
protein from ER 
UGGT1 UDP-glucose:glycoprotein glucosyltransferase. ER quality control 
UQCC2 Nucleoid protein localized to the mitochondria inner membrane 
UQCR10 Mitochondrial respiratory chain 
UQCRQ Mitochondrial respiratory chain 
VCP Golgi stacks during mitosis and for their reassembly after mitosis. Vesicle transport 
VEGFA Growth factor. Cell growth. Migration 
VIMP Degradation process of misfolded ER luminal proteins 
VPS26B Component of the retromer complex 
VSTM2L V-set and transmembrane domain containing 2 like 
WDR37 Cell cycle 




Regulator of the Hippo/SWH signaling pathway. Tumour suppression. Apoptosis. 
Activation of ERK1/1 
XBP1 Acts during ER stress by activating unfolded protein response (UPR) target genes 
YIF1A Possible role in transport between endoplasmic reticulum and Golgi 
YIPF1 RNA bindingand ribonuclease activity 
YKT6 Functions in endoplasmic reticulum to Golgi transport; as part of a SNAREn complex 
ZBTB16 Cell cycle. Transcription factor 
ZCCHC6 Uridylyltransferase that mediates the terminal uridylation of some specific RNAs 
ZDHHC23 Palmitoyltransferase that mediates palmitoylation of KCNMA1 
ZDHHC8P1 Zinc Finger, DHHC-type containing 8 pseudogene  
ZDHHC9 Zinc finger DHHC domain-containing protein family. Palmitoyltransferase 
ZG16B Zymogen granule protein  
ZNF350 Transcriptional repressor 
ZNF613 May be involved in transcriptional regulation 
















Genes down-regulated in response to androgen treatment in LNCaP cells, but up-
regulated in 7 PCa patient samples post ADT. 
Gene Information 
ABLIM1 May act as scaffold protein 
ACACB Provision of malonyl-CoA or in the regulation of fatty acid oxidation 
ADAM22 Probable ligand for integrin in the brain. Cell adhesion. Inhibits cell proliferation 
AJUBA 
Repression of gene transcription, mitosis, cell-cell adhesion, cell differentiation, 
proliferation and migration 
ANTXR1 
Plays a role in cell attachment and migration. Mediates adhesion of cells to type 1 
collagen and gelatin 
ARHGEF17 Acts as guanine nucleotide exchange factor (GEF) for RhoA GTPases 
ARHGEF25 Guanine nucleotide exchange factor for Rho family of small GTPases 
ASPH Probable role in mitotic spindle regulation and coordination of mitotic processes 
ASS1 Arginine biosynthetic pathway 
ATP11C Phospholipid-Transporting ATPase 
ATP2B4 Hydrolysis of ATP coupled with the transport of calcium out of the cell 
BARX2 Transcription factor. Adhesion 
BCHE Cholinesterases inactivate the neurotransmitter acetylcholine 
BTG2 Anti-proliferative protein. G1/S cell cycle 
C14orf132 Not characterised  
C16orf45 Not characterised  
C9orf106 Not characterised  
C9orf47 Not characterised  
CAMK1D Calcium/calmodulin-dependent protein kinase 
CDK18 Protein serine/threonine kinase 
CELSR2 Flamingo subfamily, part of the cadherin superfamily, contact mediated communication? 
CERK Converts ceramide to ceramide 1-phosphate (C1P), a sphingolipid metabolite 
CLU Extracellular chaperone that prevents aggregation of nonnative proteins 
COL16A1 
Alpha chain of type XVI collagen, cell attachment and inducing integrin-mediated cellular 
reactions 
DDB2 Required for DNA repair 
DDC Catalyzes the decarboxylation 
DIO3 Catalyzes the inactivation of thyroid hormone 
DPYSL2 Neuronal development and polarity. Migration 
EFNB3 Cell surface transmembrane ligand for Eph receptors. Migration, adhesion 
ELF3 ERBB2 signaling pathway. Epithelial-specific transcriptional activator 
ENO2 lncRNA?. Neuroprotector, cell survival 
EPB41L2 Erythrocyte membrane protein band 4.1 like-protein 22 
EPHA2 Receptor tyrosine kinase. Migration. ERK1/2 




FAM86B1 Not characterised  
FAM86B2 Noy 
FRMD6 lncRNA? 
FZD7 Receptor for Wnt proteins 
GALK1 Major enzyme for galactose metabolism 
GBP2 Guanine-binding protein (GBP) family 
GLIS2 Transcriptional repressor or as a transcriptional activator. Wnt signalling 
GPC3 
Cell surface proteoglycan that bears heparan sulfate. Suppresses growth in mesoderm 
tissues 
GPM6B Membrane glycoprotein. Membrane trafficing. Cell cell communication 
GPR126 Orphan receptor 
HLF bZIP transcription factors 
HOXB3 Sequence-specific transcription factor 
HOXB5 Sequence-specific transcription factor 
HOXB6 Sequence-specific transcription factor 
HSPB8 Displays temperature-dependent chaperone activity. Carcinogenesis 
ID1 
Cell growth. Senescence. inhibit the DNA binding and transcriptional activation ability of 
basic HLH proteins 
ID3 Inhibits the DNA binding of any HLH protein 
ITGA2 Integrin alpha-2/beta-1. Adhesion 
ITGB4 
Integrin alpha-6/beta-4 is a receptor for laminin. regulation of keratinocyte polarity and 
motility 
KANK2 transcription regulation by sequestering nuclear receptor coactivators 
LINC00161 lncRNA. Prostitis 
LOC100130417 lncRNA uncharacterised 
LOC101926935 ncRNA 
LOC145837 Not characterised  
LOC283070 lncRNA 
LPCAT2 Acyltransferase and acetyltransferase 
LRP1 Endocytosis and in phagocytosis of apoptotic. Lipid homeostasis 
LYPD6B Cancer/Testis Antigen 1161  
MAP1B Facilitates tyrosination of alpha-tubulin 
MAP7D3 Not characterised  
MATN2 Involved in matrix assembly 
MECOM Transcriptional regulator and oncoprotein 
MGAT5 Glycosyltransferase. regulation of the biosynthesis of glycoprotein oligosaccharides 
MID1 
Deprotection of protein phosphatase PP2A. formation of multiprotein structures acting as 
anchor points to microtubules 
MIR4697HG lncRNA 
MXRA8 Matrix-Remodelling Associated  
NFASC Cell adhesion 
NOTCH1 
Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to 
regulate cell-fate 
NOVA1 




NRM Nuclear envelope membrane protein 
NUAK1 Serine/threonine-protein kinase. ATM p53. Cell adhesion 
OSR2 Odd-skipped related transciption factor 2 
PBX1 PBX homeobox family of transcriptional factors. 
PFKFB3 Synthesis and degradation of fructose 2,6-bisphosphate 
PKIG Competitive inhibitor of cAMP-dependent protein kinase activity 
PLCD3 Phospholipases are a group of enzymes that hydrolyze phospholipids into fatty acids 
PLK2 Tumor suppressor serine/threonine-protein kinase, centriole duplication. G1/S transition 
PRNP Glycosylphosphatidylinositol-anchored glycoprotein 
  
PTPN14 Protein tyrosine phosphatase. Adhesion an migration 
RAPGEFL1 Probable guanine nucleotide exchange factor (GEF) 
RASSF5 Tumor suppressor, and is inactivated in variety of cancers 
RCAN2 Inhibits calcineurin-dependent transcriptional responses 
ROBO1 
Receptor for SLIT1 and SLIT2 which are thought to act as molecular guidance cue in 
cellular migration 
S1PR3 Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P) 
SCD5 Fatty acid delta-9-desaturase that introduces a double bond in fatty acyl-coenzyme A 
SELENBP1 Selenium-binding protein. Golgi transport 
SERPINB5 
Tumor suppressor. It blocks the growth, invasion, and metastatic properties of mammary 
tumors 
SLC16A2 Very active and specific thyroid hormone transporter 
SLITRK3 Suppresses neurite outgrowth 
SMARCD3 SWI/SNF family of proteins. Chromatin remodelling. Wnt signalling. EMT 
SORBS1 Required for insulin-stimulated glucose transport. Focal adhesions 
SPRY1 Antagonist of fibroblast growth factor (FGF) pathways 
STXBP1 Regulation of synaptic vesicle docking 
TIMP2 Natural inhibitors of the matrix metalloproteinases. Degrades ECM. Suppress proliferation 
TRIM29 Transcriptional regulatory factor involved in carcinogenesis 
TSLP Cytokine 
TSPAN7 Cell surface glycoprotein. May be involved in cell proliferation and cell motility 
TYRP1 Melanosomal enzyme 
UNC5B Mediates apoptosis by activating DAPK1 
USP27X Ubiquitin-Specific-Processing Protease 
VRK1 Serine/threonine kinase involved in Golgi disassembly during the cell cycle 
VWA2 Structural protein. Willebrand factor A-like domain protein superfamily 
WNT10A WNT gene family 
ZAK S/G2 cell cycle. pCHEK2. protein kinase. Regulates the JNK and p38 pathways 
ZC3H6 Zinc finger CCCH-type containing 6 
ZFP36L1 Probable regulatory protein involved in regulating the response to growth factors 





Complete list of real-time quantitative PCR (RT-qPCR) primer sequences used in 
this thesis: 
Primer Sequence 
ABCA1 F CGAGACTAACCAGGCAATCC 
ABCA1 F GAACACAATACCAGCCCAGAA 
ACTIN F CATCGAGCACGGCATCGTCA 
ACTIN R  TAGCACAGCCTGGATAGCAAC 
ALG2 F ATCGTGGCAGGTGGTTATGA 
ALG2 R GCTGTGGAGGAGGGAGATTT 
ALG5 F TGGGACTCACCTACCAAACA 
ALG5 R GCTTCATCCATCATCACAGG 
ARF4 F TGGCAAGACAACCATCATTCTGT 
ARF4 R ACCACCAACATCCCATACTG 
B2-MICROGLOBULIN (HLA-G) F TGTCCTTGCAGCTGTAGTCA 
B2-MICROGLOBULIN (HLA-G) R GCAGCTGTTTCACATTGCAG 
B3GNT2 F CAAGGGCGATGACGATGTTT 
B3GNT2 R CTGCATAGGGTGGGTAGAGG 
B4GALT1 F TGTTGGGAGCTATTGAGCCA 
B4GALT1 R CTCAACCCTGGGATTAGGCA 
B-CATENIN (CTNNB1) F CTTACACCCACCATCCCACT 
B-CATENIN (CTNNB1) R TGCACGAACAAGCAACTGAA 
BICC1 F TCCTCGGACTTGAAAGCAGT 
BICC1 R CAAGGCCTGCTGAAGCTAAG 
BST1 F CCCATCCTGACTGTGCCTTA 
BST1 R TGATAAGACCCGCCCTTTGT 
B-TUBULIN F CTTCGGCCAGATCTTCAGAC 
B-TUBULIN R AGAGAGTGGGTCAGCTGGAA 
C1orf116 F ACTGGACACGGAGGCTGAC 
C1orf116 R CCTTGCTGAGTGATGGTCTC 
CALR F CGAATCCAAACACAAGTCAGA 
CALR R GCCGACAGAGCATAAAAGC 
CCND1 F ACAGATCATCCGCAAACACG 
CCND1 R ATCACTCTGGAGAGGAAGCG 
CDA F ACAAGGATTTCAGGGCAAT 
CDA R AAAGGAGGAGGGCAGCAG 
CDNS F CGTATCACCTCCCCTAACGA 
CDNS R CTTCTGGCACTGGAAATGGA 
CHPF F CCTGTGCGTGACCCTGTG 
CHPF R CGGGATGGTGCTGGAATAC 
CORO1B F GCCTCCACCACCACTGCT 
CORO1B R GTCGGCCTGCTCCTTGAC 
CREB3L4 F AGGCACAACATCTCCTTGGT 
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CREB3L4 R CCGTGAGGCTGGTAATCCT 
CSGALNACT1 F ACTTTGGATTTGGGATGACG 
CSGALNACT1 R GGTTGCTGTGGAGATACTTGC 
CTBS F GGTCTTTGTGTTTGATGTTGGA 
CTBS R ACTCTGGCTCCTTTTGAATGA 
CYS1 F TGCCTGATACTGGCTTTCCA 
CYS1 R ACCAGGAACATTCCAAGGCT 
DCAF6 F CACATCCGTTTGACCCAAT 
DCAF6 R GAGGCTGGAACTGTAATGGTG 
DSP F GACTGGAGCGACAAGAACAC 
DSP R TGTCTGAAGCTGGATGCTGA 
E-CADHERIN (CDH1) F ACGCATTGCCACATACACTC 
E-CADHERIN (CDH1) R AGAGGTTCCTGGAAGAGCAC 
EDEM1 F CTCCAGCTCCAACTGCAATC 
EDEM1 R TTTGGCATGGTCTGGGTTTG 
EDEM2 F AGAGGCTGAAGGAAGAGCAG 
EDEM2 R ATTTCGACCTGCTCCGTTTG 
EDEM3 R TGGAACAGAGGGGCAGTATC 
EDME3 F CAGAAAAGGCACGCAACAT 
ERLEC1 F GTGACAAGTGGGGATGAGGA 
ERLEC1 R CTGCCGAATGTGTTTTCCAT 
ESRP2 F CCTGAACTACACAGCCTACTACCC 
ESRP2 R TCCTGACTGGGACAACACTG 
EXT1 F TGCCAACTCCAGCATCTACA 
EXT1 R GGGTGAAATCGAAGCAGGAC 
FIBRONECTIN (FN1) F GGTACAGGGTGACCTACTCG 
FIBRONECTIN (FN1) R GGGCTGGCTCTCCATATCAT 
FUT1 F GCCACGAAAAGCGGACTG 
FUT1 R ATGGAGGAAGAAGATTACAGAGAGG 
FUT8 F TTGGAACGGGAAGCTCATCT 
FUT8 R CCCAGCACACAAAGTAGTCG 
FZD5 F GGCAACCAGAACCTGAACTC 
FZD5 R CGTGTAGAGCAGCGTGAAGA 
FZD7 F GGTAGACGGGGACCTGCT 
FZD7 R GATACGGAAGAGGGACACGA 
FZD8 F GGCTTCGTGTCCCTCTTCC 
FZD8 R CGGTTGTGCTGCTCGTAGA 
GALNT10 F TACCGCAAAGACAAGACCCT 
GALNT10 R GGTGTGTTCAAACAGCCACT 
GALNT12 F AGCCTGGTCAACTCTCCTTC 
GALNT12 R CAGTCCCGAAAGCTCATTGG 
GALNT14 F ATCGAGCACATAGCATCCCA 
GALNT14 R TTGACGACGATTTCCTTGCC 
GALNT3 F TGATCACTGCTCGGTTGCTA 
GALNT3 R TTCTGGCCAACAGAGGTTCT 
GALNT7 F TCACCTCACACTACCCTTTGC 
250 
 
GALNT7 R CTGATTCCCTCCCATCCTGT 
GAPDH F AACAGCGACACCCATCCTC 
GAPDH R CATACCAGGAAATGAGCTTGACAA 
GCNT1 F AACCTGGAAACGGAGAGGAT 
GCNT1 R TGACCACGAAGTAGGCACTG 
GCNT2 F AGTGCTGCCTCCTGACCAC 
GCNT2 R CCGTGCCAAAGTAAATCACC 
GLB1L2 F TTTTGACCACCTGATGTCCA 
GLB1L2 R GTCCTCCAGTGCCTTCTTGA 
GLIS2 F ATGTCAAGCCCGAGAAGGAT 
GLIS2 R GTGTGCGGATGTGGATGA 
GNPNAT1 F GTGCTAAGAGAGGAAGAGTAGAAGATG 
GNPNAT1 R TTTTGTGGTAGACATTCAAGGGTA 
GSKIP F CAGGGCTCAAGGTGGTAGG 
GSKIP R TCCAAATGCTTCTCGGTAGG 
GSTA4 F ATTGACGGGATGAAGTTGGT 
GSTA4 R TGATAAGCAGTTCCAGCAGA 
ID3 F AAATCCTACAGCGCGTCATC 
ID3 R AAGCTCCTTTTGTCGTTGGA 
IFIT2 F AAGCCTCATCCCTTCAGCAT 
IFIT2 R AACCCTGTCCAGTGGTATGG 
JUP F GCACACAGCAGCCCTACAC 
JUP R GATGTTCTCCACCGACGAGT 
KLKP1 F TACCATTTCGGCAACTTCCA 
KLKP1 R CAGCACAGTCAACACAGTAATCA 
LHX2 F CACTTCGGCATGAAGGACAG 
LHX2 R TAGGGAAGACCCAGAGGGTT 
LINC00161 F AGGCTTAGGAAGAAGAGAACTGT 
LINC00161 R GTCCATCTGAATGCCCACAC 
LINC00920 F AACTCTGCCTTTGGCTTTTG 
LINC00920 R TCACTCTTCCCTATGCTTTGC 
LMAN2 F TTCAAAGTCCACGGCACAG 
LMAN2 R ATCATTGGGGTAGGTGTCCA 
LOC100130417 F GAGTGAGGGTGGAGGGATG 
LOC100130417 F CAGCAGACATTGCCCAGT 
LOC100130417 R TCAGAACAAGCGGTGTGG 
LOC100130417 R CAGGACACCGCCTTGGAT 
LOC101926935 F GTGTGCGTGTGTGTGTGTGT 
LOC101926935 R AACCGCCAGAAAAATGACTG 
LOC283070 F CACTCACCTGGCACCTGTT 
LOC283070 R GCTGACTCCTTCCCACTGAC 
LOC440910 F GGCAGCACCAGTTGAAAGC 
LOC440910 R CATCTCCTGACCCCGTGAT 
LRP4 F ATGGAACAGGACAGGAGGTG 
LRP4 R CTGCCATCTGTGTTGGCTAC 
MALAT1 F CTGGGAGCAGAAAACAGCAG 
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MALAT1 R GGAAGGGGTCAGGAGAAAGT 
MAN1A1 F AGCAGAGTTTCTTCCTGGCA 
MAN1A1 R ACAGTGAAGGGAATGGAGCA 
MAN1C1  R TATGCAAACCTCCGGTCCTT 
MAN1C1 F CAGCAGATGTGTCGGACAAG 
MAN2A2 F GGCCCTTTCTTCTCAGAGGT 
MAN2A2 R CCCTGGCAGATTGTAAAGCC 
MANBA F TTCTTTGCTCCACTGTTGCC 
MANBA R GTTCAGTCACACGAGAGCAC 
MGAT2 F AGTTGCGGGTTGTCATAACG 
MGAT2 R CCTCTGCGCTCTCATCCTTA 
MIEN1 F GCTGTGAAGGAGCAGTATCC 
MIEN1 R GGGAAAGCCCCCATTCTC 
MIR4697HG F GGCTTGGTTGACAGTTTTGG 
MIR4697HG R GGGGAGTGTTCTCAGCAGTT 
MLEC F GAGGAGACCTTTGGCTACGA 
MLEC R TACCTTTTGCTGGGACTGTG 
MUC3A F CTGGGACCCAAACATCTCCT 
MUC3A R GCTCAAGGCTGTTGATGGAG 
MVD F CGCCCATCTCTTACCTCAAT 
MVD R ACACAGCAGCCACAAATCCA 
NANS F TGGATGAGATGGGAGTTGAA 
NANS R GCAGAAGTTGGGGTTGAGG 
N-CADHERIN (CDH2) F AATCGTGTCTCAGGCTCCAA 
N-CADHERIN (CDH2) R TGGGATTGCCTTCCATGTCT 
NEAT1 F ACCCCTTCTTCCTCCCTTTA 
NEAT1 R GCCTCTCTTCTTCCACCATT 
NES F AAGTCTGCGGGACAAGAGAA 
NES R TCCACAGACTCCAGTGGTTC 
NEU1 F GCAAGGATGATGGTGTTTCC 
NEU1 R GTGGCTCCCGCTGTTTCT 
NOTCH F TCAAGCGTCTTGTGCTATGC 
NOTCH R GTATTGGCACGGCTGAACAT 
OAS3 F CAGTTCTGGCACCAAACCAA 
OAS3 R GCTTCACCAGCAGAATCAGG 
PGM3 F GCTGGTGATGCTATTTCTGACA 
PGM3 R CTCGGGGTGTAACTGCTTGT 
PKP1 F TGGGCAAGAGCAAGAAAGAT 
PKP1 R GACCGCACCACATCAGAGTT 
PKP2 F GCAGCACACCCGAAAGAT 
PKP2 R TGGAAACCAAATCAGGGAGA 
PKP3 F CCCGAGACCTGCTGTATTTT 
PKP3 R AAGTCCTCCTTCCGATAGCC 
PKP4 F AACCCAGCCACCTTGGAA 
PKP4 R CACGGAAGAAACAACTCTATCG 
PNN F AGAAGAGAATCACGCCAGGA 
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PNN R ACCCATCAACAAGCCAAATA 
PPL F ACA GACAGCCTCGCCAAATA 
PPL R TCCTCCCATTCTCCAAGTCG 
PPP1CA F AGTGTGGACGAGACCCTCAT 
PPP1CA R GGGCTATTTCTTGGCTTTGG 
PREB F CTCCAACTTCTTGCCCCTTC 
PREB R CCACATCCGTCACCACAA 
PVRL2 F GGCTATGACTGGAGCACGAC 
PVRL2 R GCAGACGAAGGTGGTATTGAA 
RAP1GAP F GCGGCTTCTTTGAGTCTTTC 
RAP1GAP R GTGTTGGGCTTCTTGTTGCT 
RHOU F GCTCTGCTTCAGTGTCGTGA 
RHOU R TAGGATGATGGGGGCTTTG 
RLN1 P1 F CCTGTTCTTGTTCCACCTGC 
RLN1 P2 F TCTCACTGGGAATCTCACCG 
RLN1 R AGCCTCGGTAATGATGGTTGC 
RLN2 P1 F CGGACTCATGGATGGAGCAA 
RLN2 P2 F TCTCACTGGGAATCTCACCG 
RLN2 R GTAGCTGTGGTAATGCTGGC 
RLN2 R CAGCCACATTCCAGAGGATT 
RPN1 F GCCCTGTGATTGTTGCCTAC 
RPN1 R CCTTGGTGATGGAGAAGTCC 
RPN2 F CCGAGCCAGACAACAAGAAC 
SAR1B F GGCATTGTATTTCTGGTGGA 
SAR1B R CTCGCAACCTCTCTTCACTG 
SCN9A F AGGACCTCAGAGCTTTGTCC 
SCN9A R AAGTCACTGCTTGGCTTTGG 
SERP1 F CAACGAGAAGCACAGCAAGA 
SERP1 R GCAGAACCACAGACAACAAAA 
SLC18A2 F CGGGAGTGTGCTCTATGAGT 
SLC18A2 R GCAGCAATGAGGATGTACGG 
SLC9A3R1 F GAAGGAGAACAGTCGTGAAGC 
SLC9A3R1 R GGTCGGAGGAGGAGGTAGAC 
SLC9A9 F TCGGCTCTTCAGAATGTGGT 
SLC9A9 R GTAAGCAGCCTGGAAATCGG 
SLUG (SNAI2) F TGTCATACCACAACCAGAGA  
SLUG (SNAI2) R CTTGGAGGAGGTGTCAGAT 
SMARCD3 F GGAGGTGGAGGAGCCATTA 
SMARCD3 R ATAGCCTTTGGGGTCTCTGG 
SNAIL (SNAI1) F CCTCCCTGTCAGATGAGGAC 
SNAIL (SNAI1) R CTTTCGAGCCTGGAGATCCT 
ST6GAL1 F ACCATTCGCCTGATGAACTC 
ST6GAL1 R CTGGGGCTTGAGGATGTAAA 
ST6GALNAC1 F AGGCACAGACCCCAGGAAG 
ST6GALNAC1 R TGAAGCCATAAGCACTCACC 
ST8SIA4 F CAGAGGTTACTGGCTGACCA 
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ST8SIA4 R GGGCCAGAATCCATACAGGT 
STT3A F GGAGGGAGCACAGATACAGG 
STT3A R GGAGGACGCTTGGCTTCT 
STYK1 F TATGGTGTTGGAGGATGTGG 
STYK1 R GACCTGCTTTCCGATGTGAT 
TMEM8A F ACAACAGCACAGCCCAGAC 
TMEM8A R GCCTCCACCAGGAAGAATC 
TSPAN1 F GAAAGGGCTCAAGTGCTGTG 
TSPAN1 R TCATTCGCTGTGTTGGTGAC 
TUSC3 F TTCACTGCTCTTCAGCCTCA 
TUSC3 R CCCCTCATCATAGTCCACCA 
TWIST1 F ATTCTCAAGAGGTCGTGCCA 
TWIST1 R TTTGCAGGCCAGTTTGATCC 
UAP1 F TGGTCTTTATCGGGCACTTG 
UAP1 R CCACCTTTGCTCCACAGTCT 
UBE2J1 F AGCCATCATTGGGTTTATGC 
UBE2J1 R CAGAGCCACATCCTTCACAA 
UGGT1 F GGTGGTTATCGTCCTCAACAA 
UGGT1 R CTCGTTCCATCACTCAGCAA 
VCP F AGAAGTCCCGTGTGGCCATC 
VCP R TCCAGAGAAGCCATTAGTCATTT 
VIMENTIN (VIM) F CCCTCACCTGTGAAGTGGAT 
VIMENTIN (VIM) R TGACGAGCCATTTCCTCCTT 
ZEB1 F TCAGGGAAGCCTGGGTTTAG 
ZEB1 R CCCTGTTAGGCAGTGAGGAA 
ZO1 F TTCACGCAGTTACGAGCAAG 










Complete list of cloning primer sequences used in this thesis: 
 
Primer Sequence 
ST6GAL1_p3XFLAG CMV10 _NotI_F AATTAAGCGGCCGCTATGATTCACACCAACCTGAAG 
ST6GAL1_p3XFLAG CMV10 
_BamHI_R AAAAAAGGATCCTTAGCAGTGAATGGTCCGGAAGC 
RLN1_pGEX-5X-1_MfeI_F AAAAAAAACAATTGATGTTGGAATTCATTGCTAATTTGCC   
RLN1_pGEX-5X-1_XhoI_R AAAAAAAACTCGAGTCAGCAATATTTAGCAAGAGACCTTTTGG  
RLN1_pET32a(+)_MfeI_F AAAAAAAACAATTGATGTTGGAATTCATTGCTAATTTGCC  











RLN2_P1_p3XFLAG CMV10_XbaI_R AAAAAATCTAGATTATGGTTTCTGTATCTTTGTTGATGAAGG 
RLN2_P2_p3XFALG 
CMV10_HindIII_F TTAATTAAGCTTATGATGTCAGAATTTGTTGCTAATTTGCC 
RLN2_P2_p3XFALG CMV10_XbaI_R AAAAAATCTAGATCAGCAAAATCTAGCAAGAGATCTTTTGG 
 
 
siRNA and shRNA details: 
ST6GAL1_siRNA1  NO03032.12.1 (IDT)  
ST6GAL1_siRNA2  NO03032.12.2 (IDT)  








Significant KEGG pathways from the up-regulated gene list: 
pathway p-value numDE numTotal pathway name 
5322 0.018926505 20 136 systemic lupus erythematosus 
4380 0.035574276 11 128 osteoclast differentiation 
4973 0.035574276 5 44 carbohydrate digestion and absorption 
4070 0.035574276 6 78 phosphatidylinositol signaling system 
 
Significant KEGG pathways from the down-regulated gene list: 
pathway p-value numDE numTotal pathway name 
5200 8.358E-09 67 326 pathways in cancer 
4141 2.08503E-07 39 165 
protein processing in endoplasmic 
reticulum 
4120 8.46749E-05 30 135 ubiquitin mediated proteolysis 
4144 0.000117322 39 201 endocytosis 
4520 0.000285038 20 73 adherens junction 
4360 0.000356825 29 129 axon guidance 
4010 0.000356825 45 268 MAPK signaling pathway 
3013 0.000482503 28 151 RNA transport 
4810 0.000482503 38 212 regulation of actin cytoskeleton 
4110 0.000546431 25 124 cell cycle 
4670 0.000738838 24 116 leukocyte transendothelial migration 
5412 0.000807649 19 74 
arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
4114 0.000845215 23 112 oocyte meiosis 
4972 0.001007929 21 101 pancreatic secretion 
240 0.001183873 19 99 pyrimidine metabolism 
5100 0.001183873 17 70 bacterial invasion of epithelial cells 
5222 0.001605772 20 85 small cell lung cancer 
330 0.00194809 13 54 arginine and proline metabolism 
480 0.002050735 11 50 glutathione metabolism 
4530 0.00235686 25 132 tight junction 
4145 0.00235686 25 152 phagosome 
5131 0.002600853 14 61 shigellosis 
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4142 0.002600982 22 121 lysosome 
4510 0.002615751 35 200 focal adhesion 
4380 0.003596872 23 128 osteoclast differentiation 
4976 0.004106219 16 71 bile secreation 
4020 0.004106219 30 177 calcium signaling pathway 
5016 0.005004073 24 177 Huntington's disease 
4514 0.005216532 23 133 cell adhesion molecules (CAMs) 
620 0.005554414 10 40 pyruvate metabolism 
4640 0.005923295 16 88 hematopoietic cell lineage 
5130 0.005939458 12 55 pathogenic Escherichia coli infection 
4270 0.005939458 21 116 vascular smooth muscle contraction 
5010 0.005939458 22 161 Alzheimer's disease 
1040 0.00620268 7 21 biosynthesis of unsaturated fatty acids 
4914 0.007164869 17 86 
progesterone-mediated oocyte 
maturation 
5146 0.007360401 20 106 amoebiasis 
4970 0.007780873 17 89 salivary secretion 
5145 0.009113855 22 132 toxoplasmosis 
3410 0.013162439 8 33 base excision repair 
280 0.013590623 10 44 
valine, leucine and isoleucine 
degradation 
230 0.013828582 24 162 purine metabolism 
4912 0.014143484 18 101 GnRH signaling pathway 
3040 0.014578268 19 127 spliceosome 
4971 0.014951751 15 74 gastric acid secretion 
5210 0.016946687 13 62 colorectal cancer 
4974 0.016946687 15 81 protein digestion and absorption 
190 0.017301769 14 119 oxidative phosphorylation 
3020 0.017301769 7 29 RNA polymerase 
4916 0.018786685 18 101 melanogenesis 
860 0.019738671 9 43 porphyrin and chlorophyll metabolism 
5142 0.0201889 17 104 
Chagas disease (American 
trypanosomiasis) 
4621 0.022022787 11 58 NOD-like receptor signaling pathway 
3440 0.024077094 7 28 homologous recombination 
5414 0.027986965 16 90 dilated cardiomyopathy (DCM) 
340 0.028443867 7 29 histidine metabolism 
3430 0.028443867 6 23 mismatch repair 
650 0.030477911 7 30 butanoate metabolism 
257 
 
4210 0.032899447 15 87 Apoptosis 
4666 0.034253961 16 94 Fc gamma R-mediated phagocytosis 
4722 0.034253961 20 127 neurotrophin signaling pathway 
561 0.036842165 10 50 glycerolipid metabolism 
3008 0.037089202 12 74 ribosome biogenesis in eukaryotes 
4512 0.039789176 16 85 ECM-receptor interaction 
5110 0.041060998 10 54 vibrio cholerae infection 
982 0.041060998 11 73 drug metabolism - cytochrome P450 
5215 0.04421863 15 89 prostate cancer 
290 0.044298387 4 11 


















Pre-absorption assay to validate the ST6Gal1 antibody. Protein from LNCaP cells treated 
with 10 nM synthetic androgen R1881 (A+) for 48 hours was separated using SDS-PAGE. 
The ST6Gal1 antibody was pre-incubated with various concentrations of a specific 
blocking peptide (0ug/ml – 10ug/ml). 1ug/ml blocking peptide reduced the intensity of the 
protein band compared to no blocking peptide, whilst higher concentrations completely 
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